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Abstract 
There is an urgent need to design novel and safe drug and vaccine delivery methods 
for efficacious prophylactic and therapeutic treatments to protect humans from new and 
re-emerging infectious diseases. Ideally, new regimens would provide protection from 
disease following a single immunization and to achieve this, the use of complementary 
strategies to stimulate both the innate and adaptive immune systems is required. This 
work has focused on the design of targeted drug and vaccine delivery platforms based 
on amphiphilic polyanhydride particles that can result in the generation of robust 
immune responses. A transdisciplinary approach that combines concepts from 
biomaterials, nanotechnology, carbohydrate and protein chemistry, molecular biology, 
immunology and computational analysis has been applied to rationally design and 
engineer novel vaccine platforms that encompass passive and active targeting 
strategies. Yersinia pestis, the causative agent of bubonic and pneumonic plague, is the 
disease of interest in this project; however, the platforms developed can be applied to 
different diseases.  
First, the intrinsic properties of the polyanhydride systems utilized in these studies 
were tailored to achieve the stability of proteins with the potential to be used as antigens 
and/or therapeutic agents. Amphiphillic polyanhydride chemistries showed the most 
optimal properties to preserve structural integrity and functionality of different proteins. 
The surface chemistry of polyanhydride particles was also identified as an important 
attribute that directs the adjuvant properties of these carriers. In this context, this work 
xxiv 
	  
revealed changes in particle uptake and activation phenotype of antigen presenting cells 
as a consequence of chemistry-dependent surface adsorption of serum proteins.  
Besides the passive targeting strategy based on the appropriate selection of polymer 
chemistry, active targeting strategies were also designed to improve and direct the 
adjuvant properties of polyanhydride particles. In this work, two approaches were taken: 
adjuvant and antigen modifications. Carbohydrate-functionalization of polyanhydride 
nanoparticles results in the development of “pathogen-like” particles with the ability to 
induce and enhance APC activation by specific interactions with the mannose receptor. 
Finally, antigenic modification with αGal residues in combination with polyanhydride 
particles as vaccine delivery vehicles results in the production of high antibody titers with 
high avidity and with the ability to recognize protective epitopes in vivo.  
In summary, the studies described in this thesis demonstrate the promise of 
amphiphilic polyanhydride particles as drug delivery devices and vaccine adjuvants. 
This work provides key insights into the rational design of targeted platforms to enhance 
the induction of antigen-specific immune responses and to facilitate the design of 
protective targeted therapeutic treatments and vaccines. 
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CHAPTER 1 
Introduction 
1.1 Introduction 
Novel diagnostic technologies and screening methods as well as the effective 
therapeutic agents have diminished mortality for several re-emerging infectious 
diseases. Even with the impressive advances in medical care witnessed over the past 
century, infectious diseases remain the second leading cause of death worldwide1,2. 
Many of these deaths occur in infants and young children from diseases that could be 
prevented by vaccination. On the other hand, the design of efficacious prophylactic and 
therapeutic treatments for emerging diseases, especially those that are considered by 
the U.S. Department of Defense as diseases with bioterrorism potential (i.e., plague, 
anthrax, etc), is also necessary3,4.  
The 2006 PhRMA report “Biotechnology Medicines in Development” identifies 418 
new biotechnology protein-based medicines (i.e., monoclonal antibodies, hormones, 
vaccine antigens) for more than 100 diseases, including infectious diseases, cancer, 
autoimmune diseases, HIV and related conditions, which are in human clinical trials or 
under review by the Food and Drug Administration5. However, the therapeutic potential 
of peptide and protein drugs, as well as their clinical application, is often hampered by a 
number of obstacles to their successful delivery5-9. Some of the obstacles in the delivery 
of these protein-based therapeutics is to deal with the physical and chemical instabilities 
of protein pharmaceuticals6. Chemical instability results when a new chemical structure 
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is formed as a result of bond formation because the reactivity of side chains or 
disruption of the primary sequence9. Physical instability refers to changes in the 
structural level of proteins that can lead to denaturation, adsorption, and precipitation6,10. 
The chemical and physical stability of proteins can be compromised by environmental 
factors such as pH, temperature, high pressure, organic solvents, detergents, agitation, 
etc6,8,10,11. And most of these factors are present in common manufacturing process as 
well as during storage, transportation and administration of these therapeutic 
formulations. The fragile three-dimensional structure of protein therapeutics must be 
maintained for biological activity and avoid compromising the protein 
immunogenicity12,13.  
Another obstacle in the delivery of protein therapeutics is that being highly 
vulnerable molecules, proteins usually present short in vivo half-lives either at the site of 
administration or in distal location, on their way to the site of pharmacological action14. 
The ability of large molecules such as pharmaceutical proteins to transport across 
biological barriers (i.e., epithelial, blood brain barrier, transmucosal) is low due to their 
low absorption15-17. For these reasons, the effectiveness of potential peptides and 
proteins drugs is dependent on a frequent administration regimen, which compromises 
the patient comfort and makes these regimens expensive. A clear example is the only 
anthrax vaccine licensed by the FDA, BioThrax® that requires a series of five doses 
administered at 0 and 4 weeks and 6, 12, and 18 months to convey protection18,19. 
Therefore, the development of single dose therapeutics (e.g., vaccines) represents a 
much-needed solution to dispense with the requirements of multiple doses and, at the 
same time, to improve the efficacy of these treatments.  
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The need to design novel drug and vaccine delivery methods to overcome these 
challenges is urgent and biodegradable polymer-based carriers have emerged as an 
effective solution. These carriers can be fabricated into different devices geometries 
(i.e., films20,21, implant coatings22,23, drug eluting stents24,25, microparticles or 
nanoparticles12,26-39) to best fit the desired application of disease treatment; however, 
particles-like devices (i.e., microparticles and nanoparticles) offer several advantages 
over other geometries such as localized drug delivery, and administration by injectable 
or non-injectable (i.e., inhalable) routes for systemic drug delivery. Controlled release of 
a variety of therapeutic and prophylactic treatments has been achieved over the years 
by using polymer particles. Controlled polymeric drug delivery has the potential to 
reduce the quantity and frequency of doses while maintaining appropriate systemic or 
local drug concentrations better than conventional delivery techniques (Figure 1.1).  
Figure 1.1 Conventional vs. controlled release of therapeutic drugs. 
 
Various polymer chemistries have been applied in the drug and vaccine delivery 
area; however polyester microparticles, especially those composed of lactic and glycolic 
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acids (e.g. poly(lactide-co-glycolide), PLGA), have been the most extensively studied 
and used as delivery devices for biomedical applications26,27,32,34,37. These devices have 
shown to provide a sustained release for different proteins and their degradation 
products are easily absorbed by neighboring cells29,40. However, these degradation 
products can create an acidic microenvironment that has shown to affect the stability of 
proteins33. In order to avoid these problems, researches have turned their attention to a 
class of surface eroding polymers: polyanhydrides41,42. A special family of 
polyanhydrides based on copolymers of sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) (Figure 1.2) have shown potential to be used as drug and vaccine carriers. 
35,43. The degradation mechanism of these polymer systems allows for controlled 
release kinetics of proteins that can vary from days to moths by choosing the 
appropriate polyanhydride chemistry30,44,45. In addition, polyanhydride degradation 
products are non-cytotoxic46,47 and do not result in a severe pH decrease upon 
dissolution and therefore provide the adequate environment for protein stability44,45. 
Finally, previous in vivo experiments performed by Dr. Narasimhan’s research group 
have shown the ability of CPH:SA and CPTEG:CPH copolymers to deliver vaccine 
antigens (i.e., tetanus toxoid and F1-V for Y. pestis, respectively) resulting in an 
enhanced and modulated immune response in mouse models36,48. All these 
characteristics make polyanhydrides promising candidates to be used as vaccine 
adjuvants.  
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Figure 1.2 Chemical structures of (from top to bottom): sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane  
(CPTEG). 
 
Even with the advances showed in the area of drug and vaccine delivery, several 
challenges such as rapid clearance from circulation, directing delivery to specific 
immune systems and immunomodulation, still remain as unsolved in order to improve 
the efficacy of these delivery systems. In order to overcome these, complementary 
strategies to stimulate both the innate and adaptive immune systems are required. 
Development of targeting strategies to overcome physical barriers and/or direct drug 
and vaccine carriers to specific target cells and tissues of immunological importance is a 
growing area of research49. Targeting strategies can be recognized as two main types: 
passive and active targeting and both types can be achieved by engineering the 
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drug/antigens to increase their immunogenicity and/or the particle-based carriers to 
enhance their adjuvant properties50,51. Passive targeting or physical targeting involves 
the preparation of an antigen and/or drug/vaccine carrier that can avoid the elimination 
due to body defense mechanisms like metabolism, excretion and opsonization followed 
by phagocytosis51. Some of the variables that can be tailor in order to achieve passive 
targeting are the size and shape of the device and the molecular weight and chemistry 
of the materials that will dictate the surface charge and hydrophobicity of the device. On 
the other hand, active targeting involves attaching molecules like antibodies, proteins, 
peptides, carbohydrates or any other ligand to the drug/antigen or the drug/vaccine 
delivery system, which allow it to meet and complex with the immune target that has the 
specific receptor for the attachment49,51. In the case of vaccines, it is imperative that the 
immune response be primed to the delivered antigen. In order for effective priming to be 
accomplished, antigen must be supplied to antigen presenting cells (APCs). If these 
APCs are properly activated and present the correct antigenic epitopes, an adaptive 
immune response can be mounted that will build long-term immunological memory52,53. 
By targeting receptors (i.e., Toll-like receptors (TLRs), and C-type lectin receptors 
(CLRs)) present on the surface of DCs, it is possible to enhance and modulate the 
generated immune response54,55. 
With all this in mind, the overall goal of this research is to design innovative 
platforms for targeted vaccine delivery based on polyanhydride particles that can result 
in efficacious immune responses. A graphical summary of the approach taken to 
rationally design these targeted platforms is presented in Figure 1.3.  
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Figure 1.3 Pictorial summary of the rational approach developed in this thesis to design 
targeted platforms. 
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CHAPTER 2 
Literature Review 
2.1 Summary 
Micro and nanoparticles have great potential to be used as delivery vehicles. 
Different natural and synthetic polymers have been used to fabricate particulate carriers 
for delivery of drugs, proteins, and vaccines. Some of these polymers exhibit adjuvant 
properties that can be explored for the design of effective vaccines. Section 2.2 
overviews the use of micro and nanoparticles as drug delivery vehicles, exploring the 
different biomaterial chemistries and their fabrication and characterization methods. In 
Section 2.3 the immune system and its interaction with vaccine adjuvants is discussed, 
with special emphasis on the adjuvant properties of polymeric particles (i.e., polyesters 
and polyanhydrides). Section 2.4 discusses current and potential strategies for the 
development of novel vaccine platforms based on targeted systems. Finally, Section 2.5 
provides an overview of Yersinia pestis, the causative agent of plague.  
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2.2 Micro and Nanoparticles as Drug Delivery Vehicles 
2.2.1 Introduction 
Even during the 20th century, drug discovery frequently resulted from empiricism 
(e.g., the accidental discovery of penicillin). As technology advanced, particularly after 
1970, methods of drug and vaccine production became more sophisticated and rational 
1. In parallel with the advent of modern pharmaceutical technology and the explosive 
ascent of biotechnology, the cellular and molecular basis for the action of many drugs is 
now understood. New technology and clearer biological insights have led to new classes 
of therapeutics and prophylactic agents. Examples of these new agents that are 
commercially available include: Recombivax HB® (Merck & Co., Inc), a hepatitis B 
subunit vaccine, Orthoclone OKT® (Ortho Biotech), a monoclonal antibody against CD3 
used in the prevention of organ rejection, and Avonex® (Biogen, Inc), which uses 
interferon beta-1a as an agent to treat multiple sclerosis 2. This wealth of new 
technology and ”ammuniton” in the war against disease has incited novel strategies for 
drug and vaccine administration.   
An increasing number of drugs are based on biomolecules such as peptides, 
proteins, oligonucleotides, and DNA. The manufacture of therapeutic proteins 
represented the first true industrial application of recombinant DNA technology 3. 
Approximately 36% of the new biopharmaceutical products currently approved within the 
EU are protein-based 4. Actually, a large fraction of biotechnology R&D is focused on 
the creation of vaccines for different kinds of diseases and many of these future 
vaccines will be based on peptide or protein subunits 5. One of the most challenging 
tasks in the development of protein pharmaceuticals is to deal with the physical and the 
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chemical instabilities of the protein 6. These molecules often show low bioavailability and 
display a need for protection against enzymatic or acid-catalyzed breakdown in the 
human body 7. The fragile three-dimensional structure of proteins must be maintained 
for biological activity and this could be lost due to physical as well as chemical 
instability8. 
Drug delivery systems are an alternative to improve the bioavailability of drugs while 
at the same time providing the necessary protection of drug molecules. Successful 
efforts to produce pharmaceutical formulations that would prolong the action of the 
therapeutic agents minimizing the frequency between dosing go back to the late 1940s 
and early 1950s with the introduction of the first commercial product, known as 
Spansules®. This product consisted of small drug spheres coated with a soluble coating 
and by varying the coating thickness, capsule dissolution times could be varied, thus 
prolonging the action of one dose of the orally administrated therapeutic agent 9. Such 
formulations are now known as “controlled-delivery” products.  
Following a single dose administration of a therapeutic agent, the blood plasma level 
rapidly rises and then exponentially decays as the drug is metabolized and/or eliminated 
from the body. The purpose behind developing systems that release drugs in a 
controlled manner is to achieve more effective therapies while eliminating the potential 
for both underdosing in which the drug is not therapeutically effective and overdosing in 
which the drug produces undesirable side effects (Figure 2.1). It is desirable to achieve 
a therapeutic index that is between the toxic and the minimum effective levels, for longer 
periods of time (i.e., “zero order” release) 7, 9-11. Other advantages of using controlled 
delivery systems can include the need for fewer administrations, optimal use of the drug 
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in question, and increased patient compliance—all of these aspects can lead to a 
reduction of costs for the pharmaceutical industry. While these advantages can be 
significant, the potential disadvantages cannot be ignored. These include the possible 
toxicity or non-biocompatibility of the materials used, undesirable degradation products, 
any surgery required to implant or remove the system, and the possibility of patient 
discomfort from the delivery device 10. 
 
 
Figure 2.1 Drug level verses time profile showing differences between zero order, 
controlled release, slow first order sustained release and conventional release. 
Reprinted and modified from 2. 
 
In order to design effective delivery systems, it is necessary to design materials that 
are biocompatible and that can provide an adequate microenvironment to maintain the 
biological activity of a drug and provide a sustained drug release profile. Polymers, 
especially biodegradable polymers, have been extensively used in the biomedical arena 
in the form of sutures, wound covering materials, and artificial skin 12-15. Polymeric drug 
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delivery systems have been considered for many applications to supplement the 
standard means of medical therapeutics. In the 1960’s, researchers discovered 
alternative uses for these biomaterials in applications for drug delivery. Recent 
advances have shown that polymeric devices are useful for high molecular weight drugs 
16 and for those drugs that should be delivered in minute quantities with zero-order 
kinetics 17.  Different types of “polymer therapeutics” have been used in order to improve 
drug functionality, for example polymer-protein conjugates, polymer-drug conjugated or 
complexes, and polymer micelles with drugs covalently or physically incorporated in the 
core 18-20. The most common polymer-protein conjugate system is PEG-protein 
conjugates. In this kind of system, therapeutic proteins are conjugated with 
poly(ethylene glycol) (PEG) by a process known as PEGylation that was first described 
by Davis, Aubuchowski and colleagues 21. There are multiple PEGylated protein drugs 
that are commercially available or in clinical trials, for example Adagen®  is composed of 
PEG-adenosine deaminase and used for SCID syndrome, and PEGASYS® marketed in 
2002 is composed of PEG-α-interferon 2a and is used to treat hepatitis C 9, 20. On the 
other hand, block copolymers constructed from hydrophilic and hydrophobic segments 
are known to assemble in an aqueous environment into polymeric micelles. Because of 
their core-shell structure, polymeric micelles have excellent potential as drug delivery 
devices. Kataoka, Okano and coworkers have published extensively on polymer 
micelles, and have designed many interesting block copolymers for use in polymeric 
micelles 22, 23. Polymeric micelles have principally been used as drug carriers in tumor 
targeting applications. Pluronics and poly(ethylene glycol) are the main used polymers 
for micelles formation 24, 25.  
 	  
17 
Even with the advantages provided by the “therapeutic polymers” described above, 
biodegradable polymeric drug carriers have been extensively studied. Such systems 
combine the advantage of long-term zero order drug release with biodegradability. In 
this type of controlled delivery system, the drug is not chemically attached to the 
polymer, and it is simply encased within the polymer matrix. Because there are no 
chemical interactions between the drug and the polymer, the drug remains in a 
biological active form, and can exert its effect upon the body as soon as it is released 
from the polymeric matrix 26. Numerous polymers have been evaluated for these types 
of drug delivery systems, and they can be classified into three basic types. These are 
water-soluble polymers, which are typically used for short-term delivery, non-
biodegradable polymers, and biodegradable polymers, which require some chemical 
reaction or alteration in the body before they become water-soluble 7, 9, 26. 
 The decision to use a suitable polymer from these three general classes depends 
upon the route of administration, the type of drug used, the amount of drug to be 
delivered, the duration of release required, and the specific site of delivery (i.e., targeted 
delivery). The same criteria that are used to select the appropriate polymer in the design 
of drug delivery systems are applicable in determining the required form of the delivery 
device. Many drug delivery devices have been fabricated as implants (i.e., wafers, films, 
multilayered disks 27. The disadvantage of this type of device is that usually the 
implantation requires surgery and there is the possibility of patient discomfort from the 
delivery device. These issues can be obviated by the development of injectable devices, 
mainly micro and nanoparticles – which can also serve as vaccine delivery devices. In 
recent years, biodegradable polymeric particles have attracted considerable attention as 
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potential drug delivery devices in view of their applications in controlled release of drugs, 
their ability to target particular organs/tissues, as carriers of DNA in gene therapy, and 
for their ability to deliver proteins, peptides and genes through a specific route of 
administration 28-31.  
This section provides an overview of biodegradable polymeric micro and 
nanoparticles and their applications as drug delivery carriers. First, the most common 
biodegradable polymers used for particle fabrication are introduced and discussed in 
context of their chemical properties and applications in drug delivery. This is followed by 
a summary of the main fabrication methods used for micro and nanoparticle preparation. 
Finally, the biological consequences of some important properties (i.e., size, surface 
properties) of micro and nanoparticles are discussed.  
 
2.2.2 Biodegradable Polymers for Drug Delivery 
2.2.2.1 Naturally occurring polymers 
Polymers are commonly found in nature. Naturally occurring polymers can be 
classified into three types: lipid-based (e.g., liposomes), proteins (e.g., collagen, gelatin, 
fibrin, and albumin), and polysaccharides (e.g., chitosan, hyaluronic acid, cellulose, and 
alginate (Figure 2.2)) 32. Generally, the degradation of these polymers is driven by 
hydrolytic or enzymatic cleavage of their main chain. 
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Figure 2.2 Chemical structure of some naturally occurring polymers. 
 
Liposomes are one of the most well-known drug delivery carriers employed in the 
treatment of different diseases 33. Liposomes can be constructed from biodegradable 
and nontoxic constituents (i.e., double lipid bilayer) and are able to non-covalently 
encapsulate molecules (i.e., chemotherapeutics agents, hemoglobin, imaging agents, 
drugs, and genetic material) within their 100-200 nm diameter interior (Figure 2.3) 7, 33-
36. The factors that must be taken into account when preparing liposome formulations 
include the size, the surface charge 37 and the membrane fluidity 38. There are many 
liposomes for the treatment of malignancies that are already approved, awaiting 
approval or in clinical trials. For example, doxorubicin liposomes have shown significant 
activity against AIDS-related Kaposi’s sarcoma, breast and ovarian cancers in different 
clinical trials 39-41. However, developmental work on liposomes has been limited due to 
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inherent problems such as low encapsulation efficiency, rapid leakage of water-soluble 
drug in the presence of blood components, and poor storage stability 31, 34, 36, 37. 
 
 
Figure 2.3 Basic liposome structure. 
 
In another example of naturally occurring polymers, green plants have the ability to 
take glucose and make long chains containing many glucose units. These long chains 
are known as cellulose. Cellulose has been routinely used in medical and 
pharmaceutical applications for many years (e.g., in pharmaceutical excipients or 
cellulose wadding for surgical use) 42, 43, and is a benign material that is well tolerated by 
the body. For example, cellulose nanocrystals of suitable sizes can be used as carriers 
in drug delivery, and have many reactive functional groups on their surface to which 
drugs or targeting molecules could be attached 44, 45.  
Other polysaccharides like chitosan and hyaluronic acid have shown promise as 
drug delivery vehicles. There are specific enzymes for chitosan (papain) and hyaluronic 
acid (hyaluronidase) degradation. In drug delivery they have been used as hydrogels, 
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microparticles, as stealth or Trojan coatings or co-polymerized with other polymers of 
interest 12, 46-48.  
Sodium alginate and gelatin have been used to prepare carrier matrices because 
they are naturally occurring, biodegradable, biocompatible, and hydrophilic polymers 
that are suitable for the entrapment of water soluble drugs 49-51. Alginate has been 
utilized as a scaffold for skeletal muscle tissue engineering due to its biocompatibility 
and ability to form gels with a gentle gelation process 52.  
The use of collagen as a biomaterial has focused on the aspects of cellular growth or 
delivery of proteins capable of stimulating cellular response. The most successful and 
stimulating applications are shields in ophthalmology, injectable dispersions for local 
tumor treatment, sponges carrying antibiotics and minipellets loaded with protein drugs 
12, 53-55.  
It is clear that the biocompatibility offered by naturally occurring polymers is an 
important characteristic that is difficult to find in synthetic polymers. However, there are 
significant limitations (i.e., difficulty for chemical modification, the low drug concentration 
that these systems can deliver) that must be addressed to improve their function. 
Next, some synthetic polymer systems for drug delivery applications are discussed. 
 
2.2.2.2 Poly(ortho esters) and Poly(phosphoesters) 
The first poly(ortho ester) was described in the 1970s in a series of patents 56-59 and 
represent the first example of a new synthetic polymer specifically designed for 
controlled drug delivery. These polymers contain hydrophobic units linked together 
along the polymer chain by functional groups very susceptible to hydrolysis. Such 
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polymers are bioerodible and the rate of hydrolytic degradation at the surface of the 
polymer is much faster than the rate of water permeation into the polymer matrix. 
However, these polymers contain an orthoester linkage which is more susceptible to 
hydrolysis under low pH conditions than basic conditions. Four families of poly(ortho 
esters) have been developed by Alza Corporation and by Dr. Heller and colleagues at 
the Stanford Research Institute 60, 61. Figure 2.4(a) show the structure of poly(ortho 
esters). Control of the degradation rate of these polymers has been achieved by 
incorporating acidic or basic excipients into the polymer matrix 62. The last family of 
poly(ortho esters), developed by Advanced Polymer Systems 26, 63, a short segment of 
lactic or glycolic acid in the polymer backbone. This segment acts as a latent acid 
catalyst and eliminates the need to add acidic excipients to the polymer to control 
erosion 64. The two most commonly used polyorthoester-based devices are implants 
and microspheres. Drug delivery applications for these polymers include the delivery of 
cancer chemotherapeutics, periodontal therapeutics, anti-inflammatory agents, 
intraocular therapeutics, anesthetics, and DNA 65-69. 
The general chemical structure of poly(phosphoesters) is shown in Figure 2.4(b). In 
the past, interest in phosphorus-containing polymers centered on their flame-retardant 
properties 70. However, it was their hydrolytic instability that renewed interest in such 
polymers for drug delivery applications 71. Because the ultimate hydrolysis products are 
phosphate ions, alcohol, and a diol, the polymer has the potential to be non-toxic. While 
these polymers are being investigated for delivery of a number of different therapeutics, 
most research has focused on the delivery of cancer and gene therapies 72-74. These 
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two types of polymers may receive more attention in the future especially for 
optimization of drug delivery carriers.  
 
 
Figure 2.4 (a) Structure of poly(ortho esters), and (b) general structure of 
poly(phosphoesters). 
 
2.2.2.3 Poly(alkylcyanoacrylates) 
Poly(alkylcyanoacrylates) (PACAs), shown in Figure 2.5, were not employed as 
polymers until the early 1980s 75. However, the corresponding monomers, 
alkylcyanoacrylates, have been used since at least 1966 because of their excellent 
adhesive properties resulting from the bonds of high strength they are able to form with 
most polar substrates, including living tissues and skin 76. Therefore, the monomers 
have been extensively as tissue adhesive for the closure of skin wounds 77-79, as 
surgical glue, and as embolitic material for endovascular surgery 79, 80. M More recently, 
PACAs have been used as nanoparticulate drug delivery carriers 31, 81-85. This area of 
research has gained increasing interest in therapeutics, especially for cancer 
treatments, which generally involve highly toxic molecules in contact with healthy tissue 
86, 87. Other molecules of interest, including poorly stable compounds such as peptides 
 	  
24 
and nucleic acids, have been combined with PACA nanoparticles for targeting purposes 
83, 84.  
Today, PACA nanoparticles are considered of the most promising polymer colloidal 
drug delivery system and are already in clinical development for cancer therapy 88-91.  
    
 
Figure 2.5 Chemical structure of alkylcyanoacrylates. 
 
2.2.2.4 Polyethers  
The two most common polyethers are poly(ethylene glycol) (PEG) and 
poly(propylene glycol) (PPG) (Figure 2.6). These polymers are water-soluble and do not 
have to undergo any chemical degradation; they simply have to become hydrated, 
ionized, or protonated to lose their form and dissolve within the body 26. PEG has been 
used widely in the pharmaceutical industry and especially in the drug delivery area. 
PEGylation is the covalent coupling of PEG to another large macromolecule (i.e., drugs, 
proteins, peptides) 9. When attached to various protein medications, PEG allows a slow 
clearance of the carried protein from the blood. This makes for a longer acting medicinal 
effect and reduces toxicity, and it allows longer dosing intervals 92, 93. Examples include 
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PEG-interferon alpha, which is used to treat hepatitis C, and PEG-filgrastim (Neulasta), 
which is used to treat neutropenia 9.  
 
 
Figure 2.6 Chemical structures of (a) poly(ethylene glycol), and (b) poly(propylene 
glycol). 
 
Researchers in the drug delivery area have taken advantage of the amphiphilic 
properties of PEG by incorporating it into the backbone of some of the most common 
polymers used for drug delivery (i.e., polyanhydrides, poly(cyanoacrylates)) because of 
their ability to alter the degradation rate of these polymers 94-96. As mentioned before, it 
has been demonstrated that the presence of PEG inhibits material interactions with 
blood components and therefore could increase the circulation time of a delivery device 
in the bloodstream 97. Taking advantage of this property, PEG has been attached by 
different methods to delivery devices (i.e., micro and nanoparticles) in order to increase 
their biocompatibility 92, 93.  
Another useful biomaterial based on polyethers is the block copolymer Pluronic® 
((PEG)n-(PPG)m-(PEG])n). This copolymer has unique micelle forming properties, via 
self assembly in water, due to the hydrophilic PEG and hydrophobic PPG, enabling the 
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formation of nanometer sized particles 98. In summary, polyethers show promise in the 
design of efficacious drug delivery vehicles.  
 
2.2.2.5 Polyesters 
Poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(ε-caprolactone) (PCL), and 
their copolymers (e.g., PLGA) (Figure 2.7) have been the most studied polyesters, 
especially in the drug delivery area. These polymers were originally developed as 
biodegradable sutures and were approved because they degrade to the natural 
metabolites L-lactic acid and glycolic acid 9, 99. Several studies have been published 
describing these polymers, their synthesis, characterization, and fabrication into 
microcapsules, films, fibers, rods, microparticles, and nanoparticles for controlled 
release of drugs ranging from low molecular weight antibiotics and steroids to high 
molecular weight proteins such as vaccines and growth hormones 2, 9, 29, 99. Although the 
majority of drug delivery systems developed with these polymers have been injected or 
implanted either subcutaneously or intramuscularly, there are studies showing their use 
in nasal and oral administration.   
The erosion rate of PLGA copolymers can be controlled by varying the ratio of 
glycolic to lactic acid in the copolymer, and the higher the glycolic acid content, the 
faster the erosion rate. However, as the amount of glycolic acid in the copolymers is 
increased, crystalline domains of PGA may form, and solubility in toxicologically 
acceptable solvents decreases; thus the highest amount of PGA normally used is about 
50 mol%. These copolymers have an average lifetime of about 2-4 weeks 94, 100-103. 
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 PCL is also an FDA-approved polyester for applications in drug delivery and 
biodegradable sutures. PCL is semi-crystalline, similar to PLA. However, PCL has a 
much slower degradation profile ranging from one to three years in vivo 95, 104-107. Due to 
this prolonged degradation rate it has been utilized in blends or copolymers with 
expedite the degradation rate 107. 
 
 
Figure 2.7 Chemical structures of the most commonly used polyesters and their 
copolymers. 
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Polyesters undergo a bulk erosion process, which can be described in four steps 
(Figure 2.8). First, water diffuses into the polymer and ester bond cleavage starts. 
Second, differentiation between the surface and interior begins, with a drastic decrease 
in molecular weight in the inner part of the matrix, where the acidic environment 
accelerates the degradation. Third, low-molecular-weight oligomers begin to diffuse 
through the thinning outer layer, and when the molecular weight of these oligomers is 
low enough to allow solubilization in the medium, weight loss begins. Finally, a polymer 
shell remains after the oligomers have solubilized and slow erosion of the shell takes 
place.   
 
Figure 2.8 Schematic representation of bulk erosion process. 
 
Such an erosion process can have a significant impact on the use of polyesters in 
drug delivery. When the polymer is used in orthopedic applications such as bone plates 
the massive release of acidic products can exceed local tissue clearance capabilities, 
and it has been shown to produce serious inflammatory responses 108. In addition to 
accelerating degradation, the low internal pH can also have adverse effects on acid-
sensitive incorporated agents, such as DNA, antigens, or some proteins. These 
limitations demonstrate significant hurdles for the use of polyesters in drug delivery. 
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2.2.2.6 Polyanhydrides 
Figure 2.9 shows the general chemical structure of polyanhydrides.  These 
materials were first prepared in 1909 and were subsequently investigated as potential 
textile fibers, but found unsuitable because of their hydrolytic instability 109. However, it is 
this hydrolytic instability that makes them excellent candidates for the design of drug 
delivery systems. Polyanhydrides are a class of versatile biomaterials and can be 
grouped into three primary classes: aliphatic, unsaturated and fatty-acid derived, and 
aromatic 110. Figure 2.10 shows the most common polyanhydrides used for drug 
delivery applications. The promising characteristics of polyanhydrides for biomedical 
applications rely on their surface erosion mechanism (Figure 2.11) that translates into 
well-controlled release kinetics, where the drug release rate coincides with the 
degradation rate of the polymer. In an aqueous environment, the macromolecules at the 
surface break into smaller chains before water penetrates into the device. Thus, the 
drug is released as the polymer degrades 110-113. Because aliphatic polyanhydrides 
hydrolyze rapidly while aromatic polyanhydrides hydrolyze slowly, good control over 
hydrolysis rate can be achieved by using copolymers of aliphatic and aromatic 
polyanhydrides. In this way, erosion rates from days to many months have been 
demonstrated 2, 9, 113-117. Another aspect that makes polyanhydrides excellent candidates 
for drug delivery carriers is their biocompatibility as they degrade into non-toxic, non-
mutagenic degradation products capable of being metabolized intracellularly 110, 112, 116, 
118. Polyanhydride-based drug delivery devices (Gliadel®) have been approved by the 
U.S. Food and Drug Administration (FDA) for the treatment of brain tumors. This device 
is a polyanhydride wafer composed of sebacic acid (SA) and 1,3-bis(p-
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carboxyphenoxy)propane (CPP) (CPP:SA copolymer in 20:80 molar ratio) loaded with 
the chemotherapeutic agent, carmustine, 1,3-bis(2-chloroethyl)-1-nitro-sourea (BCNU) 
110.   
 
Figure 2.9 General structure of polyanhydrides. 
 
Sebacic acid is the most widely used aliphatic polyanhydride and it degrades within 
weeks. When copolymerized with the aromatic CPP, this aliphatic-aromatic system can 
be used for drug delivery. Sebacic acid can also be copolymerized with unsaturated 
polyanhydrides like poly(fumaric acid) (FA) and acetylenedicarboxylic acid (ACDA) 
increasing their bioavailability for the oral delivery of proteins 110, 111. Another aromatic 
polyanhydride that has been widely used in drug delivery is 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and it has been copolymerized with SA in order to result 
in controlled degradation times 110, 119. Several modifications of anhydride monomers 
have been carried out in order to obtain desired characteristics for particular 
applications. An example is the incorporation of triethylene glycol (TEG) into an aromatic 
monomer (CPH) in order to enhance the hydrophilicity of the monomer, resulting in 
faster degradation rate with a combination of bulk and surface erosion. The resulting 
polymer is poly(1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane) (CPTEG) 120, 121.  
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Figure 2.10 Typical polyanhydrides used for drug delivery applications. 
 
Recent efforts have focused on the use of two polyanhydride-based copolymer 
systems (i.e., CPH:SA and CPTEG:CPH) as drug delivery carriers. Different device 
forms including tablets, films, microparticles and nanoparticles have been fabricated for 
a broad range of drug delivery applications including injectable microparticle delivery, 
inhalable/injectable nanoparticle delivery, multi-component implants, and tissue 
engineering constructs 114, 115, 122, 123. The chemistry of the copolymer has been shown to 
play a significant role in the release kinetics, the ability to stabilize proteins, and the 
immunomodulatory capabilities of these polyanhydride systems 113-115, 117, 124-130.  
 
Figure 2.11 Schematic representation of surface erosion process. 
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The release kinetics of both the CPH:SA and the CPTEG:CPH systems have been 
well studied 114, 115, 125, 128, 130. By changing the ratio of the monomers during fabrication, 
the degradation rate of the copolymers can be extended from days to months. As the 
release profile of an encapsulated drug depends on the degradation rate of the 
copolymer (because of the surface erosion mechanism), the release kinetics can be 
tailored by choosing the appropriate copolymer composition. Increasing the CPH 
content results in slower release profiles, while the presence of CPTEG generates 
higher initial bursts and faster release. 
One of the most important issues related to the rational design of drug delivery 
carriers is their ability to maintain the biological activity of the different payloads (e.g., 
peptides, recombinant proteins) that they have to deliver. In this sense, previous 
research has studied the effects of polyanhydride degradation products on several 
proteins. Determan et al. 126 demonstrated the stability of tetanus toxoid (TT), ovalbumin 
(Ova), and lysozyme when incubated with anhydride (i.e., CPH and SA) monomers. The 
stability of Ova and bovine serum albumin (BSA) after encapsulation and release from 
CPH:SA microspheres was also shown by Determan et al 114. Torres et al. 117 studied 
the stability of lysozyme and Ova in the presence of degradation products of the 
CPTEG:CPH system and found that the CPTEG:CPH system preserves the structural 
integrity of these two proteins. 
These studies demonstrated the potential of polyanhydride carriers for controlled 
drug delivery and make them serious candidates for the design of efficacious drug 
delivery vehicles.  
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2.2.3 Polymeric Particle Fabrication 
As previously described, in order to improve the efficiency of drug delivery and 
targeting, biodegradable polymers have been fabricated into different devices to be 
used for controlled delivery. Of the different devices forms, microparticles and 
nanoparticles have gained much attention, due to their tendency to accumulate in 
inflammation areas 28, 81, 82, 84. A special interest has arisen in particulate systems for 
vaccine delivery because they facilitate injection. In this regard, nano and microparticles 
offer attractive properties.  
Microspheres are, in a strict sense, spherically empty particles. In addition different 
terms are commonly used to refer to microparticles, for example microbeads or beads 
are used alternatively. The term “microparticle” refers to a particle with a diameter of 1-
100 µm and it has become the most well studied device geometry for polymeric drug 
delivery. Nanoparticles were first developed around 1970. The term “nanoparticle” is 
used when the particle is <1 µm in size and they were initially devised for vaccines and 
anti-cancer drugs. Next, the most common fabrication techniques for polymeric micro 
and nanoparticles are briefly described.  
 
2.2.3.1 Microparticles 
Microparticles have been fabricated based on both natural occurring and synthetic 
polymers. The most common synthetic polymers used for microparticles fabrication are: 
polyesters (i.e., PLGA, PCL) 5, 8, 66, 100, 102, poly(orthoesters) 68, poly(alkylcyanoacrylates) 
35, poly(amino acids) 7, polyacrylamides 12, and polyanhydrides 98, 115-117, 128.  
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Four general techniques have been used to fabricate microparticles: (i) hot-melting, 
(ii) emulsion solvent extraction, (iii) phase separation processes, and (iv) spray drying or 
atomizing. 
The hot-melt technique involves heating the polymer and drug in a non-solvent 
above the melting point of the polymer. Particles are formed and dispersed by the use of 
mechanical stirring 109, 112. However this method is not ideal for encapsulating 
temperature sensitive drugs, such as proteins. 
In phase separation processes particle formation is triggered by addition of an anti-
solvent to a solution. This type of fabrication method has been applied especially for 
naturally occurring polymers (i.e., chitosan) 82. 
Solvent extraction is the most common method for polymeric microparticles 
fabrication. Oil-in-water (O/W), and water-in-oil (W/O) emulsions, and water-oil-water 
(W/O/W), water-oil-oil (W/O/O), and solid-oil-oil (S/O/O) double emulsions can be used. 
In the w/o/w method the drug (typically proteins) is dissolved in an aqueous phase and 
then emulsified with a larger volume of polymer dissolved in an organic solvent, typically 
methylene chloride. The inner emulsion is then added to a larger volume of water that 
contains a surfactant, usually PVA, and allowed to stir for several hours in order to 
extract the solvents. In the case of w/o/o or s/o/o the outer aqueous PVA phase is 
replaced with an immiscible organic, i.e. silicone oil 7, 131. 
In the spray-drying technique (Figure 2.12(a)), a solution stream breaks down into 
droplets while passing through a nozzle, followed by drying of the droplets prior to their 
collection 34, 82, 131. Benefits of spray drying include one step fabrication without the use 
of multiple solvents or secondary drying and easy scale-up for mass production. In the 
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case of spray-atomization (Figure 2.12(b)), the drug/polymer suspension passes 
through an atomizing nozzle. As the polymer/drug particles leave the nozzle they are 
collected in a bath of liquid nitrogen sitting on top of a frozen layer of non-solvent (e.g., 
ethanol) 115, 117, 131. The liquid nitrogen/non-solvent bath is then stored at -80ºC for three 
days, allowing the non-solvent to thaw and the frozen microparticles to fall into it. As the 
microparticles reside in the non-solvent the organic solvent (e.g., methylene chloride) 
slowly diffuses out, leaving solid spheres to be collected by filtration. More recently, 
microspheres of controlled size have been fabricated using acoustic excitation to force 
single droplet emulsions to precipitate in a passing non-solvent stream 132. 
 
 
Figure 2.12 Schematic representation of (a) spray-drying, and (b) spray atomization 
methods for polymeric micro/nanoparticle fabrication. 
 
2.2.3.2 Nanoparticles 
Several methods have been developed for preparing nanoparticles and are 
optimized on the basis of their physicochemical properties (e.g., size and hydrophilicity) 
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with regard to their in vivo fate after parenteral administration. The selection of the 
appropriate method for preparing drug-loaded nanoparticles depends on the 
physicochemical properties of the polymer and the drug. On the other hand, the 
procedure and the formulation conditions will determine the inner structure of these 
polymeric colloidal systems 7, 12, 31, 34, 82, 133. 
Preparation methods of nanoparticles are broadly divided into two categories, those 
based on physicochemical properties such as phase separation and solvent 
evaporation, and those based on chemical reactions such as polymerization and 
polycondensation. The first route is normally been used to produce nanoparticles from 
hydrophobic or crosslinked water-insoluble hydrophilic polymers (i.e., PLGA, PCL, 
poly(alkylacrylates, and polyanhydrides). For the second route, emulsion polymerization 
and precipitation polymerization methods have been described. 
Solvent precipitation techniques have been generally applied for hydrophobic 
polymers. Several techniques described in the literature are based on the mechanism of 
polymer precipitation. In a solvent extraction-evaporation technique, a hydrophobic 
polymer is dissolved in an organic solvent, such as chloroform, ethyl acetate, or 
methylene chloride and is emulsified in an aqueous phase containing a stabilizer (e.g., 
PVA) 12. Just after formation of the nanoemulsion, the solvent diffuses to the external 
phase until saturation. The solvent molecules that reach the water-air interphase 
evaporate, which leads to continuous diffusion of the solvent molecules from the inner 
droplets of the emulsion to the external phase; simultaneously, the precipitation of the 
polymer leads to the formation of nanospheres. 
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In the solvent displacement or nanoprecipitation method, the organic solvent 
selected is completely dissolved in the external aqueous phase, obviating the need for 
evaporation or extraction for polymer precipitation. The organic solvent diffuses 
instantaneously to the external aqueous phase, followed by precipitation of the polymer 
and drug 12. The advantage of this method is that no surfactant is employed; however, 
the method is limited to drugs that are highly soluble in a polar solvent.  
Recently, many studies have been published describing modified methods according 
to the specific properties of the polymer matrix. For example, PACA nanoparticles have 
been prepared by an emulsion polymerization method in which droplets of water-
insoluble monomers are emulsified in an aqueous and acidic phase that contains a 
stabilizer 12, 84, 86, 92. Another recent study used a modified water-oil-water double-
emulsion/solvent evaporation technique that could be tuned to fabricate nanospheres 
using polyanhydrides as polymer matrix 134. 
 
2.2.4 Particle Characterization 
Microparticles and nanoparticles as colloidal carriers mainly depend on the particle 
size distribution, surface charge, and hydrophilicity. These physicochemical properties 
affect not only drug loading and release, but also the interaction of these particulate 
carriers with biological membranes 12, 31, 35, 84. 
 
2.2.4.1 Particle Size Analysis 
Two techniques have been used to determine the particle size distribution of 
colloidal systems: Photon correlation spectroscopy (PCS) and electron microscopy 
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including both scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM). PCS is based on dynamic light scattering at constant temperature, 
and the method requires knowledge of the viscosity of the suspending fluid for an 
estimation of the average particle size and its distribution function 135. Quasi-Elastic 
Light Scattering (QELS) also offers an accurate procedure for measuring the size 
distribution of nanoparticles.  
SEM provides images of the particles to be measured and imaging software (e.g., 
ImageJ) can be used to determine size distribution. Images obtained with TEM can be 
used to determine the size of particles but also offers a more detailed analysis of shape 
and inner structure of the particles.  
 
2.2.4.2 Surface Charge and Hydrophobicity 
The surface charge of colloidal particles can be determined by measuring the 
particle velocity in an electric field. Laser light scattering techniques are fast enough to 
measure the surface charge with high resolution. The hydrophobicity of the 
nanoparticles can be determined by methods including the adsorption of hydrophobic 
fluorescent or radio labeled probes, two phase partitions, hydrophobic interaction 
chromatography, and contact angle measurements. Recently, XPS has been developed 
which offers the identification of chemical groups in a 5 Å-thick coat on the external 
surface of the nanospheres136. 
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2.2.5 Particles Properties: Consequences for their Biological Fate 
As mentioned before, the in vivo behavior of microparticles and nanoparticles as 
drug delivery carriers depends on properties such as particle size and surface 
characteristics (i.e., surface charge and hydrophobicity). These properties can affect not 
only the particle interaction with the payload that needs to be released, but also the 
barriers that they will encounter in the biological system.  
At various steps of the different fabrication methods described above, the payload 
(i.e., drug, protein, peptides, DNA) can be added and encapsulated in situ while the 
particles form. As described before, it is important to select the appropriate polymer 
matrix that possesses chemical properties that are compatible with the chemical 
characteristics of the drug. The release of encapsulated drug occurs via diffusion trough 
aqueous channels or pores within the polymer matrix or during surface or bulk erosion 
of the carriers. Both the percent of encapsulation and the release profile depend not 
only on the chemistry of the polymer matrix but also the shape and the size of the 
delivery device. In the case of particulate systems, size plays an important role in the 
biological fate of the carrier. A successful particulate delivery system may have high 
loading capacity to reduce the quantity of the carrier required for administration 31. In this 
sense, microparticles will offer a high encapsulation capacity. In addition, microparticle 
size seems to be adequate for administration through peritoneal delivery route, but 
injections of microparticles can be sometimes difficult and painful leading to patient non-
compliance while other delivery routes (i.e., intranasal) cannot be explored with 
microparticles because of their size.  
 	  
40 
The motivation to develop an alternative drug delivery system using nanoparticles 
instead of microparticles is based on several assumptions and observations. First, more 
administration routes can be explored for a more efficacious delivery. Second, the larger 
surface area to volume ratio of nanoparticles compared to microparticles should result in 
a faster polymer degradation and drug release. However, this effect might not be as 
pronounced as expected 7, 35. Third, particles having a size below 100 nm can evade 
mechanical filtration from the blood stream and accumulate in liver, spleen and kidneys, 
resulting in longer blood circulation times 7, 81. Fourth, nanoparticles are able to deliver 
payloads across a number of biological barriers, for example the blood-brain barrier 
(BBB) 133, different types of mucosa and epithelia 2, 12, and cell membranes for 
transfection applications 47. Finally, nanoparticles offer a large surface area that could 
be used for surface-modification for specific targeting 93, 134 (Section 2.4).    
The interaction of particles with their biological environment and electrostatic 
interaction with biological compounds occur due to the charge on the surface, e.g., a 
negative charge promotes the adsorption of positively charged drug molecules such as 
proteins. Apart from the size and the surface charge of the particles, the surface 
hydrophobicity determines the amount of adsorbed blood components, mainly proteins 
(opsonins). These will also have an effect in the in vivo fate of these delivery vehicles. 
Binding of these opsonins on to the surface of particulate devices, called opsonization, 
acts as a bridge between particles and phagocytes 90, 124. 
A detailed characterization of the properties of micro or nanoparticle-based delivery 
carriers and their interactions with biological components is extremely important in the 
design of adequate and efficacious delivery carriers.  
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2.3 Vaccine Adjuvants 
2.3.1 Introduction 
One of the most successful medical interventions in the reduction of disease caused 
by infectious agents over the last 200 years is the use of vaccines 137. A good example 
of this is the worldwide eradicated of the human smallpox virus through vaccination 138. 
Programs that include a childhood vaccination schedule have been implemented in 
different countries to eradicate diseases such as polio 139. In addition to human benefits, 
vaccines have been used in veterinary medicine to control and eradicate diseases such 
as pseudorabies virus 140. Therefore, vaccination is one of the greatest medical 
achievements in the 20th century.  
Even with all the advancements and improvements in the efficacy and 
implementation of vaccines over the past several decades, infectious disease still 
remains the largest cause of death worldwide; many of these diseases could be 
prevented by efficacious vaccination 140, 141. This shows that there are many challenges 
that still remain unsolved to derive the full benefits of immunization programs. These 
obstacles include the low level of understanding of the immune system and all the 
biological events that a vaccine will initiate in order to generate an immune response, 
the development of single-dose vaccines, methods to increase the poor immunogenicity 
of immunogens, and the ability to rapidly develop vaccines against emerging pathogens.  
Promising solutions include the development of new vaccine adjuvants or carries 
that enhance the effectiveness of vaccines. Although recent developments in synthetic 
and naturally derived adjuvants suggest that single-dose vaccines for many pathogens 
may be realized in the near future, no single adjuvant will be effective for all vaccine 
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applications. Therefore, it is important to design effective vaccine adjuvants which can 
be adjusted to different diseases. In order to do this, it is necessary to develop 
interdisciplinary science-based approaches.  
The next sections report and discuss the most common vaccination techniques 
employed during the past years as well as new approaches based on the use of vaccine 
adjuvants. Special attention is given to polymeric carriers as the new generation of 
vaccine adjuvants.  
 
2.3.2 Innate and Adaptive Immune Responses: An overview 
When designing vaccine systems, it is essential to have a detailed understanding of 
the complex interplay between the cells of the innate and adaptive immune systems. 
Protection from diseases includes the activation of both the innate and adaptive immune 
systems working together as an integrated system 138. The innate immune system is 
described by Janeway and Mezhitov as “a non-specific first line of defense of the 
immune system” and involves a variety of cells including phagocytic cells (i.e., 
macrophages and dendritic cells (DCs)), NK cells and the complement system 137, 138, 142. 
The components of the innate system use pattern recognition receptors (PRRs) (e.g., 
Toll-like receptors (TLRs), mannose receptor (MR) on macrophages, and C-type lectin 
receptors) to recognize pathogen-associated-molecular-patterns (PAMPs) present on 
foreign invaders 137, 138. The innate immune system has evolved two main functions: to 
react quickly to molecular patterns found in microbes, and to develop slowly, precisely 
targeted specific adaptive immune responses.   
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In contrast to the innate system, the adaptive system involves a more direct immune 
response in which antigen presenting cells (APCs) recognize specific antigen epitopes 
by specialized receptors. Then, APCs become responsible for the activation of killer T 
cells, helper T cells, and B cells that will provide an adequate immune response 138. The 
APCs responsible for connecting the innate system with the adaptive system are mainly 
DCs, which are present in blood and tissues in an “immature” state characterized by 
their phagocytic functions. After encountering pathogens or antigens, DCs migrate to 
lymph nodes (LN) where they “mature” increasing the surface expression of co-
stimulatory molecules (i.e., CD80, CD40, and CD86) and starting the release of 
cytokines 138, 143. Inside the DC, pathogens are degraded into small peptide fragments 
that will bind to Major Histocompatibility Complexes (MHC) to be displayed on the 
surface of the cell for T cell recognition 138, 144. There are two main pathways of antigen 
presentation. In the first pathway, MCH I molecules present antigenic peptides to CD8+ 
T cells, also known as cytotoxic T lymphocytes (CTLs), which are responsible for killing 
infected cells directly (cell-mediated immunity (CMI)). In the second pathway, antigen is 
presented by MHC II molecules to CD4+ T cells (T helper cells) which are classified as 
Th1 and Th2 138, 145. Th1-type immune responses are characterized by the production of 
cytokines, like interferon gamma (IFN-γ) and tumor necrosis factor beta (TNF-β), and 
generate a cell-mediated immunity 138, 145. An immune response of the type Th2 is 
characterized by the secretion of a variety of interleukins, such as IL-4, IL-5, IL-10, and 
activation of B cells to produce antibodies (humoral response), specially IgG1 138, 144. 
Figure 2.13 shows a cartoon representation for DC maturation and activation.  
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The induction of the appropriate immune response is necessary for a successful 
vaccination 146. 
 
 
Figure 2.13 Cartoon representation of dendritic cell maturation and activation and the 
resulting immune response pathways. 
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2.3.3 Current Vaccine Strategies 
Vaccines have been designed to mimic the immune response induced by an active 
infection, but by avoiding the effects of disease. To be effective, a vaccine must contain 
some portion of the disease-causing agent and may include an immune-enhancer (e.g., 
adjuvant). Generally, vaccine regimens include an initial dose that initiates immune 
responses that involve DCs, followed by booster doses that not only induce the 
activation of effector cells but also memory cells 138. Memory cells provide a faster 
immune response of greater magnitude 147. In a general way, vaccines can be classified 
into three categories: live, killed, or subunit. 
 
2.3.3.1 Live Vaccines 
Relative to other vaccines, those that consist of live, attenuated organisms, induce 
the most potent and lasting immune response in the host. These vaccines generally 
require the fewest number of inoculations, require no adjuvants, confer lifelong 
immunity, and can be delivered through the same route as the natural infection 148. One 
of the advantages of these vaccines is that they retain many of the natural microbial 
compounds, enhancing immunity.  
Attenuation, which is the reduction of the virulence capacity of the organism, is 
necessary so that these vaccines can be used in a safe way. There exist different 
strategies to attenuate organisms, like genetic changes to delete critical virulence 
attributes through repetitive passages (several 100 to 1,000 times) in a non-human host 
or in vitro. Some examples of this kind of vaccine are the Sabin oral polio vaccine and 
the Flu-mist 149. 
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However, modified live vaccination can cause the opposite effect because they can 
replicate in the host and generate an infection and reversion to the more virulent form. 
Another problem with this class of vaccines is that the live organism can spread and 
induce the disease in other non-vaccinated individuals 149. Even when live vaccines 
effectively induce both cellular and humoral immunity, they can cause severe reactions 
and their effectiveness also depends of their proper handling before administration 150-
152. 
 
2.3.3.2 Killed Vaccines 
To produce this kind of vaccine the whole organism is treated with either heat or 
chemicals, so that the organism is not able to replicate in the host but the cellular 
integrity of the pathogen is preserved. Killed vaccines can also induce a potent humoral 
immune response but without the risk of live vaccines because the organism cannot 
replicate and therefore, cannot cause infection, spread to other individuals or revert to a 
virulent form 148. Another advantage is that these types of vaccines possess a longer 
shelf life and are less sensitive to changes in storage conditions 153. Some of the 
limitations of killed vaccines are that they require multiple doses to achieve protective 
immunity and as with live vaccines, are associated with high incidence of side effects, 
such as high fever, severe pain, redness, and swelling 154.  
 
2.3.3.3 Subunit or Recombinant Protein-Based Vaccines 
Subunit vaccines contain only a portion of the infection agent; some examples of 
these kinds of vaccines are those against diphtheria and tetanus toxoids 148. These 
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vaccines offer several advantages including the reduction or elimination of side effects. 
However, subunit vaccines lack strong immunogenicity and require multiple doses for 
protection. Usually to reverse the poor immunogenicity that subunit vaccines offer, they 
are delivered with an immunoenhancer (adjuvant) 155. Subunit vaccines are easier to 
produce and safer than live vaccines, but require an efficacious adjuvant 154, 156.  
 
2.3.4 Current Vaccine Adjuvants 
2.3.4.1 Ideal Adjuvant Properties 
Adjuvants are functionally defined as components added to vaccine formulations that 
enhance the immunogenicity of antigens in vivo 137. The functions that an adjuvant 
performs are: provide an adequate environment for the antigen including an antigenic 
reservoir for slow release, facilitate targeting of the antigen to APCs, increase 
phagocytosis, and modulate and enhance the type of immune response induced by the 
antigen alone 157-160. They may also provide the danger signal that the immune system 
needs to respond in the case of an infection 138.  
In order to provide an adequate environment for the immunogen, the antigen is 
entrapped in a non-dissolving or slowly dissolving substance; alums and their gel-like 
matrix are examples of adjuvants that create a slow-release environment 156. This 
adjuvant function can also be achieved by incorporating the antigen into biodegradable 
polymeric micro or nanoparticles. As the particles degrade, the antigen is released.  
Adjuvants have different ways of enhancing the immune response; by targeting the 
antigen to immune cells, enhancing phagocytosis, and/or activating APCs. There are 
some properties of the antigen carriers that accomplish this function. For example, 
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lipopolysaccharide (LPS), a bacterial-derived immunostimulant, interacts directly with 
the innate system via LPS receptors like CD14 161. 
Immune modulation can be influenced by many factors including the route of antigen 
delivery, antigen dose, duration of antigen presentation, number of immunizations and 
their frequency and even the inclusion of co-stimulatory molecules with the antigen 162. 
Adjuvants can affect all these factors, and that is why it is important to use the correct 
adjuvant to generate the desire immune response 162. 
Currently, adjuvants have been divided into two classes based on their dominant 
mechanisms of action: i) immune potentiators which activate innate immunity directly 
(e.g., cytokines) or through PRRs (e.g., bacterial components 161), and ii) delivery 
systems which may concentrate and display antigens in repetitive patterns, target 
vaccine antigens to APCs and help co-localize antigens and immune potentiators (e.g., 
polymeric micro and nanoparticles)137, 160. 
Thus, both immune potentiators and delivery systems can serve to augment antigen-
specific immune response in vivo. Even so, for each specific situation there will be a set 
of characteristics that would constitute an ideal vaccine adjuvant. Within those 
characteristics are the particular delivery route, the desired immune response, the 
pathogen, and the stage of the disease. For example, for subunit vaccines it is likely that 
a combination of delivery systems, immune potentiators, and isolated antigens will be 
required to elicit optimal immune responses.  
The use of vaccine adjuvants should reduce the amount of antigen necessary to 
generate an immune response. On the other hand, a good vaccine adjuvant must 
stimulate the desired immune response without toxicity or the induction of excessive 
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inflammation 163. The production of an appropriate cytokine profile to the desired 
immune response is another characteristic of a good vaccine adjuvant 164, 165. 
Other factors such as stability over time and the ability to provide immunity with a 
single dose should be considered in the selection of an ideal adjuvant 166.  
 
2.3.4.2 Current Adjuvants 
Table 2.1 presents the different categories of adjuvants that are commercially 
available or in development. Most of the currently licensed adjuvants were developed 
using empirical methods, thus they are not optimal for many of the challenges in 
vaccination today.  
 
Table 2.1 Current adjuvants that are commercially available or in development. 
Adjuvant category Examples 
Mineral salts Aluminum and calcium salts 162, 168, 169 
 
Emulsions and surfactant-based 
formulations 
 
MF59, AS02, ISA-51 and ISA-720 172 
Microbial derivatives Monophosphoryl lipid A, CpG 
oligonucleotides, heat labile toxin from 
Escherichia coli, lipoproteins 173, 174 
 
Cells and cytokines Dendritic cells, IL-12 and GM-CSF 176 
 
Particulate delivery vehicles Micro and nanoparticles, immunostimulatory 
complexes; liposomes, virosomes, virus-like 
particles 127, 176 
 
Alums are salts of aluminum hydroxide or aluminum phosphate and were the first 
compounds used as adjuvant in 1926 167. Alum-based vaccines are prepared by 
suspending the antigen in a phosphate buffered solution and allowing the antigen to 
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adsorb to the aluminum hydrogel 163. This type of adjuvant may not be ideal for antigens 
with low immunogenicity (i.e., small peptide vaccines) 162, and its use induces IgE 
production which is associated with allergy 163. Other disadvantages of alums are their 
limited shelf lives due to the impossibility of lyophilizing them 168, and their non-suitability 
for oral or intranasal immunization 162.  
Calcium phosphate has been used for many years as adjuvant in the DTP 
(diphtheria-tetanus-pertussis) vaccine 163, 169. It is used in the delivery of allergens 
because it does not induce IgE production 169.  
Freund’s complete (CFA) and incomplete (IFA) adjuvants are very potent systems 
and are comprised of a water-in-mineral oil emulsion with the emulsifier mannide 
monooleate 170. Recent studies have been shown that CFA induces a very strong 
immune response while IFA is thought to induce tolerance 170. 
Introduced in Europe in 1997, MF59 is an oil-in-water microemulsion that has been 
shown to stimulate a strong Th2 biased immune response to a large number of antigens 
and may be more suitable for subunit vaccines than alum 171. MF59-based vaccines that 
have incorporated recombinant antigens induce high titer antibody responses and T cell 
proliferative responses 172. 
Bacteria-based adjuvants have also been widely used. Lipopolysaccharide (LPS) is 
known to stimulate the production of cytokines and chemokines that control DC 
movement and maturation 173. But even with its potency to induce immune responses, 
LPS is used only as experimental adjuvant because of its toxicity. Monophosphoryl Lipid 
A (MPLA) can bind to Toll-Like Receptor 4 (TLR-4) initiating the synthesis of interleukin-
12 (IL-12) and interferon-gamma (IFN-γ) which induce DC maturation, migration and 
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initiation of the T cell response 174. Bacterial toxins have a high degree of 
immunogenicity and immune enhancing capabilities as well as a high cellular receptor 
specificity. These characteristics have led researchers to study their potential as vaccine 
adjuvants. Pertussigen and Cholera enterotoxin are some examples of bacterial toxins 
that are currently under study 175.  
Virosomes and virus-like particles are generated by inserting viral fusion proteins 
into pre-formed liposomes 176. These particles allow the induction of both humoral and 
cell mediated immunity because they deliver the antigen directly into the cytosol of the 
target cell by mimicking infectivity of native viruses 176. Vaccines for human influenza 
and human papiloma virus are based on these adjuvants 137, 176. 
 
2.3.5 Biodegradable Polymers as Vaccine Adjuvants 
Biodegradable polymers have characteristics that make them promising for the 
development of single dose vaccine adjuvants 177, 178. Some of the advantages of these 
compounds are: the ability to stabilize and sustain the release of antigens by a 
controlled mechanism over extended periods of time, which eliminates the need of 
booster doses, and their immunomodulatory properties that can be achieved with the 
appropriate polymer chemistry 179.  
Polymeric particles can be administered by various routes (e.g., intramuscularly, 
subcutaneously, intranasal or orally), and they have been shown to induce immune 
responses in all these regimen 174. The biggest advantage of these materials is that 
because they are biodegradable, they do not have to be removed after administration 
because they degrade into compounds that are not toxic for the body 180.  
 	  
52 
Currently there are two main classes of biodegradable polymers that have been 
studied for controlled release vaccines: polyesters 102, 179, 181-185 and polyanhydrides 114, 
117, 118, 127, 178, 186-191. 
 
2.3.5.1 Polyesters 
Lactic acid and glycolic acid (e.g. poly(lactide-co-glycolide),PLGA) have been utilized 
in biomedical applications and recently have been proven effective as vaccine delivery 
vehicles for the induction of protective immunity in laboratory animals 179, 182, 183, 192, 193. 
Specifically, microparticles based on polyester chemistries have been widely studied 
and recently, nanoparticles are being used as vaccine adjuvants 194, 195. PLGA has the 
benefit that its degradation products are naturally occurring metabolites and are 
absorbed by neighboring cells. However, these degradation products create an acidic 
environment that does not benefit the stability and immunogenicity of proteins 8. 
Antigen-loaded PLGA microparticles have been shown to enhance phagocytic 
uptake by APCs (i.e., DCs) 184. These particles also enhance cytokine production and 
cell proliferation in in vitro experiments 181.  
A large number of antigens (i.e., Yersinia pestis antigens, ovalbumin, tetanus toxoid, 
malaria antigens, influenza antigens, cancer cell antigens) have been encapsulated in 
PLGA, PLA, or PGA variant microparticles and nanoparticles resulting in the induction of 
immune responses 175, 177. Encapsulation of antigen in PLGA microspheres was shown 
to enhance antigen presentation via MHC class I, increasing the activation of T-cytotoxic 
cells 102. However, most of these studies were conducted in vitro and with the inclusion 
of known Th1 immune response activators such as MPLA.  
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Even when different studies have shown the ability of PLGA microparticles to induce 
and modulate immune response, there are others that have shown low 
immunomodulatory efficacy by these materials. These can be due by variations in 
experiment conditions such as dose of antigen, method of encapsulation, route of 
immunization and/or size of the particles118, 182. For example, it is known that 
microparticles ≤10 µm in diameter are readily phagocytosed by macrophages and DCs 
and would enhance antigen presentation 127. It is important to remark that all this 
extensive research done with PLGA has not shown induction of an immune response in 
humans; therefore there is still an amount of experimental research that need to be 
accomplished in order to determine the effectiveness of this vaccine delivery system.  
 
2.3.5.2 Polyanhydrides 
Polyanhydrides are surface erodible polymers that have been used as carriers for 
controlled drug delivery 110, 127, 178, 187, 188, 191 and are approved by the FDA for biomedical 
applications. These biomaterials degrade into carboxylic acids that are non-cytotoxic 112. 
These polymers have shown a controlled release profile that ranges from days to 
months, depending on the copolymer composition and this is because of their surface 
erosion mechanism 113, 114, 117, 128, 130. Other features of polyanhydride delivery systems 
are: improved adjuvanticity 129, 189, antigen stabilization 125, 126, 128, and enhanced immune 
responses 127, 178. 
Figure 2.14 compares the adjuvant properties of polyesters and polyanhydrides. 
The main advantage of polyanhydrides over polyesters is that polyanhydrides offer 
protein stability after encapsulation, release, and storage from micro and nanoparticles. 
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The hydrophobicity and surface erosion properties of these biomaterials prevent water 
from penetrating to the interior of the particles increasing protein stability and providing a 
sustainable release profile 114, 128. In addition, polyanhydride degradation products are 
less acidic than those of polyesters, which also contributes to the enhanced protein 
stability 117, 125, 126. 
 
Figure 2.14 Comparison between the adjuvant properties of polyesters and 
polyanhydrides. 
 
Even though polyanhydrides have not been extensively studied as adjuvants, recent 
in vivo studies with antigen-loaded microparticles based on the anhydride monomers 
sebacic acid (SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) demonstrated that 
tetanus toxoid (TT) maintains its immunogenicity and antigenicity following 
encapsulation 178. Furthermore, the type of immune response generated, Th1 vs. Th2, 
was evaluated by antibody isotype production, resulting in observations that suggest 
that different copolymer chemistries induce different immune responses. These studies 
indicate that polyanhydrides are promising adjuvants for single dose vaccines.  
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Current research has focused on the CPH:SA system as well as on the adjuvant 
properties of novel amphiphilic polyanhydride chemistries that include copolymers of 
CPH and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 110, 120, 121. These studies 
included in vitro adjuvanticity experiments that have shown the ability of CPH:SA and 
CPTEG:CPH-based micro and nanoparticles to activate APCs (i.e., DCs). These studies 
showed an adjuvant chemistry effect on cell surface marker expression (i.e., MHCI, 
MHCII, DC40, CD86) and cytokine production (i.e., IL-6, IL-12, TNF-α) by murine DCs 
129, 189. A chemistry effect has been also observed in micro and nanoparticles 
phagocytosis experiments conducted with human monocyte 196 cell lines and murine-
derived DCs 189. Finally, in vivo studies are ongoing to evaluate the efficacy of these 
polyanhydride systems as vaccine delivery vehicles for different antigens (i.e., Yersinia 
pestis antigens, anthrax antigens, ovalbumin, influenza antigens). 
The design of improved adjuvants can lead to the solution of various problems 
related to effective vaccine design, and in this context, biodegradable polymer particles 
(i.e., polyanhydride-based) may play an important role, especially because of their ability 
to modulate the immune response. More in vitro and in vivo studies with these adjuvants 
are necessary to understand the role that chemistry and particle size play in the 
modulation of immune response and to design more efficacious vaccines. 
 
2.4 Targeted Vaccines Strategies 
2.4.1 Introduction 
The ultimate goal of vaccination is to stimulate a specific immune response and to 
induce a long lasting immunologic memory to protect against subsequent disease 137, 197. 
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Vaccines are considered to be one the most successful medical interventions against 
infectious diseases (i.e., small pox, tetanus, diphtheria, malaria, hepatitis B, etc) 198. 
Even so, many significant obstacles in the design of effective vaccines remain. These 
include improving current suboptimal vaccines, developing new vaccines for disease for 
which vaccines have not yet produced, and responding rapidly to newly emerging 
pathogens 199.  
In order to design efficacious vaccines many key elements are required. First, an 
antigen is required to which a memory immune response will be developed. An 
important aspect in the selection of adequate antigens for a specific pathogen is its 
presentation and this includes the preservation of its structural conformation (i.e., 
preservation of adequate epitopes) for induction of specific functional antibodies 200-202. It 
is well known that an effective adaptive immune response is necessary to fight pathogen 
infection and it is now known that the innate system plays a crucial role in the evolution 
of the adaptive immune response 203. Thus, inclusion of immune potentiators (i.e., 
vaccine adjuvants), which trigger early innate immune response to aid in the generation 
of robust and long-lasting adaptive immune responses, is crucial to vaccine 
effectiveness. Finally, delivery systems that target the vaccine to appropriate cells of the 
immune system will ensure optimal stimulation 172.  
In the search for novel platforms for a more effective vaccine design, researchers 
have identified different immune targets that could be used to generate the require 
immune response. The selection of the appropriate target, as well as the selection of the 
target-agent (i.e., target strategies), will depend greatly upon the type of disease to 
confront. As an example, the effectiveness of cancer treatments will depend on their 
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ability to target and kill cancer cells while affecting as few healthy cells as possible 195. In 
other cases, the success of novel vaccine technologies will depend on an adequate 
antigen presentation by antigen presenting cells (APCs) (i.e., macrophages, dendritic 
cells, B cells) that can activate effector cells of the immune defense 137, 197, 204, 205. It is 
crucial for the design of novel targeted vaccine platforms to have a clear understanding 
of the specific immune cell to target and the downstream activation mechanisms.  
Targeted vaccines that can direct their action to a specific immune target represent a 
potential solution to overcome the remaining obstacles in the design of effective 
vaccines. Many strategies have been developed in the targeted vaccine area, and the 
most studied one involves the use of monoclonal antibodies that are recognized by 
specific receptors on immune cells directing antigens to the place of action 206. 
Monoclonal antibodies can be delivered together with the antigen or by a different 
administration route to target specific receptors on immune cells; however, a new 
approach focuses on the chemical attachment of macromolecules to antigens (i.e., 
monoclonal antibodies, synthetic peptides, carbohydrates).  
As mentioned before, the inclusion of vaccine adjuvants can help in the stimulation 
of an immune response 207, 208. Four major reasons have turned research efforts towards 
the development of new adjuvants. First, single dose vaccination is desirable, especially 
when considering the necessity to deliver health care to developing countries 209. 
Second, the use of many protein and peptide based antigens requires an adjuvant. 
Even when such antigens have shown to be more safe than traditional vaccination 
methods (i.e., live and killed vaccines 191), they are poorly immunogenic and need the 
inclusion of effective adjuvant 210. Third, a better understanding of innate immunity has 
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drawn attention to the mechanism(s) of adjuvanticity and guided new design 
approaches 211-213. Finally, it has been recognized that adjuvants (mimicking pathogens) 
can direct the nature of the immune response as well as its magnitude207, 214-216.  
Polymeric micro and nanoparticles have shown to be effective as delivery carriers 
and have properties that make them ideal as vaccine adjuvants 11, 28, 92, 152, 175, 177, 181. 
Engineering these particle-based vehicles (i.e., controlled antigen delivery, size 
manipulation, and surface modification) can induce passive or active targeting, leading 
to an enhanced and specific immune response. The use of these novel biomaterial-
based platforms has clear potential for the design of effective targeted vaccines. The 
next sections described the current options for targeted vaccines and show the potential 
of functionalized-polymer particles for the design of effective vaccines against a new 
range of diseases.  
 
2.4.2 Immune System Targets 
Currently, vaccines act mainly through the humoral arm of the immune system (i.e., 
antibody-mediated), but this does not seem to be sufficient to offer protection from many 
diseases. Many chronic diseases, including cancer, malaria, hepatitis, HIV, and 
tuberculosis are better defended against though cell mediated immunity, which indicates 
that a balanced immune response is desired 217.  
In order to generate new strategies that can provide optimal immune responses, it is 
necessary to have a better understanding of the immune system components and their 
functions in the disease of interest. This knowledge will allow for the identification of 
immune targets and will guide the rational design of vaccines.  
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2.4.2.1 Cancer cells 
Current cancer therapy involves intrusive processes including chemotherapy, and 
surgery to remove the tumors if possible, followed by more chemotherapy and radiation 
195. Lately, a more important role has emerged via immunotherapy (i.e., cancer 
vaccines) as a treatment for cancer. The selection of the cancer treatment to apply to a 
specific cancer patient depends on the particular cancer cell to attack. In all cases, the 
effectiveness of the treatment is directly related to the ability of the treatment to target 
and eliminate cancer cells while reducing the number of healthy cells affected.  
Research in cancer therapy has identified different properties of cancer cells that can 
be used to target treatments to the specific tumor site. The first step in order to target 
cancer cells is to engineer technologies that are able to avoid the reticuloendothelial 
system (RES) (i.e., liver and spleen) and ascertain transport to the solid tumor from the 
bloodstream 218. Cancer’s own structure is also used to target treatment to specific 
cancer cells. In many cases, cancer cells overexpress particular antigens on their 
surfaces and these antigens become ideal targets or drug delivery, but it is important 
that the targets for a particular cancer cell type can be identified with confidence and 
that they are not expressed in significant quantities anywhere else in the body 195, 219, 220. 
Angiogenesis is defined as a physiological process involving the growth of new blood 
vessels from pre-existing vessels and is a vital process for the development of a tumor 
mass 221, 222. This process is the result of numerous interactions between regulators, 
mediators and stimulatory molecules. Many angiogenesis stimulatory molecules have 
been identified (e.g., vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor, platelet-derived growth factor) 223. However, there are also different angiogenesis 
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inhibitors that can be used to regulate angiogenesis as a target strategy. Some 
examples of angiogenesis inhibitors are the interferon family, thrombospondin-1 and -2, 
and protein fragments such as angiostatin and endostatin 224, 225. Finally, targeting of the 
tumor vasculature can be also used as a strategy to target delivery to a wide range of 
tumor types 224, 226.  
Developing strategies to target these different properties of cancer cells can lead to 
adequate design of immunotherapy for cancer treatment.  
 
2.4.2.2 Dendritic cells 
Dendritic cells (DCs) have emerged as the most potent antigen-presenting cell 
because of their unique T cell stimulatory capacities 176. In their immature state, DCs 
can efficiently take up antigens, and then process them through both MHC class I and II 
which are required for the activation of CD8+ cytotoxic T lymphocytes (CTL) and CD4+ T 
helper cells, respectively 191. In order to activate T cells, DCs have to undergo 
maturation and migrate to lymphatic organs. Antigen recognition can initiate DC 
maturation and therefore induce T cell differentiation. Normally, the immune system’s 
response to a pathogen initiates because they share similar structures known as 
pathogen-associated molecular pattern (PAMPs), which enable their recognition 227, 228. 
DCs express pattern recognition receptors (PRRs) that interact with PAMPs leading to 
DC activation and secretion of cytokines that can recruit other cells creating an 
inflammatory environment that consequently leads to an adaptive immune response 137, 
229. PRRs include Toll-like receptor (TLRs) as well as non-TLRs, retinoic acid-inducible 
gene I-like receptors and C-type lectin receptors (CLRs) 227, 228.  
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So far the most studied PPRs have been TLRs and this is mainly because eleven 
such receptors have been identified in humans 230-232. TLR signaling plays an important 
role in determining the quality of the T cell response. For example, the use of 
lypopolysaccharide (LPS), which is a TLR4 ligand, leads to a preferential cell-mediated 
response (TH1) 233, 234. Table 2.2 shows some of the identified TLRs and their ligands. 
The role of TLRs in the initiation of innate immune response makes them potential 
targets for vaccines by using their ligands as vaccine adjuvants.   
 
Table 2.2 Toll-like receptors and their ligands 137, 236. 
Toll-like receptors Ligands 
TLR1 Bacterial lipoproteins from Mycobacteri, 
Neisseria 
TLR2 Lipoproteins, glycolipids, 
lipopolysaccharide 
TLR3 Viral double-stranded RNA 
TLR4 Bacterial lipopolysaccharide 
TLR5 Bacterial flagellins 
TLR6 Yeast zymosan particles, lipotechoic acid, 
lipopeptides from mycoplasma 
TLR7 Single-stranded RNA, synthetic 
compounds such as loxoribine and 
bropirimine 
TLR8 Single-stranded RNA 
TLR9 CpG oligonucleotides 
TLR10 Unknown 
TLR11 Bacterial components from uropathogenic 
bacteria 
 
 	  
62 
C-type lectin receptors bind sugars (i.e., mannose, fucose, and glucan) in a calcium-
dependent manner using highly conserved carbohydrate-recognition domains 228, 235. 
CLRs exist both as soluble and transmembrane receptors that function as PRRs. 
Together, these CLRs recognize most classes of human pathogens (i.e., viruses, fungi, 
and mycobacteria) 197, 227, 235, 236. Recognition by CLRs leads to the internalization of the 
pathogen, its degradation and subsequent antigen presentation 237 and these properties 
are important for vaccine efficacy. However, it is believed that targeting of the signaling 
pathways of CLRs can be more powerful to tailor the immune response. These signaling 
pathways are complex processes that depend on crosstalk with other PRRs (i.e., TLRs), 
the ligand (i.e., carbohydrate specific signaling pathway) and the DC subset 235, 238-240. 
Some examples of CLRs that are expressed by DCs are the mannose receptor 241-245, 
DEC-205 246-249, DC-SIGN 250-254, Dectin-1 205, 228, 235, 255, 256, and Dectin-2 238, 257. Table 
2.3 offers more complete information about the CLRs, the cells that express these 
receptors, and their ligands. Even while research on CLRs is relatively new and most of 
their ligands are not yet identified and their mechanism of action is unclear, they 
represent a promising opportunity to be used in the design of targeted vaccines.  
Fc family receptors (i.e., FcγRs, FcεRs) 258-260, integrin receptors (i.e., CD11c) 261 
and the TNF-receptor superfamily (i.e., CD40) 262, 263 can be also used for DC targeting 
purposes. The diversity of DC targeting makes it one of the most recurrent strategies for 
the design of targeted vaccines.  
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2.4.3 Current Targeting Strategies 
2.4.3.1 Antibody-Targeted Vaccines 
The high binding and specificity of antibodies are ideal properties for delivering a 
payload to target cells. Monoclonal antibody (mAb)-based therapies have become an 
important part of the treatment of patients with cancer, autoimmune, and infectious 
diseases.  
 
Table 2.3 C-type lectin receptors and their ligands. 
Receptor Expression by cells Ligands Function 
Mannose Receptor 
(CD206) 241-245 
Dendritic cells (DCs), 
Langerhans cells 
(LCs), monocytes, 
macrophages 
Mannose, fucose 
and sulfate 
sugars 
Phagocytosis and 
antigen 
presentation 
DEC-205  
(CD205) 246-249 
DCs, LCs, thymic 
epithelial cells, NK 
cells, B cells and T 
cells 
Unknown Endocytosis and 
antigen 
presentation 
DC-SIGN  
(CD209) 250-254 
DCs, macrophages HIV-1, SIV, 
mannan, ICAM-
2, ICAM-3 
T cell interaction, 
HIV-1 pathology, 
migration, antigen 
uptake 
Dectin-1 255, 256 DCs, LCs, monocytes, 
macrophages, 
neutrophils, B cells, 
subpopulation of T 
cells 
β-Glucan T cell interaction 
Dectin-2 238, 257 DCs, monocytes, 
macrophages, B cells 
and neutrophils 
High mannose Antigen uptake, 
induction of TNF 
and IL-6 production 
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In the case of cancer treatment, tumor-antigen specific mAbs are used to target 
chemotherapy drugs and/or tumor-growth inhibitors to cancer cells 195. There are many 
mAb-based cancer treatments that are approved by the FDA, for example Rituximab 
(Rituxan®) that consist of an anti-CD20 antibody to fight Hodgkins’s lymphoma 264. While 
cancer treatments try to kill cancer cells directly, cancer vaccines (like any other 
vaccine) look for the activation of the immune system to respond against the cancer 
cells.  
Antibody-targeted vaccines (ATVs) exploit the same targeting properties of 
antibodies, but are directed to normal cells of the immune system. Mainly, mAbs are 
used to deliver a cargo of antigens to APC (i.e., dendritic cells) with the goal of inducing 
or enhancing immunity to the antigen. With biotechnology advances, fusion proteins 
between antibodies and antigens can be constructed and used as target agents to 
different DC receptors 265. MHC molecules and Fc receptors (FcR) were the first targets 
of antibody-targeted vaccines. Based on the knowledge that FcRs mediated recognition 
of opsonized antigens by APCs 266-268, Snider et al. 268 targeted antigen specifically to 
FcRs for IgG or MHC molecules on APCs in vitro resulting in enhanced antigen 
presentation to T cells 268. Later, the same targets were evaluated in vivo corroborating 
a strong humoral response to the antigens targeted in the absence of adjuvants 205, 269, 
270. Studies that apply mAbs to target CD11c, which is expressed on DCs, resulted in 
high antibody titer responses 271, 272.  
ATVs have also explored CLRs as targets. For example, studies have demonstrated 
that targeting of tumor antigens to the mannose receptor (MMR) on monocyte-derived 
DCs using a human MMR-speific mAb allows for antigen-specific T cell proliferation 273, 
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274. Monoclonal antibodies specific to other CLRs (i.e., DC-SIGN 252, 275, 276, DEC-205 277-
279, Dectin-1 255, 280, 281, and Dectin-2 238, 282, 283) have shown promising results in directing 
different antigens to DCs in in vitro and in vivo studies. 
Even when the highest improvement in targeting strategies has been in the mAb 
area (i.e., ATVs), there are some disadvantages (e.g., high cost in mAb production) that 
have turned researches’ attention to the development of alternative approaches.  
 
2.4.3.2 Cell-Based Targeting 
Most of the efforts in DC targeting have been focused on ex vivo approaches. DCs 
were isolated for the first time ca. 1994 205. In ex vivo targeting, DCs are isolated from 
the blood of patients, then the cells are exposed, in vitro, to an antigen or other 
maturation stimuli (i.e. peptides, loaded with proteins or transfected with RNA encoding 
specific antigens), and, finally, re-injecting them into the patient 172, 208, 284-286. An 
example of DC-based therapy is in cancer immunotherapy. The first attempt to use cell-
based targeting in cancer immunotherapy was to directly take tumor cells and conjugate 
them with antibodies that are specific for certain tumor antigens and in this way direct 
the antibody-based therapy to cancer cells and not to healthy cells 195. Other 
approaches have used DC cell-based therapy for the creation of cancer vaccines. 
Several clinical trials have evaluated the effect of DCs that have been transfected with 
tumor-derived RNA or even fused with tumor cells; these tumor-hybrids have been able 
to induce antigen-specific T cell responses 287, 288. Researchers have explored the option 
of using alginate gels as DC delivery vehicles, and recent studies have shown the ability 
of these alginate-DC systems to accumulate in tumors areas 288, 289.  
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Although encouraging results have been obtained with cell-based targeting, there 
are many medical, economic, and logistic complexities that make it difficult to apply this 
approach for many different diseases and especially when trying to get vaccination 
regimes to third world countries.   
 
2.4.3.3 Modified Antigens as Target Agents 
As described in Section 2.4.3.1 monoclonal antibodies have been used as targeting 
strategies, and they are usually delivered together or by different routes with the antigen 
of interest. However, other approaches are available including the chemical binding of 
mAbs to the antigen to form antibody-antigen complexes that can be delivered as target 
agents 249, 290-292. The targets remain the same (i.e., cancer cells, dendritic cells 
receptors), but having antibodies and antigens as one complex allow for a more direct 
delivery of the antigen.  
Antibody-antigen complexes have been used to target different antigens to FcRs 293, 
294, CLRs (i.e., mannose receptor 295-297, DEC-205 279, 298), and other receptors like CD40 
263, 299, and B7 300. Antibody-based modification can be performed in two ways: (i) by 
chemically attaching the antibody to the antigen (i.e., proteins and/or peptides), and (ii) 
by encoding the antigens with the desired mAbs and creating a DNA vaccine. The 
second approach has been widely used to target DC receptors. Chaplin et al. 300 used a 
DNA vaccine encoding detoxified phospholipase D fused to the CTLA-4 gene (a B7 
ligand); the DNA vaccine was tested in sheep and show to be partially effective against 
Corynebacterium pseudotuberculosis 300. 
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Not only have mAbs been linked to antigens for targeting purposes, synthetic 
peptides have been also used as target agents. In this approach, amino acids 
sequences are identified by immune cells and initiate an immune response 301. This 
targeting strategy has been especially applied to attack virus-based diseases (i.e., 
influenza) 302-304. 
Glycosylation is a natural enzymatic process that consists of the linking of 
saccharides to proteins, lipids, or other macromolecules 305. The majority of the proteins 
that are produced in the endoplasmic reticulum undergo glycosylation. These 
glycosylate proteins are part of the immune system in a soluble or membrane bound 
form and usually serve in the immune system to recognize sugar residues on the 
surface of pathogens 305. Taking advantage of this natural process, sugars (i.e., 
mannose, mannan, glucan) have been chemically linked to antigens to target some 
receptors on immune cells (i.e., C-type lectin receptors) 306, 307. In different Phase I 
clinical trials, patients with advanced carcinoma of breast, colon, and stomach were 
treated with mannan-conjugated MUC1 (tumor-associated antigen mucin 1) 308. Results 
showed that most of the patients were able to develop an antigen-specific humoral 
response while some of them also developed a cell-mediated response 308.  
Even when modified antigens have been successfully used as target agents in some 
clinical trials, they still have the disadvantage that protein-based antigens are generally 
poor immunogenic. Even when they can be targeted to specific cells by modifications 
(i.e., antibody, synthetic peptides and/or sugar attachment) their fragile structure can be 
affected during the delivery process (e.g., breaking linkages that keep the antigen and 
target molecule together) leading to a failed immune response.   
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2.4.4 Polymeric Particles as Target Agents 
Polymeric particles (i.e., microparticles and nanoparticles) may overcome the 
weakness shown by other strategies in order to design effective targeted vaccines. 
Different degradable polymers have been used to fabricated particulate delivery 
systems, including polyesters (i.e., poly(lactic-co-glycolic acid) (PLGA)), polyorthoesters, 
poly(alkylcyanoacrylates), and polyanhydrides 28, 29, 309. Polymeric particles have shown 
to be effective as drug delivery vehicles but also offer suitable properties to be 
considered as vaccine adjuvants. The physical and chemical properties of polymeric 
particles (i.e., chemistry of the polymer matrix, surface charge, surface hydrophobicity, 
size) have to be carefully selected and triggered in order to design effective carriers for 
efficacious targeted vaccines. This section reviews the strategies used to design 
polymeric particles as target agents for vaccine design.  
 
2.4.4.1 Passive Targeting 
The main property that attracted the attention of researchers to degradable 
biomaterials (i.e., synthetic polymers) is their ability to delivery payloads in a controlled 
manner 310-312. Antigens (i.e., proteins, peptides, DNA) can be encapsulated and/or 
conjugated to polymeric particles allowing for their protection and leading to the delivery 
of intact antigens that can be presented and processed by APCs (i.e., DCs) 114, 125, 128, 
207. The release of antigens from polymeric particles can be controlled by choosing the 
adequate polymer chemistry; for example, more hydrophobic chemistries offer long-time 
release profiles while the incorporation of hydrophilic motifs can accelerate the 
degradation of the polymer matrix and therefore the antigen release kinetics 76, 82, 116, 117, 
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128, 130. Tailoring the release kinetics by controlling the chemistry of the polymer matrix in 
particulate delivery systems has been used as an indirect approach (i.e., passive 
targeting) to target delivery of antigens to DCs because it allows for structurally intact 
delivery of the payload plus long term release simulating the effect of boosting doses in 
vaccination 137, 191.   
Before an antigen can be processed and presented by DCs, the particulate delivery 
vehicle has to be internalized by DCs. The mechanism by which DCs uptake and 
internalize particles will determine the subsequent processing and presentation pathway 
(i.e., MHC class I, MHC class II, or cross-presentation pathways) 208, 313-315. The uptake 
of particles can be partially controlled by their properties (i.e., particle size and surface 
charge); particle size appears to be a key determinant for the uptake and internalization 
of particles 208, 316. Particles having a size range between 0.5 to 10 µm (i.e., 
microparticles and large nanoparticles) are optimally taken up by phagocytosis 189, 196, 
317, 318. Both in vitro and in vivo studies have shown that microparticles (1-10 µm) and 
nanoparticles (200-600 nm) made of PLGA 183, 194, 317, 319-322 and polyanhydrides 189, 196 
(i.e., CPH:SA and CPTEG:CPH) are efficiently taken up by DCs. On the other hand, 
macropinocytosis is the uptake mechanism that DCs use for small nanoparticles (<50 
nm) 313, 323. Reddy et al. 324 showed that ca. 25 nm pluronic-stabilized polypropylene 
sulfide (PPS) nanoparticles are able to be efficiently transported into lymphatic 
capillaries and their draining lymph nodes targeting DCs present in lymph nodes 324. 
Particle size is also an option to target a specific and desirable delivery route; for 
example, for mucosal delivery it is known that particles between 100 and 500 nm in size 
are preferred because they can pass through the nasal cavity into the lungs 325. 
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After internalization, polymeric particles should be able to deliver the payload for 
processing by DCs. In order to achieve antigen delivery into the cytoplasm (to allow for 
MHC I presentation) a group of pH-sensitive biomaterials have developed and tested 326-
329. As an example, pH-responsive core-shell PDEAEMA nanoparticles have been 
developed that can achieve delivery of small molecules and proteins to the cytosol in 
DCs 329. 
While the passive-targeting strategies described above allow for a more direct and 
controlled delivery of payloads, in many cases, they are not sufficient to strategically 
target DCs because other APCs (i.e., macrophages) can also uptake particulate 
vehicles, but they are not effective at activating T cells 207.   
 
2.4.4.2 Active Targeting 
Strategies to preferentially target biomaterials to DCs in vivo will improve their 
efficacy as vaccine adjuvants. As mentioned before, nanoparticles can migrate into the 
lymphatic system and accumulate in DC-rich lymph nodes 208, 324. Other strategies have 
included the release of cytokines or chemokines that can attract DCs and initiate an 
immune response 330, 331. A novel strategy has been to conjugate molecules (i.e., mAbs, 
peptides, sugar), known as active targets, to the particle surface that will interact with 
specific receptors on DCs. One of the first attempts in surface modification of polymeric 
particles was the attachment of poly(ethylene glycol) (PEG) chains to the surface of 
micro and nanoparticles 92, 93. The reason behind the inclusion of PEG on particle 
surface is that the hydrophilic nature of this polymer reduces interactions between the 
polymer device and blood components (i.e., proteins) increasing its biocompatibility 124.  
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Figure 2.15 shows the possible uptake mechanisms of particulate devices by DCs 
and their relation with particle size was discussed in the previous section. There is a 
third mechanism (i.e., receptor-mediated endocytosis) that is also used for pathogen 
uptake and can be targeted for micro and nanoparticle uptake. Receptor-mediated 
endocytosis can be achieved by targeting specific receptors on DCs. As mentioned 
before, a variety of TLRs and CLRs and their functions have been identified 137, 228, 235 
(Tables 2.2 and 2.3) and many of them are involved in antigen uptake and presentation 
(i.e., receptor-mediated endocytosis, and DC maturation) and can, therefore, be used as 
targets to enhance and direct the resulted immune response. Some biomaterials used 
for vaccine delivery exhibit adjuvant properties that can help DC maturation. For 
example, PLGA 332-335 and polyanhydride 129, 189 micro and nanoparticles have shown to 
help DC maturation by the upregulation of maturation cell surface markers (i.e., CD40, 
CD86, CD80, MHC II). A second attempt to improve antigen uptake and presentation 
(including DC maturation) is the functionalization of the particle surface for targeting 
purposes. 
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Figure 2.15 DC-particle interactions for antigen uptake and processing: particle 
internalization through phagocytosis or micropinocytosis (size-dependent), particle 
internalization through receptor-mediated endocytosis (interaction of functionalized 
particles and pattern recognition receptors (e.g., C-type lectin receptors), conjugation of 
molecular danger signals to induce DC maturation (interaction of functionalized particles 
and pattern recognition receptors (e.g., Toll-like receptors). Particle uptake and 
internalization end in DC maturation and migration as well as antigen specific T cell 
activation.  
 
 The synthesis of functionalized polymeric micro and nanoparticles is a relatively 
new area and it has been mainly focused on the physical (i.e., adsorption) and chemical 
(i.e., chemical linking) of mAbs specific to DCs receptors 261, 336-340. CLRs (i.e., DEC-205, 
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and the mannose receptor (MMR)) have been targeted using functionalized particles 
that include anti-DEC-205 261 or anti-CD206 336-338, 341 on their surfaces. CLRs have 
carbohydrate recognition domains, and therefore, can be also target sugar residues. 
Copland et al. 338 showed that DCs can internalize mannosylated liposomes at a higher 
degree than free antigen or neutral liposomes resulting in a more efficacy presentation 
to T cells 338. Jiang et al.341 performed in vitro and in vivo studies that showed the 
potential of mannosylated chitosan microparticles to target the mannose receptor in 
alveolar macrophages, and these results are important for intranasal administration 341. 
Sugar-based functional micro and nanoparticles have been rarely explored using 
synthetic polymers because of the difficulty of solid-phase coupling reactions involving 
sugars. In one example, polyesters and poly(alkylcyanoacrylate) (PACA) nanoparticles 
decorated with polysaccharides (i.e., dextran, and chitosan) were fabricated, but the 
targeting properties of these particles were not tested 342.  
Another novel and rarely applied strategy for the active targeting of immune cells is 
the chemical inclusion of synthetic peptides on the surface of micro and nanoparticles. 
Townsenda et al.343 showed the in vitro efficacy of nanoparticles based on a novel 
PLGA-PEG-biotin polymer to which tetanus toxin C fragment (TTC) was surface-
conjugated, to selectively target neuroblastoma cells 343.  
Functionalized particles based on polymeric biomaterials present an intriguing 
opportunity to improve the design of targeted vaccine platforms.   
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2.5 Yersinia Pestis: An Overview 
2.5.1 Introduction and Facts about Y. Pestis 
Y. pestis is the etiological agent of bubonic and pneumonic plagues to which an 
estimated 200 million human deaths are attributable 344-346. History has recorded three 
plague pandemics. Although some of the numerous references to plagues in ancient 
texts may be attributable to Y. pestis, the cycles of plague epidemics between 541 and 
750 A.D. are called the first pandemic. The first plague, the Justinian plague, began in 
Egypt in 541 A.D. and quickly spread throughout Mediterranean Europe and the Middle 
East over the next 3 years 346. From the 8th to the 14th centuries, Europe appaers to 
have escaped most epidemic diseases, and it experienced a population increase. 
Plague spread from 1330 to 1346, probably from the steppes of central Asia along trade 
routes, and its introduction into Sicily in 1347 heralded the start of the second pandemic, 
which again encompassed the “known world” 347. The second pandemic is believed to 
have accelerated and in some instances directed great changes in economic, societal, 
political, religious, and medical systems and convictions. The third pandemic started in 
1855 in the Chinese province of Yunnan; troop traffic from the war in that area caused 
rapid spread of the disease to the southern coast of China 348. It was during the last 
period of the third pandemic when the causative agent of the pandemic, Y. pestis, was 
identified by Alexander Yersin 349, 350. By 1900, plague had spread throughout the world 
including the United States. The 1994 outbreak of two plague epidemics in western 
India was the latest demonstration that plague is not an eradicated disease 346. This 
disease, with reservoirs on nearly every major continent, exhibits an impressive ability to 
overcome mammalian host defenses.  
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After the last endemic events, considerable amount of research has been focused 
on the development of effective treatments to avoid the spread of Y. pestis. Even when 
antibiotics (e.g., Ciprofloxacin) can prevent mortality, they cannot avoid the spread of 
the bacteria and should be administered within 24 hours in order to be effective 350. 
Thus, new therapeutic and prophylactic strategies are necessary to correctly fight 
this disease. This become especially important given the bacteria’s potential as a 
bioterrorism agent. The ability of Y. pestis to be genetically modified to overcome 
vaccination may be used for the creation of bacteria-based terrorism weapons. 
Therefore, it is necessary to design adequate technology platforms (i.e., recombinant 
antigens, vaccine delivery vehicles) for the generation of effective and robust vaccines 
that allow for a quick reaction against possible plague spreads.  
 
2.5.2 Bubonic, Systemic and Pneumonic Plague 
Through the start of the third pandemic, transmission from urban rodents (especially 
rats) was the norm 351, 352. In the United States, transmission to humans occurs primarily 
via the bites of fleas from infected rodents 353, 354. Most human cases present three 
different forms: bubonic, systemic or pneumonic plague. Over the past 25 years, the 
majority of patients in the United States have had either bubonic or septicemic plague 
355. Case fatalities for untreated bubonic plague range from 40 to 60%, while untreated 
septicemic and pneumonic forms of the disease are invariably fatal 355.  
Bubonic plague is the classic form of the disease. Patients usually develop 
symptoms of fever, headache, chills, and swollen, extremely tender lymph nodes 
(buboes) within 2 to 6 days of contact with the organism either by flea bite or by 
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exposure of open wounds to infected materials 346. Bacteremia or secondary plague 
septicemia is frequently seen in patients with bubonic plague causing 50% of the 
deaths.  
Clinically, plague septicemia resembles septicemias caused by other gram-negative 
bacteria. The mortality rate for people with septicemic plague is fairly high, ranging from 
30 to 50% 346. 
Primary pneumonic plague is a rare but deadly form of the disease that is spread via 
respiratory droplets through close contact (i.e., 2 to 5 ft) with an infected individual. It 
progresses rapidly from a febrile flu-like illness to an overwhelming pneumonia with 
coughing and the production of bloody sputum 355, 356. The incubation period for primary 
pneumonic plague is between 1 and 3 days. In general, patients who develop secondary 
plague pneumonia have a high fatality rate. 
 
2.5.3 Vaccines against Y. Pestis 
As with many other diseases, the first plague vaccine consisted of the killed infection 
agent (i.e., Y. pestis) 357 and it was shown to provide immunity to bubonic plague, but, 
as expected, it caused severe side effects that made this vaccine unsuitable for human 
use. Another disadvantage of the killed-vaccine is that it did not provide protection 
against pneumonic plague 358, 359. 
In recent years, plague vaccine design, like that for many other diseases, has 
focused on the use of recombinant proteins such as F1 and V 360-363, which are found on 
the surface of the Y. pestis bacterium. Previous work demonstrated that the full length 
F1-V fusion protein offers protection in several animal models 345, 363, 364. Powell et al. 345 
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proposed a subunit vaccine in which the active component included an improved 
combination of the F1 capsular protein and V virulence antigen of Y. pestis. This antigen 
provided protection to wild-type mice and is now commercially available 345. Vaccination 
with F1-V monomer and its multimeric forms resulted in protection in mice after 
subcutaneous administration as shown by Goodin et al 363. In another study, it was 
shown that the same full length F1-V antigen provides protection in murine models, 
especially when different prime and boost routes are used; this study also highlights the 
importance of the inclusion of an appropriate adjuvant for immunization 364. Tripathi et al. 
365 developed a peptide-based vaccine, based upon the constructs between B and T cell 
epitopes of the F1 antigen of Y. pestis. In their work, a new F1-V construct, F1B2T1-
V10, was developed and it consists of three F1 immunogenic epitopes (B1, B2 and T) 
and the V protein without the interleukin-10 inducing sequence (-V10). This recombinant 
antigen induced both cell-mediated and humoral immunity. The efficacy of these 
antigens could be enhanced by using vaccine adjuvants (i.e., polymer particles). 
 
2.6 Conclusions 
Micro and nanoparticles based on polymeric materials could be used as vaccine 
delivery vehicles. Both micro and nanoparticles offer different opportunities based on 
their interaction with the immune system that is triggered by physical and chemical 
properties like polymer chemistry, size, and surface charge. Different natural and 
synthetic polymers can be used for particle fabrication; however, the unique properties 
of polyanhydrides (i.e., surface erosion, amphiphilicity, controlled release kinetics) make 
them excellent candidates for vaccine adjuvants. A direct target of these novel delivery 
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carriers to immune cells (i.e., dendritic cells) responsible for the initiation of an immune 
response can be achieved by the functionalization of the surface of the particle. These 
strategies can be combined and optimized for the design of novel vaccine platforms to 
convey protection against current and emerging diseases.  
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CHAPTER 3 
Research Objectives 
The overall goal of this research is to design innovative platforms for targeted 
vaccine delivery based on polyanhydride particles that can result in efficacious immune 
responses. In order to achieve this goal, a transdisciplinary approach was adopted by 
combining concepts from biomaterials, nanotechnology, carbohydrate and protein 
chemistry, molecular biology, immunology, and computational analysis. This rational 
pathway to the design of vaccine delivery platforms combines passive and active 
targeting strategies. The specific goals (SGs) of this research are: 
 
SG1: Evaluation of stabilization and release mechanisms of protein antigens from 
polyanhydride particles. 
SG2: Determination of serum protein adsorption patterns on polyanhydride particles and 
their effect on in vitro interactions with antigen presenting cells.  
SG3: Design and characterization of novel targeted vaccine delivery vehicles based on 
carbohydrate-functionalized polyanhydride particles and mechanistic evaluation of their 
interactions with antigen presenting cells.  
SG4: In vivo evaluation of immune responses induced by loading novel galactose-
containing carbohydrate modified F1-V antigen within polyanhydride particles to 
rationally design a protective vaccine against Y. pestis. 
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Passive strategies evaluated in this work involved the selection of appropriate 
polyanhydride chemistries for antigen stability, which is an important determinant of an 
effective immune response. To this end, a systematic assessment of antigen stability 
after release from polyanhydride particles was evaluated for several protein antigens 
including antigens candidates for Yersinia pestis (Chapter 4) and monoclonal antibodies 
with potential to be used in passive immunotherapy (Chapter 5). Additionally, serum 
protein adsorption patterns on polyanhydride particles were determined was evaluated 
(Chapter 6) and extended to study the effect of the chemistry-dependent adsorption of 
serum proteins on the uptake and activation of antigen presenting cells (Chapter 7).  
The knowledge obtained by the experiments designed to understand the role of 
particle chemistry on the adjuvant properties of polyanhydride particles and their 
interactions with antigens and immune system components was translated to generate 
novel active targeting strategies based on chemical modification of both the antigens 
and the vaccine carriers. Novel approaches to target specific receptors on antigen 
presenting cells and/or specific uptake pathways were developed and evaluated. First, 
polyanhydride particles were functionalized with specific carbohydrates and their 
targeting capabilities were evaluated by activation studies of antigen presenting cells 
(Chapter 8). In this work, we also studied the mechanisms dictating the interaction of 
these novel materials with immune cells. A second active targeting approach was 
pursued by modifying a vaccine antigen (i.e., F1-V) attaching novel galactose-containing 
carbohydrate (αGal) epitopes in Chapter 9. This technology was combined with the use 
of amphiphilic polyanhydride particles as a delivery system and evaluated in murine 
models for its capacity to induce robust immune responses.  
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Taken together, these approaches provide key insights into the rational design of 
targeted platforms that will enhance the induction of antigen-specific immune responses 
and facilitate the design of protective vaccines and therapeutic treatments.  
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CHAPTER 4 
 
Encapsulation into Amphiphilic 
Polyanhydride Microparticles Stabilizes 
Yersinia pestis Antigens 
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4.1 Abstract 
The design of biodegradable polymeric delivery systems based on polyanhydrides 
that would provide for improved structural integrity of Yersinia pestis antigens was the 
main goal of this study. Accordingly, the full length Y. pestis fusion protein (F1-V) or a 
recombinant Y. pestis fusion protein (F1B2T1-V10) were encapsulated and released from 
microparticles based on 1,6-bis(p-carboxyphenoxy)hexane (CPH) and sebacic acid (SA) 
copolymers and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and CPH 
copolymers fabricated by cryogenic atomization. An enzyme-linked immunosorbent 
assay was used to measure changes in the antigenicity of the released proteins. The 
recombinant F1B2T1-V10 was unstable upon release from the hydrophobic CPH:SA 
microparticles, but maintained its structure and antigenicity in the amphiphilic 
CPTEG:CPH system. The full length F1-V was stably released by both CPH:SA and 
CPTEG:CPH microparticles. In order to determine the effect of the anhydride monomers 
on the protein structure, changes in the primary, secondary, and tertiary structure, as 
well as the antigenicity of both Y. pestis antigens were measured after incubation in the 
presence of saturated solutions of SA, CPH, and CPTEG anhydride monomers. The 
results indicated that the amphiphilic environment provided by the CPTEG monomer 
was important to preserve the structure and antigenicity of both proteins. These studies 
offer an approach by which a thorough understanding of the mechanisms governing 
antigenic instability can be elucidated in order to optimize the in vivo performance of 
biodegradable delivery devices as protein carriers and/or vaccine adjuvants. 
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4.2 Introduction 
According to the American Association of Pharmaceutical Researchers and 
Manufacturers, approximately 80% of the biopharmaceutical products in development 
are protein-based 1. Many current efforts in biotechnology are focused on the creation of 
vaccines based on peptide or protein subunits and the design of new and effective 
delivery vehicles is a key objective in this area. One of the most challenging tasks in the 
development of protein pharmaceuticals is to deal with the physical and the chemical 
instabilities of proteins 2; these changes can be induced by factors such as temperature 
and pH 3, 4. The fragile three-dimensional structure of a protein must be maintained for 
biological activity and this could be lost due to physical as well as chemical instability 5. 
In order to avoid these problems, it is necessary to design vehicles that will minimize 
protein degradation, maximize its in vivo immunogenicity, and provide controlled release 
of the encapsulated protein 6, 7. 
It is well known that the mechanisms affecting protein stability are protein-specific 8; 
therefore, it is necessary to elucidate principles that will rationally select polymer 
formulations to stabilize the specific protein of interest. Preservation of protein structure 
is important in order to generate effective immune responses when recombinant or 
purified proteins are used in vaccines 9-11. Conformational stability of the immunogen is 
a key factor in maintaining the ability to induce T and B cell responses 10, 11. Instability of 
antigenic epitopes often favors induction of Th2 and allergic immune responses 
because of the antigenic low dose resulting from the degradation 10, 11. Thus, 
immunogens exposed to aqueous environments with a low pH may lose key elements of 
tertiary, secondary, or even primary structure that may affect the type of immune 
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response induced following vaccination. For the development of efficacious vaccines, it 
is desirable to use protein antigens containing multiple immunogenic epitopes as 
opposed to peptide antigens containing a single epitope 12. This suggests that antigen 
stability is a critical factor in the development of subunit vaccines. Indeed, antigen 
stability influences the outcome of antigen processing and presentation by antigen 
presenting cells (APCs) that govern the outcome of the resultant immune response 10, 11. 
Polymers have been well-studied as matrices for drug delivery systems in the 
pharmaceutical industry 13, and encapsulating proteins into polymer microparticles is 
one of the most commonly used methods for parenteral delivery 14. The most 
extensively investigated biodegradable polymers are polyesters such as poly(glycolic 
acid), poly(lactic acid) and their copolymers. These polymers undergo bulk erosion 
which can result in aggregation of proteins 14. In addition, this class of polymers creates 
an acidic pH microenvironment during degradation that may lead to chemical instability 
of proteins 14-18. 
Polyanhydrides are surface-erodible polymers and provide advantages that enhance 
protein stability and controlled release. However, these materials are hydrophobic which 
can lead to protein instability 19, 20. A well-studied aliphatic-aromatic copolymer system 
for protein delivery is based on copolymers of sebacic acid (SA) and 1,3-bis(p-
carboxyphenoxy)hexane (CPH) (Figure 4.1) 19, 21. In order to prevent deleterious 
protein-polymer interactions, the ideal protein delivery device must be amphiphilic. One 
way to achieve this is by introducing oligomeric ethylene glycol units into the backbone 
of an aromatic polyanhydride (i.e., CPH) 22, 23. In previous work, a novel amphiphilic 
polyanhydride system based on CPH and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
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(CPTEG) monomers (Figure 4.1) was shown to provide a more favorable environment 
for encapsulated proteins 23. Another advantage of these polyanhydride systems (i.e., 
CPH:SA and CPTEG:CPH) is that by changing the ratio of the monomers during 
fabrication, the degradation rate of the copolymers can be extended from days to 
months 20. Previous studies evaluated the effects of polyanhydride degradation products 
on several proteins. Determan et al. 14 demonstrated the stability of tetanus toxoid (TT), 
ovalbumin (Ova), and lysozyme when incubated with anhydride (i.e., CPH and SA) 
monomers. The stability of Ova and bovine serum albumin (BSA) after encapsulation 
and release from CPH:SA microparticles was also shown by Determan et al 7, 24. Torres 
et al. studied the stability of lysozyme and Ova in the presence of degradation products 
of the CPTEG:CPH system and found that the CPTEG:CPH system preserves the 
structural integrity of these two proteins 25.  
 
 
Figure 4.1 Chemical structures of (from top to bottom) poly(SA), poly(CPH), and 
poly(CPTEG). 
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The work outlined in this study demonstrated the preservation of the structure and 
antigenicity after release from polyanhydride microparticles of two candidates that may 
be used as antigens for Yersinia pestis. Y. pestis is the etiological agent of bubonic and 
pneumonic plagues to which an estimated 200 million human deaths are attributable 26, 
27. In recent years, plague vaccine design, like that for many other diseases, has 
focused on the use of recombinant proteins such as F1 and V 28-31, which are found on 
the surface of the Y. pestis bacterium. Previous work demonstrated that the full length 
F1-V fusion protein offers protection in several animal models 27, 31, 32. Powell et al. 27 
proposed a subunit vaccine in which the active component included an improved 
combination of the F1 capsular protein and V virulence antigen of Y. pestis. This antigen 
provided protection to wild-type mice and is now commercially available through BEI 
Resources 27. Vaccination with F1-V monomer and its multimeric forms resulted in 
protection in mice after subcutaneous administration as shown by Goodin et al 31. In 
another study 32, it was shown that the same full length F1-V antigen provides protection 
in murine models, especially when different prime and boost routes are used; this study 
also highlights the importance of the inclusion of an appropriate adjuvant for 
immunization 32. Tripathi et al. developed a peptide-based vaccine, based upon the 
constructs between B and T cell epitopes of the F1 antigen of Y. pestis 33. In their work, 
a new F1-V construct, F1B2T1-V10, was developed and it consists of three F1 
immunogenic epitopes (B1, B2 and T) and the V protein without the interleukin-10 
inducing sequence (-V10). This recombinant antigen induced both cell-mediated and 
humoral immunity. The efficacy of these antigens could be enhanced by using vaccine 
adjuvants (i.e., polyanhydride microparticles), but an important consideration is that the 
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adjuvants have to prolong the antigen release and stabilize them. This study compares 
the stabilization of F1B2T1-V10 and full length F1-V antigens using different 
polyanhydride microparticle adjuvants. 
 
4.3 Materials and Methods 
4.3.1 Materials 
Chemicals needed for monomer synthesis and polymerization, sebacic acid (99%), 
p-carboxy benzoic acid (99+%), and 1-methyl-2-pyrrolidinone anhydrous (99+%), were 
purchased from Aldrich (Milwaukee, WI); 4-p-hydroxybenzoic acid,1,6-dibromohexane, 
1-methyl-2 pyrrolidone, and tri-ethylene glycol were purchased from Sigma Aldrich (St. 
Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
acetonitrile, acetic anhydride, methylene chloride, and petroleum ether were purchased 
from Fisher Scientific (Fairlawn, NJ). F1-V fusion protein and monoclonal anti-Y. pestis 
LcrV protein were purchased from Biodefense and Emerging Infections Research 
Resources Repository (Manassas, VA). Polyclonal goat anti-LcrV antisera was obtained 
from Dr. John Clements from Tulane University, and donkey anti-goat IgG-alkaline 
phosphatase (AP) conjugated was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Goat anti-mouse IgG (H+L)-AP was purchased from Jackson 
ImmunoResearch (West Grove, PA). Phosphatase substrate was purchased from 
Aldrich (St. Louis, MO). Polyacrylamide 4-20% Tris-HCl pre-cast gradient gels, 
unstained protein standards, pre-stained broad range molecular weight standards, and 
Flamingo Gel Stain were purchased from BioRad Laboratories (Richmon, CA). 
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Bicinchoninic acid (BCA) and Micro BCA protein assay kits and Slide-A-Lyzer dialysis 
cassettes (10,000 MW cut-off membranes) were obtained from Pierce Biotechnology 
Inc. (Rockford, IL).  
 
4.3.2 F1B2T1-V10 Protein Construction and Purification 
4.3.2.1 Plasmid Construction  
To express the recombinant F1B2T1-V10 protein, a gene construct was first 
synthesized (Integrated DNA Technologies, Coralville, IA) and then cloned into the 
expression vector pDEST17 (Invitrogen, Carlsbad, CA). The synthetic gene was 
designed to encode a product with an amino terminal region comprised of 3 distinct 
immune-stimulating domains/epitopes of the F1 capsular protein 33. Specifically, these 
regions comprised amino acids 32-50 and 53-76 of the full-length F1 antigen 
representing B cell epitopes, and amino acid residues 79-93, a T cell epitope. The 
fusion of these three F1 regions was designated as F1B2T1. These epitopes were shown 
to elicit a humoral immune response and protect mice against Y. pestis challenge 33. 
The carboxy-terminal region of the fusion construct (amino acids 96-390 of the 
recombinant antigen) represents a modified version of LcrV lacking a domain (residues 
271-300 of Y. pestis LcrV) shown to trigger induction of interleukin 10 by host immune 
cells 34 and was designated as V10.  
To enable purification of F1B2T1-V10, the synthetic gene also includes bases that 
encode an enterokinase cleavage site near the amino-terminus (amino acids 25-29) of 
the recombinant gene product. To maximize expression, the nucleotide sequence of the 
F1B2T1-V10 coding region was also modified so the codon usage of the resulting 
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transcript matches that of highly expressed genes in E. coli. Finally, the synthetic gene 
also includes attB1 (5'-end) and attB2 (3'-end) sequences that enabled use of the 
Gateway cloning system (Invitrogen, Carlsbad, CA) for insertion into pDEST17, yielding 
pISM51. The final construct expresses a 390 amino acid product that includes an 
amino-terminal hexa-histidine epitope tag (amino acids 5-10) to simplify protein 
purification. F1B2T1-V10 is expressed from pISM51 by the T7 promoter.  
Purification of F1B2T1-V10 protein was followed by western blot analysis using anti-V 
antigen antisera. Approximately 10 µg of unpurified induced or uninduced whole cell 
lysate and 200 ng of purified unmodified fusion F1-V protein  were loaded on a 10% 
Criterion Tris-HCl gel (Bio-Rad), resolved by electrophoresis and blotted to 
nitrocellulose. The immunoblot was developed with anti-V antiserum (1:10,000) and 
alkaline phosphatase-labeled donkey anti-goat conjugate antiserum (1:50,000). 
 
4.3.2.2 Protein Purification of F1B2T1-V10  
E. coli BL21 (E. coli B F– dcm ompT hsdS(rB–, mB–) gal l(DE3)) containing plasmid 
pISM51 was grown overnight at 37°C in Luria-Bertani broth containing 100 µg/mL 
ampicillin, diluted 1:100 in the same media and then induced with 1 mM isopropyl β-D-l-
thiogalactopyranoside for 4 h. Cell pellets were obtained by centrifugation (6,000 x g, 30 
min) and washed once with phosphate buffered saline (0.05 M, pH 7.2) by 
centrifugation. The final cell pellet from a 2 L culture was resuspended in 50 mL of lysis 
buffer (20 mM Tris, 100 mM sodium chloride, 20 mM imidazole, 8 M urea, pH 8.0), 
passed through three cycles of freeze-thaw, and then cellular debris was removed by 
centrifugation at 12,000 x g for 10 min followed by filtration through a 0.45 µm filter.  
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A BioLogic Protein Purification system (Bio-Rad Laboratories, Hercules, CA) was 
used for recombinant F1B2T1-V10 protein purification. Fifty mL of induced cell lysate was 
passed through a 1.2 x 20 cm column packed with 5 mL of Proaffinity IMAC nickel 
chromatography resin (Bio-Rad). The column was then washed with 10 column volumes 
of binding buffer (50 mM sodium phosphate, 300 mM sodium chloride, 10 mM 
imidazole, 8 M urea, pH 8.0) until baseline was achieved. The protein was eluted with a 
linear gradient of 20 – 500 mM imidazole in binding buffer. Aliquots of 5 mL fractions 
were analyzed by western blot using anti-Yersinia V antigen or anti-6xHis monoclonal 
(Clontech Laboratories, Inc., Palo Alto, CA) with its appropriate conjugant [alkaline 
phosphatase labeled donkey anti-goat (Santa Cruz Biotechnology, Santa Cruz, CA) or 
alkaline phosphatase labeled goat anti-mouse Ig (H+L) (Southern Biotechnologies, 
Birmingham, AL).  
Recombinant protein containing fractions were combined, and endotoxin was 
removed using ActiClean Etox (Sterogene Bioseparations, Inc., Carlsbad, CA). The 
combined fractions from one chromatography run were passed through 5 mL of resin 
and then dialyzed against water using 7000 Da MW cutoff dialysis tubing (Pierce 
Chemical Co., Rockford, IL). Endotoxin levels were determined using a chromogenic 
QCL-1000 Limulus Amebocyte Lysate assay (Lonza Group Ltd, Basel, Switzerland) and 
protein was considered “endotoxin-free” if contamination was below 50 ng of 
contaminants per mg of protein (as determined by a Bicinchoninic Assay [Thermo 
Scientific, Waltham, MA] against a BSA standard). If contaminants were found to be 
above this level, the protein solution was run over a Detoxi-Gel endotoxin removal 
column three times (Thermo Scientific) and the LAL assay was re-run. This procedure 
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was repeated until contamination fell below the designated acceptable level. The protein 
yield after endotoxin removal was 74%. 
 
4.3.3 Polymer Synthesis and Characterization 
Diacids of CPH and CPTEG were synthesized as described previously 23, 35. SA and 
CPH prepolymers were synthesized by the methods described by Shen et al. 36 and 
Conix et al 35. Subsequently, 20:80 CPH:SA and 50:50 CPTEG:CPH copolymers were 
synthesized by melt polycondensation as respectively described by Kipper et al. 37 and 
Torres et al. 23. 1H nuclear magnetic resonance (NMR) spectroscopy on a Varian VXR 
300 MHz spectrometer (Varian Inc., Palo Alto, CA) was used to characterize the 
polymer structure. NMR spectra were consistent with previously published data 23 and 
confirmed the synthesis of the desired copolymer compositions. In addition, polymer 
molecular weight was determined utilizing gel permeation chromatography (Waters 
HPLC System, Milford, MA using Varian Inc. GPC columns). The 20:80 CPH:SA 
copolymer had a Mw of 21000 g/mol and polydispersity index (PDI) of 2.1, while the Mw 
and PDI of the 50:50 CPTEG:CPH copolymer were 9000 g/mol and 1.8, respectively. 
These values are consistent with previous published data 7, 23. 
 
4.3.4 Microparticle Fabrication 
Encapsulation of F1-V and F1B2T1-V10 in 20:80 CPH:SA and 50:50 CPTEG:CPH 
microparticles was performed by cryogenic atomization using parameters specified by 
Torres et al. and Lopac et al 25, 38. Briefly, 100 mg of each copolymer composition was 
dissolved in methylene chloride and 2 mg of lyophilized F1-V or F1B2T1-V10 was 
 	  
115 
suspended in this solution using a Tissue-TearorTM (10,000 rpm, 1 min). The solution 
was sprayed with a syringe pump through an 8700-1200 MS ultrasonic atomizing nozzle 
(SonoTek Corporation, Milton, NY) into 200 mL of frozen ethanol (with an excess of 
liquid nitrogen). The procedure was carried out at 4°C for the CPTEG:CPH composition 
and at room temperature for 20:80 CPH:SA. The resulting solution was stored at -80°C 
for three days. For CPTEG-based compositions, after the first 24 h, ~200 mL of cold 
ethanol was added to avoid aggregation; the solutions were stirred at 300 rpm for 15 
min and placed back in the freezer at – 80°C. After this period, microparticles were 
collected by vacuum filtration and dried overnight at vacuum conditions. This procedure 
yields at least 70% recovery. The microparticle morphology was analyzed by scanning 
electron microscopy (SEM) (JEOL 840 A, JEOL Peabody, MA) using four replicates per 
sample. The particle size distribution was obtained from SEM images using ImageJ 
image analysis software (National Institutes of Health, Bethesda, MD). An average of 
200 particles per image was analyzed. 
 
4.3.5 Protein Release Studies 
In vitro release kinetics of the two antigens were measured by suspending fifteen mg 
of the protein-loaded microparticles in 1 mL of saline phosphate buffer (0.1 M, pH 7.4) 
with 0.01% w/v of sodium azide, and incubated at 37°C and 100 rpm. Aliquots of 750 µL 
were taken at different time intervals and replaced with fresh buffer. The aliquots were 
stored at 4°C to measure protein concentration using a Micro BCA analysis at an 
absorbance of 570 nm and gel electrophoresis (SDS-PAGE) under non-reducing 
conditions. A SDS-PAGE quantification method was performed as previously described 
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39. Equal amounts of the released proteins were mixed with non-reducing buffer (SDS 
(10% w/v), Tris-HCl (1M, pH 6.8), glycerol (3 mM), bromophenol blue (0.01% w/v)) at a 
1:1 volume ratio. The samples were heated at 70°C for 10 min and cooled to room 
temperature, after which they were loaded onto 4-20% Tris-HCl pre-cast gels and run at 
140 V and 4°C for 90 minutes. Five µL of unstained protein standard were used as 
reference to determine the molecular weight of the samples. The gels were incubated in 
fixative solution (40% ethanol, 10% acetic acid) at 4oC for 3 h. Next, they were stained 
with fluorescent flamingo gel stain overnight, and washed with a 0.01% Tween 20 
solution to reduce non-specific fluorescence. A Typhoon 8600 (GE Healthcare, 
Piscataway, NJ) fluorescence scanner was used to obtain the images of the gels and 
fluorescence intensity was quantified by ImageQuantTL (GE Healthcare, Piscataway, 
NJ) using a standard curve with corresponding protein concentrations from 250 to 1 
ng/mL. At least three replicates of each sample were analyzed. The cumulative release 
was normalized by the total protein encapsulated that was determined as described by 
Torres et al 25. 
 
4.3.6 Protein Antigenicity after Release 
F1-V and F1B2T1-V10 Specific Enzyme-Linked Immunosorbent Assay (ELISA) 
High protein binding 96-well Costar microtiter plates (Corning Life Sciences, Lowell, 
MA) were coated overnight with 100 µL of phosphate buffer saline (PBS) at a pH of 7.4 
containing 5 µg/mL of released protein. Samples collected after release from 20:80 
CPH:SA and 50:50 CPTEG:CPH were analyzed in triplicate. In some cases, Vivaspin 
500 centrifugal concentrators (Sartorius Stedim Biotech, Aubagne, France) were used to 
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concentrate the released samples. PBS containing 0.05% Tween 20 (PBS-T) and 2% 
(w/v) gelatin as a non-specific blocking agent (BD Biosciences, San Jose, CA) was used 
to block plates for at least 2 h at room temperature. After the blocking period, plates 
were heated at 60 °C for 10 min in a dry oven to melt gelatin and then, they were rinsed 
three times to remove any unbound blocking reagent. Two sets of ELISAs were 
performed by using monoclonal anti-Y. pestis LcrV protein and hyperimmunized serum, 
which was obtained from repeated injections of F1-V fusion protein to adult female 
C57BL/6 mice. Plates were incubated with primary antibodies in PBS-T with 1% (v/v) 
goat serum (1:10000) overnight at 4 °C. PBS-T was used to wash plates three times 
followed by the addition of 100 µL of PBS-T (1% (v/v) goat serum) containing AP-
conjugated goat anti-mouse IgG(H&L) antiserum  at a 1:1000 dilution. After 2 h of 
incubation at room temperature, the plates were washed four times with PBS-T and 
then, 100 µL of sodium carbonate (50 mM) and magnesium chloride (2mM) buffer (pH 
9.3) containing 1 mg/mL phosphatase substrate was added. Plates reacted from 20 to 
40 min at room temperature. Optical density (OD) of each well was measured at 405 nm 
using a Spectramax 190 Plate Reader (Molecular Devices, Sunnyvale, CA). The results 
were normalized with the data for the protein (only) solution in PBS and reported as 
relative epitope availability. 
 
4.3.7 Protein Incubation in Saturated Solutions of Monomers 
Saturated solutions of the SA, CPH, and CPTEG diacids were obtained by adding an 
excess of each diacid in deionized water and phosphate buffer. All the data presented in 
the Results and Discussion section is based on the use of PBS, except for the 
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secondary structure data from circular dichroism, which is based on deionized water due 
to the high background absorbance of the PBS. The solutions were filtered with 0.22 µm 
syringe filter after incubation for 48 h (37°C and 100 rpm). The pH of the SA, CPH, and 
CPTEG monomer saturated solutions was 4.2, 5.5, and 6.5, respectively. Stock 
solutions of F1-V fusion protein and recombinant F1B2T1-V1 were made in phosphate 
buffer (0.1 M, pH 7.4) and deionized water at a concentration of 1 mg/mL. The final 
solutions were obtained by adding the protein solution to the diacid solution at a volume 
ratio of 15:85 to achieve a final protein concentration of 150 µg/mL. These samples 
were incubated for 0 and 7 days at 37°C and shaken at 100 rpm for stability analysis. All 
experiments were performed in triplicate. 
 
4.3.8 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE): 
Primary Structure 
The primary structure of each protein was evaluated using SDS-PAGE. Separate 
samples that had been incubated for 0 or 7 days were centrifuged (10,000 rpm, 10 min) 
and 25 µL of each sample was mixed with equal volumes of non-reducing (SDS (10% 
w/v), Tris-HCl (1M, pH 6.8), glycerol (3 mM), bromophenol blue (0.01% w/v)) and 
reducing sample buffers (SDS (10% w/v), Tris-HCl (1M, pH 6.8), glycerol (3 mM), 
bromophenol blue (0.01% w/v), and β-mercaptoethanol (0.05% v/v)). Samples were 
mixed and heated at 95 °C for 5 min. The next steps of the SDS-PAGE protocol 
experiments were previously described in the Protein Release section.  
 
 
 	  
119 
4.3.9 Circular Dichroism (CD): Secondary Structure 
The secondary structure of the antigens was monitored after 0 and 7 days of 
incubation by far UV CD at a wavelength range of 190-260 nm 7, 14, 25. Samples in water 
were used to avoid high absorbance. The spectra were collected using Jasco J-170 
software (Easton, MD). The spectra of the monomer solutions were subtracted from the 
protein spectra. The spectra shown are the average of three experiments.  
 
4.3.10 Hydrogen-Deuterium Exchange Monitored by Fourier-Transform Infrared 
(FTIR) Spectroscopy: Tertiary Structure 
The F1B2T1-V10 protein is a small molecular mass protein composed of 390 amino 
acids of which only one is a tryptophan and only thirteen are tyrosine. The low content of 
these two amino acids makes it difficult to study the tertiary structure of this protein 
using spectroscopic techniques (i.e., fluorescence spectroscopy). 1H/2H exchange 
kinetics allows the characterization of protein stability in different experimental 
conditions 40. FTIR spectra of proteins in the presence of deuterium are used for 
estimation of slowly and rapidly exchanging amide protons and information about 
hydrogen bond stability of amide protons can be obtained from these exchange rates 41. 
Specifically, changes in tertiary structure of proteins can be followed by monitoring 
changes in the amide II band intensity (1600-1500 cm-1) over time when proteins are 
exposed to deuterium 40, 41. This approach was used to determined changes in the 
tertiary structure of F1-V fusion protein and F1B2T1-V10. After 0 and 7 days of incubation 
with monomers, 500 µL of each of protein samples were placed in glass vials and an 
equal volume of deuterium (Sigma Aldrich) was added. Immediately after addition of 
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deuterium, the headspace of the glass vials was flushed with argon and all vials were 
stored in an argon-flushed desiccator. At 0, 1, 2, 3, and 4 h, 80 µL of each sample were 
removed from vials with a syringe and immediately placed on silica nitride substrates; 
the samples were dried overnight at room temperature in order to obtain protein films to 
collect FTIR spectra. Films made from protein only and deuterium solutions were used 
as controls for each time interval; deuterium spectra were subtracted from sample 
spectra. Spectra were obtained using an FTIR spectrometer using a Nicolet Nexus 470 
(Madison, WI), equipped with a liquid nitrogen cooled MCT/A detector. For each sample, 
256 scans were recorded at a resolution of 4 cm-1. Omnic 5.2 software was used to 
collect the data and to obtain the areas under the amide I (1700- 1600 cm-1) and amide 
II regions. The amide II region was normalized to the amide I region to eliminate 
possible fluctuations in intensity 41. Amide II/amide I ratios were expressed as fractions 
of non-exchanged protons and used to follow changes in tertiary structure.  
 
4.3.11 Statistical Analysis  
All data was statistically analyzed by using a student’s t-test with the statistical 
software JMP® 7 (Cary, NC). Comparisons between treatments were made and p-
values of less than or equal to 0.05 were considered significant.  
 
4.4 Results and Discussion 
Preservation of protein structure, and thus, immunogenicity, is important to be able 
to induce effective immune responses when proteins are used as vaccine immunogens 
9-11. Previous studies have shown that mechanisms of protein alteration are protein-
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specific. In order to design adequate protein carriers for vaccination, it becomes 
necessary to select polymer formulations that can stabilize the hierarchical structures of 
specific proteins of interest and maintain their antigenicity. The experiments described in 
this work were performed in order to determine the effect of polyanhydride chemistry on 
the stabilization of proteins (i.e., F1-V fusion protein and recombinant F1B2T1-V10) that 
have the potential to be used in designing vaccines against Y. pestis.  
 
4.4.1 F1B2T1-V10 Protein Construction and Purification 
The F1B2T1-V10 antigen is encoded by a 1,170-bp DNA construct as described 
above. Of the three immune-stimulating domains from the F1 capsular protein, B1, B2 
and T1, B1 and B2 represent B cell stimulating epitopes and T1 is a T cell stimulating 
epitope 33. It also includes a coding region of the LcrV antigen, with the 
immunomodulatory domain encoded by amino acids 133-175 deleted. Following 
purification of the F1B2T1-V10 protein, it was analyzed by western blot analysis using 
anti-V antisera (Figure 4.2). This Figure also compares the purified F1B2T1-V10 protein 
with the full length F1-V fusion protein obtained from the Biodefense and Emerging 
Infections (BEI) Research Resources Repository (catalog number NR-4525, lot number 
FIN-0229). This Figure depicts the molecular size difference between the two proteins 
and demonstrates that the selected anti-sera reacted with both proteins. 
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Figure 4.2 Electrophoretic analysis of F1B2T1-V10 and F1-V.  Lanes 1 and 4: induced 
whole cell lysate expressing F1B2T1-V10; Lanes 2 and 5: uninduced whole cell lysate 
control; Lanes 3 and 6: purified F1-V (BEI). Left panel: Coomassie blue stained gel; right 
panel: immunoblot. The blot was developed with anti-V antiserum and alkaline 
phosphatase-labeled donkey anti-goat conjugate antiserum. 
 
4.4.2 Microparticle Fabrication and Protein Release 
F1-V fusion protein and F1B2T1-V10 were encapsulated in 20:80 CPH:SA and 50:50 
CPTEG:CPH microparticles in order to study the release kinetics of these two proteins. 
The specific polymer chemistries were chosen based on previous work suggesting that 
these chemistries may stabilize globular proteins 24, 25. Microparticles were fabricated 
using the cryogenic atomization method and visualized by SEM. Figure 4.3 shows 
electron photomicrographs of F1-V-loaded 20:80 CPH:SA and F1B2T1-V10-loaded 50:50 
CPTEG:CPH microparticles with morphologies (size and surface topography) that are 
consistent with previous work on polyanhydride microparticles encapsulating other 
proteins 7, 25, 38. The size of the majority of the microparticles was between 2 and 15 µm 
or 6 and 10 µm for the 20:80 CPH:SA and 50:50 CPTEG:CPH, respectively. 
 	  
123 
 
Figure 4.3 SEM images: (top) F1-V-loaded 20:80 CPH:SA microparticles and (bottom) 
rF1B2T1-V10-loaded 50:50 CPTEG:CPH microsparticles. Scale bar: 20 µm and 10 µm, 
respectively. 
 
After encapsulation, the F1-V and F1B2T1-V10 antigens were released from both 
20:80 CPH:SA and 50:50 CPTEG:CPH microparticles. The release profiles for both 
proteins are similar and depend on the microparticle chemistry (Figure 4.4). The profile 
of proteins released from 20:80 CPH:SA microparticles (Figure 4.4(a)) showed an initial 
burst release of ~20% with an eventual release of ~75% of the total encapsulated 
protein after 32 days. These release profiles are consistent with previous work 
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evaluating other combinations of proteins and polyanhydride chemistries with similar 
hydrophobicities 38. It can be observed from Figure 4.4(b) that the 50:50 CPTEG:CPH 
microparticles display a faster release of the proteins with more than 90% of the total 
encapsulated protein released during the first 32 days, which is consistent with previous 
work on ovalbumin release from 50:50 CPTEG:CPH microparticles 38. 
 
Figure 4.4 Protein release kinetics from polyanhydride microparticles: ( ) Cumulative 
fraction of F1-V fusion protein, and ( ) rF1B2T1-V10 released from 20:80 CPH:SA (a) 
and 50:50 CPTEG:CPH (b) microparticles. Error bars represent standard error of two 
different experiments run with triplicate samples. 
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4.4.3 Protein Antigenicity following Release 
Initial studies investigated the antigenic stability of the commercially available F1-V 
fusion protein and the recombinant F1B2T1-V10 that had been released during the initial 
first 72 h of incubation from 20:80 CPH:SA and 50:50 CPTEG:CPH microparticles. 
Figure 4.5 shows the effect of polymer chemistry on protein antigenicity, as measured 
by a protein-specific ELISA using monoclonal anti-Y. pestis LcrV protein. It can be 
observed that antigenicity of the recombinant F1B2T1-V10 decreased significantly when 
released from 20:80 CPH:SA microparticles with a greater than 50% reduction in the 
optical density (OD) value compared with the unencapsulated protein. The antigenicity 
of the F1-V fusion protein after release from the 20:80 CPH:SA microparticles was 
statistically indistinguishable from that of the unencapsulated protein. In contrast, both 
proteins retained their antigenicities when released from 50:50 CPTEG:CPH 
microparticles. Similar results were obtained from protein-specific ELISA using 
hyperimmunized serum indicating maintenance of multiple immunological epitopes (data 
not shown). The deleterious effect of the CPH:SA chemistry on F1B2T1-V10 antigenicity 
may be attributed to several reasons. First, it is known that there is a decrease in the pH 
when poly(SA) degrades 14, exposing proteins to an acidic microenvironment that may 
be detrimental to protein structure and function 7, 14, 38. Second, of the three 
polyanhydrides studied, CPH is the most hydrophobic polymer following by SA, which 
makes 20:80 CPH:SA more hydrophobic than 50:50 CPTEG:CPH 38. Hydrophobicity 
has been shown to induce non-covalent protein aggregation 7, 14, so this phenomenon 
may also contribute to the reduction of protein antigenicity. On the other hand, the 
presence of ethylene glycol in the CPTEG-containing polymers results in an amphiphilic 
and less acidic microenvironment that has been shown to preserve protein activity 25, 38. 
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When comparing the two antigens, a reduction in antigenicity was observed for F1B2T1-
V10, suggesting that the omission of specific peptides in this novel protein construct 
may have resulted in a more fragile protein.  
 
 
Figure 4.5 Antigenic analysis after encapsulation and release from polyanhydride 
microparticles. Error bars represent standard deviation of three different experiments 
with duplicate samples in each. Groups identified with the same letter are not 
statistically different (p-value = 0.3). 
 
4.4.4 Incubation of Antigen with Monomer Solutions 
An indirect way to mimic the microenvironment inside polymeric devices during 
fabrication and release is to study the stability of proteins in the presence of saturated 
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monomer solutions. To better understand the contribution from each of the polymer 
degradation products to the detrimental effect observed on the released antigens, the 
F1-V fusion protein and the F1B2T1-V10 were exposed to the degradation products of 
SA, CPH, and CPTEG polymers for zero and seven days. The antigenicities of F1-V and 
F1B2T1-V10 were also assessed by ELISA and using a monoclonal anti-Y. pestis LcrV 
and the results are shown in Figure 4.6. Similar ELISA results were obtained using 
hyperimmunized serum to evaluate protein antigenicity (data not shown). For the F1-V 
fusion protein, a statistically significant decrease in its antigenicity was observed in the 
presence of the SA monomer whereas for the F1B2T1-V10 protein there was a loss in 
antigenicity (characterized by a 60-80% reduction in the OD values) when incubated in 
the presence of either SA or CPH monomer solutions. These results are consistent with 
the argument that acidity has a more significant impact on the antigenicity of both Y. 
pestis antigens, and in addition, there is a further detrimental effect on the antigenicity of 
F1B2T1-V10 due to hydrophobic interactions. Collectively, the data indicates that the 
presence of the CPTEG monomer preserves antigenicity of fragile antigens. A detailed 
analysis of protein structure alterations was next performed to provide a more detailed 
evaluation of protein structure as it related to loss of antigenicity and to identify the 
structural levels at which the changes are occurring. 
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Figure 4.6 Antigenic analysis after 0 and 7 days of incubation at 37°C of: (a) F1-V 
fusion protein and (b) F1B2T1-V10 protein with polyanhydride degradation products. Error 
bars represent standard deviation of three different experiments with duplicate samples 
in each. Groups identified with the same letter are not statistically different (p-value > 
0.05). 
 
The primary structure of F1-V (MW ~53 kDa) and F1B2T1-V10 (MW~37 kDa) 
incubated with the polyanhydride degradation products was analyzed by SDS-PAGE 
under reducing conditions (Figure 4.7). In the top panel, a dominant band at 53 kDa is 
 	  
129 
observed and this characteristic band was consistently observed after seven days of 
incubation in saturated monomer solutions indicating that no degradative changes in the 
primary structure of the F1-V fusion protein occurred nor is there any evidence of 
increased protein aggregation. The bottom panel of Figure 4.7 shows the SDS-PAGE 
results for F1B2T1-V10. At day 0, similar banding patterns are observed for protein 
samples taken from PBS and all the anhydride monomer solutions as evidenced by the 
presence of the intact protein at ~37 kDa and the similar banding pattern for the less 
intense bands. After seven days of incubation in the CPH monomer solution, however, 
much of the parent protein was altered or degraded based on a less intense band at 37 
kDa, while a more intense band around 150 kDa is detectable. The ability to detect a 
higher molecular weight F1B2T1-V10 polypeptide band is likely a consequence of protein 
aggregation by non-covalent interactions, which may be attributed to the hydrophobicity 
of the CPH monomer 14, 25. When incubated with SA, a less intense dominant band (~37 
kDa) was observed, but other bands with similar intensities were also present at lower 
molecular weights (e.g., around 37, 25, and 15 kDa). Keeping in mind that the same 
amount of protein was loaded in each lane of the gel, the presence of lower molecular 
mass bands may be indicative of protein hydrolysis 14. This may be a consequence of 
the acidic microenvironment produced by the SA monomer. Consistent with the 
antigenicity studies, no changes occurred in the protein primary structure when 
incubated with CPTEG (Fig. 7, lanes 3 and 4). These changes in primary structure in the 
F1B2T1-V10 incubated in SA monomer solutions indicate that the loss in antigenicity may 
be a direct consequence of primary structure changes associated with protein 
degradation.  
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Figure 4.7 SDS-PAGE under reducing conditions results for F1-V (top) and F1B2T1-V10 
(bottom) incubated at 37 °C in saturated polyanhydride monomer solutions in PBS. 
Approximately, 3 µg of protein was loaded in all the lanes. Lane 1: molecular mass 
ladder (from top to bottom: 250, 150, 100, 75, 50, 37, 25, 20, 15, and 10 kDa) ; lane 2: 
protein in PBS; lane 3: CPTEG day 0; lane 4: CPTEG day 7; lane 5: CPH day 0; lane 6: 
CPH day 7; lane 7: SA day 0 and lane 8: SA day 7. 
 
The CD spectra for F1-V and F1B2T1-V10 incubated in polyanhydride monomer 
solutions at day zero showed two minima occurring at 209-211 nm and 217-222 nm, 
where the first minima is dominant, indicating substantial coil and α-helix content 
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together with comparably less β-sheet structure (Figure 4.8). In the case of the F1-V 
fusion protein, the minima are better defined and they occur at a lower molar circular 
dichroism absorbance (∆ε) showing a more defined and complex secondary structure. 
These results are in agreement with studies by Powell et al. for the full length F1-V 
fusion protein 27. From Figure 4.8(b) and Figure 4.8(d) it can be observed that after 
seven days of incubation, the two characteristic minima cannot be distinguished and a 
clear reduction is observed in the ∆ε absorbance for F1-V incubated in SA monomer 
and F1B2T1-V10 incubated in SA and CPH monomers. It is also important to note that the 
stronger positive band between 190 and 195 nm is also characteristic of β-sheet content 
42. This maximum is clearly reduced after incubation with SA monomer for both antigens 
and also after incubation with CPH monomer for the F1B2T1-V10 protein. These two 
observations suggest that a severe unfolding of the protein may be occurring in the 
presence of these monomer solutions. In the case of the protein incubated with SA 
monomer, the changes described are observable at day zero itself, suggesting a strong 
acidity-dependent unfolding of both proteins. This change in the secondary structure of 
the protein can be attributed to the acidity of the SA monomer, which is consistent with 
previous work showing that the F1 portion of the protein is not stable in acidic 
environments 27, 31, 43. In particular, Goodin et al. 31 showed that the F1-V protein exhibits 
a strong tendency to multimerize with reduction of pH 31. Based on previous 
observations and the results from this study, it becomes extremely important to identify 
suitable carriers that are able to maintain adequate pH conditions to stabilize Y. pestis 
antigens.  
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Figure 4.8 CD spectra of (a) and (b) F1-V fusion protein and (c) and (d) F1B2T1-V10 
protein in the presence of CPTEG, CPH, and SA monomers at (a) and (c) day 0 and (b) 
and (d) day 7. All the water spectra correspond to the specific protein in solution used as 
a control to identify structural changes. 
 
Exchange rates of amide hydrogen for deuterium were used to follow changes in 
tertiary structure of the F1-V fusion protein and the recombinant F1B2T1-V10 protein. 
These rates depend on the stability of protein secondary structure and the accessibility 
of N-H groups to solvent 41. The FTIR spectra F1B2T1-V10 incubated in the solution of SA 
monomer showed a clear decrease in the absorbance in the amide II region with 
increased exposure to deuterium (spectra not shown). Similar results were obtained for 
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the F1-V fusion protein incubated in the presence of SA monomer (Figure 4.9(a)) but 
with a less pronounced reduction in the non-exchanged fraction. Reduction in the 
absorbance of the amide II region suggests a conformational change in the presence of 
SA monomer. The fraction of non-exchanged ratio was obtained by normalizing the 
intensity of the amide II band to the amide I band and is expected to be around one for 
tightly folded proteins 40, 41. Data obtained at time zero indicate that the exchange is 
greater in the solutions of SA monomer as shown by the decrease in the fraction of non-
exchanged hydrogen ions (Figures 4.9(a) and 4.9(c)). This data confirms a 
conformational change in both antigens in the presence of SA and this change in tertiary 
structure may be attributed to the change in the secondary structure previously 
observed and to the acidity of this monomer. On the other hand, the structures of F1-V 
and F1B2T1-V10 are largely unperturbed after the initial incubation with CPH and CPTEG 
monomers. After seven days of incubation, a clear decrease in the non-exchange ratio 
is observed in the presence of SA monomer, which is consistent with the structural 
changes that were observed during the initial incubation. A decrease in the fractional 
non-exchange is observed when F1B2T1-V10 is incubated in CPH monomer for seven 
days (consistent with the change in the secondary structure) while the protein incubated 
with the CPTEG monomer maintains its tertiary structure (Figure 4.9(d)). No statistical 
decrease in the fractional non-exchange was observed after seven days of incubation of 
F1-V with CPH and CPTEG monomers (Figure 4.9(b)). The changes in secondary and 
tertiary structure of the F1-V fusion protein and the F1B2T1-V10 recombinant protein in 
the presence of SA monomer may be sufficient to cause the observed alterations in 
protein antigenicity.  
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Figure 4.9 Tertiary structure characterization of F1-V fusion protein and F1p-V10 
recombinant protein. Fraction non-exchanged hydrogen ions during a 4 h incubation of 
F1-V in anhydride monomers (a) day 0 and (b) day 7 with deuterium; fraction non-
exchanged hydrogen ions during a 4 h incubation rF1B2T1-V10 in anhydride monomers 
(c) day 0 and (d) day 7 with deuterium. Specific protein in PBS ( ), SA ( ), CPH ( ), 
and ( ) CPTEG ( ). All the PBS curves correspond to the specific protein incubated 
with PBS used as control to determined structural changes. Error bars represent 
standard deviation from triplicates. 
 
As discussed before, other protein carriers have been studied (i.e., poly(glycolic 
acid), poly(lactic acid) and their copolymers), but these are not highly suitable for protein 
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stabilization because their bulk erosion mechanism generates a low pH 
microenvironment that has a detrimental effect on protein antigenicity 13, 14. However, 
with the combined surface and bulk erosion mechanisms exhibited by polyanhydrides, 
water ingress into the bulk is controllable and in most cases is not significant; therefore, 
these low pH microenvironments would mostly be located on the surface of polymeric 
particles during release helping to maintain the structural levels and antigenicity of 
proteins. Further, the solubility in water of the hydrophobic anhydride monomers studied 
in this work is lower than that of the corresponding ester monomers (like lactic acid and 
glycolic acid). This lower solubility is one of the factors leading to a higher pH 
microenvironment with the anhydride degradation products as compared to the ester 
degradation products, thus favoring greater protein stability.  
In order to avoid the side effects generated by the use of live and killed whole cell 
vaccines, an increasing number of polypeptide subunit and recombinant protein 
vaccines have been designed 44. However, these next generation vaccines generally are 
poorly immunogenic and often fail to provide protection against pathogens 44. Therefore, 
it is essential to design carriers that maintain structural integrity and immunogenicity of 
these subunit proteins in order to avoid the induction of inadequate immune responses. 
Our results show that primary, secondary, and tertiary structure as well as the 
antigenicity of two Y. pestis vaccine antigens is affected by the acidic pH 
microenvironment within saturated solutions of SA. The F1B2T1-V10 structural 
conformation was shown to be sensitive to acidic conditions and indeed, some 
precipitation of the F1B2T1-V10 protein was observed after incubation in a solution of the 
SA monomer. This can be attributed to the fact that the pH of the monomer solution 
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approaches the isoelectric point of the protein (pI~ 5) of F1B2T1-V10 recombinant protein, 
resulting in aggregation 25, 45. In addition, changes in the structure and antigenicity of 
F1B2T1-V10 were also observed in the presence of the CPH monomer solution; these 
changes were attributed to the hydrophobicity of the monomer as opposed to the pH. In 
contrast to globular proteins that exhibit a stable structure 7, 14, F1B2T1-V10 appears to be 
affected by multiple mechanisms of instability when incubated with CPH or SA 
monomers. The amphiphilic CPTEG-containing polymers provided the most stabilizing 
environments for both the F1-V fusion protein and the F1B2T1-V10 recombinant protein 
because of the less acidic pH microenvironment and their amphiphilic nature. These 
results indicate that amphiphilic chemistries are promising carriers and adjuvants for Y. 
pestis antigens.  
 
4.5 Conclusions 
This work identified polyanhydride monomers with chemical properties that 
maintained the structural integrity of two protein antigen candidates for Y. pestis. The 
results provide promising insights for the rational design of new and effective vaccine 
delivery vehicles based on biodegradable and biocompatible polyanhydrides. The 
importance of selecting the appropriate polymer chemistry that will maintain structural 
integrity resulting in a biologically stable protein (e.g., antigen) was demonstrated. The 
antigenicity of proteins released from the amphiphilic CPTEG:CPH microparticles was 
preserved, suggesting that these polymers are promising carriers for Y. pestis antigens. 
The increased protein stabilization afforded by the chemistry and microenvironment of 
polyanhydrides makes this polymer system likely to provide a means to deliver nascent 
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immunogens that have maintained multiple immunological epitopes to facilitate vaccine 
efficacy in a genetically diverse population. 
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5.1 Abstract 
It has been suggested that antibodies (e.g., anti-serum or monoclonal antibodies) 
could be used in early, passive immune treatments for HIV as well as to help fight off an 
infection. As with the development of protein pharmaceutics, one of the most 
challenging tasks in passive immunotherapies is to deal with the physical and the 
chemical instabilities of the protein (i.e., antibodies), which invariably leads to loss of 
biological activity. In order to avoid these problems, it is necessary to design delivery 
vehicles that will minimize the degradation, maximize the in vivo activity, and provide 
controlled release of the encapsulated protein.  
In this study, the use of polyanhydride nanoparticles is suggested for the delivery of 
two antibodies in order to show their ability to release stable therapeutic payloads. 
Tetanus antitoxin and anti-TNF-α monoclonal antibody were encapsulated and released 
from polyanhydride nanoparticles. These nanoparticles provide the ability to control 
antibody release kinetics and additionally, preserve antibody functionality and bioactivity 
upon fabrication and release. The amphiphilic 50:50 CPTEG:CPH nanoparticles 
demonstrated the best combination of characteristics compatible for either anti-serum or 
mAb preservation and release, making it an ideal candidate for a future used as a 
delivery system for therapeutic proteins. 
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5.2 Introduction 
Protein-based drugs have emerged as a promising class of therapeutics1. There are 
currently ~200 protein-based medicines (e.g., therapeutic proteins and peptides, 
monoclonal antibodies, etc) on the market, and ~400 in development2. Specifically, 
antibodies have become a major class of protein-based therapeutic agents3. About a 
fifth of new drugs in clinical testing today are antibodies4.  
Passive antibody therapy has been widely used to provide immunity against disease, 
or help fight off infections5,6. Antibodies against microbial, cellular and soluble targets 
produce and exploit various effector functions for therapeutic purposes: opsonization, 
activation of complement, antibody-dependent cell cytotoxicity, virus and toxin 
neutralization, direct antimicrobial activity, etc3,6. Several diseases are targets for 
therapeutic antibodies that are clinically approved or currently being tested in clinical 
trials. These include transplant rejection, rheumatoid arthritis, Crohn’s disease, 
osteoporosis, asthma, arthritis, Herpes simplex virus, HIV and different types of 
cancer3,6-9. Delivery of antibodies is typically performed intravenously, with a need for 
multiple and large doses in order to achieve effective systemic levels5,6. The route of 
administration and the large doses required make antibody therapies expensive. 
Therefore, there is a clear need to reduce the required number of doses without 
compromising the bioavailability and effectiveness of the treatment.  
In this regard, polymer matrices have been exploited as controlled release vehicles 
to deliver therapeutic levels of antibodies at the intended site of action10-13. Direct local 
delivery at diseased sites, spatial control over antibody distribution, reduced toxicity, co-
administration with other therapeutic agents (i.e., antibiotics, small molecule drugs), and 
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control over release kinetics are some of the advantages of using polymeric matrices to 
for the controlled delivery of antibodies. However, there are still several disadvantages 
with the use of polymeric devices for the delivery of antibodies, including poor loading 
capabilities that result in low antibody bioavailability, reduced systemic antibody 
exposure, and poor antibody stability within the delivery device3. In order to achieve 
good therapeutic performance, it is necessary that the polymer chemistry and the device 
fabrication methods do not inactivate the antibody; it is ideal that antibody release 
correlates with preservation of its bioactivity.  
Biodegradable polyanhydride particles have emerged as promising carriers for 
vaccine delivery because of their ability to release antigen in a controlled manner as 
they degrade, which can eliminate the need for multiple doses14-16. Polyanhydrides 
undergo surface erosion, allowing no moisture penetration into the bulk, thus making 
payload release kinetics more predictable17,18. Another advantage of polyanhydrides is 
that, due to the limited water solubility of their degradation products, a much less acidic 
microenvironment is produced compared to that of degrading polyesters; this is 
beneficial to the stability of the (protein) payload19,20. Biodegradable polyanhydride micro 
and nanoparticles have been shown to stabilize and provide sustained release of 
several proteins used in vaccine formulations against different diseases (i.e., tetanus, 
pneumonic plague, anthrax)19-21. These particles also have several other attractive 
properties, such as the ability to act as an adjuvant and enhancing the immune 
response14,16,22-24, while providing a platform which can be programmed to degrade over 
different times, depending on the chemistry17,18,21,25  
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In this study, the use of polyanhydride nanoparticles is investigated for the delivery 
of two therapeutic antibodies in order to show their ability to release stable payloads. 
Polyanhydrides based on 1,6-bis(p-carboxyphenoxy)hexane (CPH), sebacic acid (SA), 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxacotane (CPTEG) monomers were used in this 
work. The antibodies studies include tetanus anti-toxin, a full anti-sera that is used to for 
the treatment of tetanus26,27, and anti-TNF-α, a monoclonal antibody applied to treat 
Crohn’s disease and rheumatoid arthritis by binding to soluble and membrane TNF-α in 
order to neutralize its activity4,6,28. The antibodies were encapsulated and released from 
polyanhydride nanoparticles and a systematic analysis of protein stability upon 
encapsulation and release was performed. The studies described herein demonstrate 
that the amphiphilic environment provided by CPTEG-containing polyanhydrides 
preserved antibody functionality suggesting that this platform can be effectively used as 
a delivery system for therapeutic proteins. 
 
5.3 Materials and Methods 
5.3.1 Materials 
Materials needed for monomer synthesis and polymerization, as well as for 
nanoparticle fabrication, including sebacic acid (99%), p-carboxy benzoic acid (99+%), 
and 1-methyl-2-pyrrolidinone, anhydrous (99+%), were purchased from Aldrich 
(Milwaukee, WI); 4-p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2 
pyrrolidinone, and tri-ethylene glycol were purchased from Sigma Aldrich (St. Louis, 
MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
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acetonitrile, acetic anhydride, methylene chloride, pentane, and petroleum ether were 
purchased from Fisher Scientific (Fairlawn, NJ). Phosphatase substrate was purchased 
from Aldrich (St. Louis, MO). Polyacrylamide 4-20% Tris-HCl pre-cast gradient gels, 
unstained protein standards, pre-stained broad range molecular weight standards, and 
Flamingo Gel Stain were purchased from BioRad Laboratories (Richmond, CA). 
Bicinchoninic acid (BCA) and micro BCA protein assay kits and Slide-A-Lyzer dialysis 
cassettes (10,000 MW cut-off membranes) were obtained from Pierce Biotechnology 
Inc. (Rockford, IL). 
 
5.3.2 Monomer and Polymer Synthesis 
Diacids of CPH and CPTEG were synthesized as described previously29,30. SA and 
CPH prepolymers were synthesized by the methods described by Shen et al31. and 
Conix et al30., respectively. Subsequently, 20:80 CPH:SA and 50:50 CPTEG:CPH 
copolymers were synthesized by melt polycondensation as respectively described by 
Kipper et al.15 and Torres et al29. The chemical structure was characterized with 1H NMR 
and the molecular mass was determined using gel permeation chromatography 
(GPC)15,29. 
 
5.3.3 Nanoparticle Fabrication 
Two percent (w/w) tetanus anti-toxin or anti-TNF-α (clone XT3.11, BioXCell 
Fermentation/Purification Services, West Lebanon, NH) encapsulated nanoparticles 
were fabricated by the anti-solvent nanoencapsulation method recently published by 
Ulery et al23. Nanoparticle morphology and size distribution were characterized by 
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scanning electron microscopy (SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan) and quasi-
elastic light scattering (QELS, Zetasizer Nano, Malvern Instruments Ltd., Worchester, 
UK), respectively. 
 
5.3.4 In vitro Protein Release 
Tetanus anti-toxin and anti-TNF-α loaded nanoparticles were placed in 
microcentrifuge tubes with 0.1 mM phosphate buffer saline (PBS, pH 7.6). Samples 
were sonicated to uniformly distribute the nanoparticles and placed an incubator at 37 
ºC with constant agitation. Supernatants were sampled over time to determine the 
amount of released antibody with the micro-BCA assay. Removed volumes were 
replaced with fresh PBS to maintain perfect sink conditions. Data is presented as 
cumulative fraction of released antibody, which was determined by dividing the amount 
released at each time point by the total amount of encapsulated antibody into the 
nanoparticles17,20,21. A second method employing dialysis tubes was utilized to avoid 
accumulation of polymer degradation products within the medium surrounding the 
particles; however, no differences were observed in the release kinetics profiles and 
resulted antibody stability (data not shown). 
For antigenicity and functionality analysis, antibodies were released for 72 h. 
Following this time, release sample supernatant was removed and Vivaspin 500 
centrifugal concentrators (Sartorius Stedim Biotech, Aubagne, France) were used to 
concentrate the released samples and antibody concentrations were measured using 
the micro BCA assay. Sample concentrations were adjusted uniformly for the 
antigenicity and functionality assays, as well as for the structural analysis. 
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5.3.5 Tetanus Anti-toxin Functionality after Release 
5.3.5.1 Tetanus Toxoid Specific Enzyme Linked Immunosorbent Assay (ELISA) 
 High protein binding 96-well Costar microtiter plates (Corning Life Sciences, Lowell, 
MA) were coated overnight with 100 µL of phosphate buffer saline (PBS) at a pH of 7.4 
containing 10 µg/mL of tetanus toxoid. PBS containing 0.05% Tween 20 (PBS-T) and 
2% (w/v) gelatin as a non-specific blocking agent (BD Biosciences, San Jose, CA) was 
used to block plates for at least 2 h at room temperature. After the blocking period, 
plates were heated at 60 °C for 10 min in a dry oven to melt gelatin and rinsed three 
times to remove any unbound blocking reagent. 100 µL of tetanus anti-toxin released 
from polyanhydride nanoparticles at a concentration of 20 µg/mL (diluted in PBS-T with 
1% (v/v) fetal calf serum (FCS)) were added to each of the tetanus toxoid pre-coated 
wells. Unencapsulated tetanus anti-toxin (protein only in PBS-T 1% FCS) at the same 
concentration was used as positive control to compare the functionality of the released 
anti-toxin. Plates were incubated with anti-toxin samples overnight at 4 °C. After 
incubation, plates were washed three times with PBS-T and 100 µL of biotin-conjugated 
anti-horse IgG (1:2000 in 1% (v/v) FCS PBS-T) was added to each well and incubated 
for 4 h at room temperature (RT). Plates were washed three times with PBS-T and 100 
µL of alkaline phosphatase conjugated streptavidin (diluted 1:1000 in PBS-T) was added 
to each well.  After 2 h of incubation at RT, the plates were washed four times with PBS-
T and then, 100 µL of sodium carbonate (50 mM) and magnesium chloride (2mM) buffer 
(pH 9.3) containing 1 mg/mL phosphatase substrate was added. Plates reacted for 1 h 
at RT. The optical density (OD) of each well was measured at 405 nm using a Varian 
Cary 50 Microplate Reader (Varian, Inc., Sunnyvale, CA). The results were normalized 
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with the data for the unencapsulated antitoxin solution and reported as % residual 
functionality, as shown in Equation 5.1: 
 
 
 
5.3.5.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE): 
Primary Structure 
The primary structure of tetanus anti-toxin was evaluated using SDS-PAGE. 
Samples released from polyanhydride nanoparticles as well as unencapsulated protein 
were incubated with equal volumes of reducing sample buffer (SDS (10% w/v), Tris-HCl 
(1M, pH 6.8), glycerol (3 mM), bromophenol blue (0.01% w/v), and β-mercaptoethanol 
(0.05% v/v)). Samples were mixed and heated at 95 °C for 5 min after which they were 
loaded onto 4-20% Tris-HCl pre-cast gels and run at 120 V and 4°C for 90 min. Five µL 
of unstained protein standard were used as reference to determine the molecular weight 
of the samples. The gels were incubated in fixative solution (40% ethanol, 10% acetic 
acid) at 4oC for 3 h. Next, they were stained with fluorescent flamingo gel stain 
overnight, and washed with a 0.01% Tween 20 solution to reduce non-specific 
fluorescence. A Typhoon 8600 (GE Healthcare, Piscataway, NJ) fluorescence scanner 
was used to obtain the images of the gels. Experiments were performed in triplicate.  
 
5.3.5.3 Circular Dichroism (CD): Secondary Structure 
The secondary structure of the tetanus anti-toxin was monitored after release from 
polyanhydride nanoparticles by far UV CD (Jasco J-710 Spectropolarimeter, Easton, 
Eq. 5.1 
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MD)) at a wavelength range of 190-260 nm18-21. The spectra were collected using Jasco 
J-170 software (Easton, MD). The PBS spectra were subtracted from the protein 
spectra. The spectra shown are the average of three experiments.  
 
5.3.5.4 Fluorescence Spectroscopy: Tertiary Structure 
Fluorescence spectra were collected using a Varian Cary Eclipse Fluorescence 
Spectrometer (Varian, Inc.). The spectra (300-500 nm) were collected at an excitation 
wavelength of 280 nm that corresponds to tyrosine and tryptophan residues19,20. The 
PBS spectral emission values were subtracted from each sample. The emission 
spectrum was analyzed for shifts in peak intensity and wavelength, which are indicative 
of alterations in protein tertiary structure. 
 
5.3.6 Anti-TNF-α Functionality and Bioactivity after Release 
5.3.6.1 TNF-α Specific Enzyme Linked Immunosorbent Assay (ELISA) 
The ability of the released anti-TNF-α to recognize and bind to TNF-α was 
determined by ELISA. The ELISA protocol was similar to the previously described 
ELISA method for tetanus toxoid. Plates were initially coated with recombinant murine 
TNF-α (PeproTech, Rocky Hill, NJ) at a concentration of 5 µg/mL. Released antibody 
samples as well as unencapsulated anti-TNF-α were added at a concentration of 10 
µg/mL. The results were normalized with the data for the unencapsulated anti-TNF-α 
antibody solution and reported as % residual functionality, as shown in Equation 5.1. 
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5.3.6.2 Cell Culture 
L929 (murine fibroblasts) cells obtained from ATCC (Manassas, VA) were 
maintained in culture at 37°C in a 5% CO2 humidity using high glucose DMEM medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated FBS (Valley 
Biomedical, Winchester, VA), 100 IU/mL penicillin and 10 µg/mL streptomycin 
(Mediatech, Herndon, VA). After 5-7 days of culturing, confluent cells were washed and 
resuspended in culturing.  
 
5.3.6.3 TNF-α Cytotoxicity Assay 
L929 cells were incubated in 96-well flat-bottomed Costar microtiter plates at a 
concentration of 3.5 x 104 cells per well overnight at 37ºC. To determine the optimal 
TNF-α cytotoxic dose, cells were incubated with serial dilutions of TNF-α (from 1000 to 
0.9 pg/mL) for 24 h at 37ºC in the presence of actinomycin D (2 µg/mL) 32,33. The MTT 
assay was utilized to determine cell viability. Optical density (OD) was measured at 570 
and 690 nm. Data is presented as % cytotoxicity (Supplemental Figure 5.1A), as 
determined by Equation 5.2: 
 
 
 
An optimal TNF-α killing dose of 500 pg/mL was determined based on 90% 
cytotoxicity in the L929 cells.  
 
 
Eq. 5.2 
 	  
152 
5.3.6.4 Titration of anti-TNF-α Antibody Neutralization Activity against TNF-α 
The optimal dose of recombinant TNF-α selected from cytotoxicity assays (500 
pg/mL) was pre-incubated 33 for 4 h with serial dilutions of anti-TNF-α antibody (clone 
XT3.1) (from 10 µg/mL to 39 ng/mL), and added to L929 cells in 96-well microtiter 
plates. Pre-incubation of cytokine with the specific neutralizing antibody prior to addition 
to responding cells prevents cytokine binding to its receptor. After 24 h of culture, cell 
viabilities were measured as described above. Data is presented as % protection 
(Supplemental Figure 5.1B), as determined by Equation 5.3, in which the positive 
control are cells cultured in the absence of TNF-α. 
 
 
 
An antibody dose of 5 µg/mL was found to achieve ~100% protection from TNF-α 
killing.  
 
5.3.6.5 Released anti-TNF-α Antibody Neutralization Bioactivity 
In these experiments, treatments including anti-TNF-α released from polyanhydride 
nanoparticles, anti-TNF-α-loaded polyanhydride nanoparticles, and unencapsulated 
antibody were pre-incubated for 4 h with 500 pg/mL of recombinant TNF-α. 
Concentrations of released antibody as well as mass of anti-TNF-α-loaded nanoparticles 
were adjusted to achieve the optimal dose of anti-TNF-α antibody required to neutralize 
cytokine cytotoxicity, as determined in the experiment described above. The amount of 
anti-TNF-α-loaded nanoparticles necessary was determined by using the release 
Eq. 5.3 
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profiles during the first 4 h of release as a reference. After 24 h of culture, cell viabilities 
were measured as described above. Data is presented as % protection (Equation 5.3).  
 
5.3.7 Statistical analysis 
Statistical analysis was carried out using a one-way model ANOVA with JMP® 7 
(Cary, NC) to account for comparison-wise error. Comparisons between treatments 
were made with Tukey’s HSD to determine statistical significance.  
 
5.4 Results 
5.4.1 Polymer and nanoparticle characterization 
1H NMR spectroscopy was used to characterize the polymer structure and the 
spectra were consistent with previously published data15,29. The synthesized 20:80 
CPH:SA copolymer had an average Mw of 15,000 g/mol with a polydispersity index (PDI) 
of 2.1 while the 50:50 CPTEG:CPH copolymer had a Mw of 8,500 g/mol with a PDI of 
1.7. These values were obtained from 1H NMR and corroborated with GPC and are 
consistent with previous work15,17,21,23,24,29.  
Tetanus antitoxin and anti-TNF-α monoclonal antibodies were encapsulated in 20:80 
CPH:SA and 50:50 CPTEG:CPH nanoparticles using an anti-solvent nanoencapsulation 
method. These two chemistries were chosen based on previous work that demonstrated 
that their ability to stabilize globular proteins20,34 as well as recombinant antigens such 
as F1-V21, and because they exhibit chemistry-specific adjuvant properties in vitro22-24 
and in vivo14,16. The morphology of the antibody-loaded nanoparticles was visualized by 
SEM and were consistent with previous work14,23,24. QELS was used to determine 
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nanoparticle size distribution; average diameters for the 20:80 CPH:SA chemistry were 
240 ± 44 nm and those for the 50:50 CPTEG:CPH particles were 176 ± 29 nm.  
 
5.4.2 In vitro antibody release kinetics is dictated by polyanhydride chemistry 
Figure 5.1 show the release profiles of tetanus antitoxin and anti-TNF-α. The 
release of both antibodies is controlled by the polymer chemistry-dependent degradation 
kinetics of the nanoparticles. A slightly faster antibody release kinetics was observed 
from the 50:50 CPTEG:CPH particles with 80 to 90% of the protein released after 25 
days compared to 70 to 75% of protein released from the 20:80 CPH:SA nanoparticles 
during the same period of time. The difference in the release profile is related to a higher 
initial burst from the 50:50 CPTEG:CPH nanoparticles, which is consistent with previous 
work with other protein antigens14,17,20,21. This behavior is a consequence of the 
amphiphilic nature of CPTEG:CPH copolymers, which exhibit a combination of bulk and 
surface erosion, while the hydrophobic 20:80 CPH:SA exhibits surface erosion. 
However, the kinetics of the initial burst was different for each antibody; in the case of 
tetanus antitoxin the initial burst for both chemistries (~20% for 20:80 CPH:SA and 
~35% for 50:50 CPTEG:CPH) occurs during the first three hours of release (Figure 
5.1A), while for anti-TNF-α antibody a higher initial burst was observed from the 50:50 
CPTEG:CPH particles (~ 35%) after 24 h of in vitro release (Figure 5.1B). This indicates 
that the nature of the protein and its interactions with the polyanhydride chemistries 
influenced the obtained release profile.  
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Figure 5.1 Cumulative release fraction of (A) tetanus antitoxin and (B) anti-TNFα 
antibody released from 20:80 CPH:SA ( )and 50:50 CPTEG:CPH ( ) nanoparticles. 
Error bars are representative of two independent experiments performed in duplicate.  
 
5.4.3 Amphiphilic 50:50 CPTEG:CPH particles released functional tetanus 
antitoxin  
The stability of the released tetanus antitoxin was evaluated and is shown in Figure 
5.2. No detrimental effect on anti-serum functionality was observed when the protein 
was exposed to the nanoparticle fabrication conditions, suggesting that the use of 
organic solvents and other processing steps in the nanoparticle fabrication does not 
impair protein stability. Functionality of the released anti-serum was evaluated by ELISA 
and the analysis demonstrates that tetanus antitoxin released from 50:50 CPTEG:CPH 
nanoparticles retained ~100% of its functionality, while antitoxin released from 20:80 
CPH:SA nanoparticles preserved only 60% of its functionality.  
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Figure 5.2 Residual functionality of tetanus antitoxin released from polyanhydride 
nanoparticles. A tetanus antitoxin-specific ELISA was used to determine changes in 
functionality of the released protein compared to unencapsulated antibody and antibody 
exposed to nanoparticle fabrication conditions. Data are normalized to the 
unencapsulated antibody control. Error bars represent standard deviation of three 
independent experiments performed in triplicate. * indicates groups that are statistically 
significant (p ≤ 0.05) from the unencapsulated antibody control.  
 
A detailed analysis of protein structure alterations was performed to understand the 
loss of functionality upon release from the 20:80 CPH:SA nanoparticles and to identify 
the structural levels at which the changes are occurring. A summary of this analysis is 
presented in Figure 5.3. SDS-PAGE was utilized to evaluate changes in primary 
structure. Tetanus antitoxin is mainly composed of immunoglobulin G (IgG) molecules 
and therefore its two main characteristics bands appear at ~50 kDa, which is 
characteristic of the heavy chains, and at ~25 kDa, representing the light chains. Figure 
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5.3A shows that the two main characteristic bands were observed for the 
unencapsulated tetanus antitoxin control together with some secondary bands at higher 
molecular weights, which correspond to other proteins that compose the anti-serum. 
While the two main bands were observed for antitoxin released from both 50:50 
CPTEG:CPH and 20:80 CPH:SA nanoparticles, the bands were significantly weaker in 
intensity when compared with the unencapsulated antitoxin. Besides, the 50 kDa band 
was observed at a slightly higher molecular weight and other bands at higher molecular 
weights were observed, which may be indicative of protein aggregation. These 
observations are more remarkable in the antitoxin released from the 20:80 CPH:SA 
nanoparticles.  
The CD spectra for tetanus antitoxin showed a minimum between 217 and 219 nm 
(Figure 5.3B) indicating a predominance of β-sheet conformation, as previously 
described by Cathou et al35. While nanoparticle fabrication conditions preserved the 
secondary structure, antitoxin released from 50:50 CPTEG:CPH nanoparticles showed 
a slight shift of the minimum to the left (~ 215 nm). A more pronounced shift to the left 
together with a significant increase in molar ellipticity (Δε) was observed when tetanus 
antitoxin was released from 20:80 CPH:SA nanoparticles, signifying a loss in secondary 
structure.  
Fluorescence spectroscopy was used to analyze changes in the tertiary structure of 
the protein. While the position of the peak is preserved for tetanus antitoxin released 
from both polyanhydride chemistries, antitoxin peak intensity was lower for the protein 
release from the 20:80 CPH:SA nanoparticles, indicating protein unfolding (Figure 
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5.3C). The nanoparticle fabrication conditions and the 50:50 CPTEG:CPH nanoparticles 
did not have any detrimental effects on the tertiary structure of the antitoxin. 
 
Figure 5.3 Structural integrity of tetanus antitoxin was best preserved by the amphiphilic 
50:50 CPTEG:CPH nanoparticles while protein released from the hydrophobic 20:80 
CPH:SA nanoparticles showed changes in primary, secondary and tertiary structure. 
Representative data from three independent experiments is presented. A) Primary 
structure analysis by SDS-PAGE, B) Secondary structure by CD spectra, and C) 
Tertiary structure by fluorescence spectroscopy.  
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5.4.4 Functionality of anti-TNF-α was partially lost upon release for 72 h from both 
polyanhydride chemistries  
Anti-TNF-α monoclonal antibody was released and its functionality upon release was 
evaluated using ELISA. The anti-TNF-α (clone XT3.1) used in this study was selected 
because it has been used for in vitro and in vivo neutralization of TNF-α28,36. Figure 5.4 
shows that ~40% loss of functionality was observed when the anti-TNF-α monoclonal 
antibody was released from 20:80 CPH:SA and 50:50 CPTEG:CPH particles. Antibody 
functionality was maintained when exposed to nanoparticle fabrication conditions.   
 
Figure 5.4 Functionality of anti-TNF-α partially lost upon release for 72 h from both 
polyanhydride chemistries. Residual functionality of anti-TNF-α released from 
polyanhydride nanoparticles was measured using an ELISA and compared to 
unencapsulated antibody and antibody exposed to nanoparticle fabrication conditions. 
Data are normalized to the unencapsulated antibody control. Error bars represent 
standard deviation of three independent experiments performed in triplicate. * indicates 
groups that are statistically significant (p ≤ 0.05) from the unencapsulated antibody 
control. 
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5.4.5 Anti-TNF-α-loaded polyanhydride nanoparticles are capable of releasing 
bioactive antibody avoiding the detrimental effect of accumulation of degradation 
products  
An in vitro TNF-α neutralization assay was employed to assess the ability of anti-
TNF-α-loaded nanoparticles to preserve the biological function of the monoclonal 
antibody directly after its release. In addition, a comparison between the effect of any 
structural changes that may have occurred to antibodies during the 72 h release 
experiment, and bioactivity directly after release was performed. Because there was no 
statistical difference in the amount of anti-TNF-α released between the two nanoparticle 
chemistries utilized in these studies in the first 4 h (as shown in Figure 5.1B), direct 
comparisons between the various groups can be made. Antibody-loaded nanoparticle 
mass was adjusted in order to obtain an antibody concentration of 5 µg/mL in the assay 
well during the 4 h of incubation. The accumulated antibody released during 72 h as well 
as the unencapsulated antibody and antibody exposed to nanoparticle fabrication 
conditions controls were also added at a concentration of 5 µg/mL to allow for direct 
comparisons between the groups.  
As observed in Figure 5, the functionality trends showed in Figure 5.4 correlate with 
the bioactivity of this monoclonal antibody, protecting L929 cells from the cytotoxic effect 
of recombinant TNF-α. Only 60% protection was achieved during 72 h of release from 
both chemistries. However, better protection was obtained when anti-TNF-α -loaded 
nanoparticles were directly used in the assay indicating that accumulation of 
polyanhydride degradation products in the media surrounding the particles has a 
detrimental effect on antibody bioactivity. This observation was chemistry-independent 
(Figure 5.5). Protection levels obtained with the direct incubation of antibody-loaded 
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nanoparticles were similar to or higher than the 90% that was also observed for the 
unencapsulated antibody and antibody exposed to nanoparticle fabrication conditions 
controls.  
 
Figure 5.5 Anti-TNF-α-loaded polyanhydride nanoparticles are capable of releasing 
bioactive antibody, while accumulation of polyanhydride degradation products affects 
antibody bioactivity. Percentage protection from TNF-α cytolytic activity achieved by 
anti-TNF-α antibody. L929 cells were cultured for 24 h in the presence of TNF-α and 
unencapsulated antibody, antibody exposed to nanoparticle fabrication conditions 
(fabrication conditions), or antibodies released from polyanhydride nanoparticles. The 
viability of the cells was quantified by the MTT assay and represented as percentages 
against control cells cultured in the absence of TNF-α. Error bars indicate standard error 
of three independent experiments performed in triplicate. Treatments with different 
letters are significantly different from one another at p ≤ 0.05, while * indicates statistical 
significance between the two nanoparticle groups (p ≤ 0.003).  
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5.5 Discussion 
Sustained delivery of antibodies using biodegradable polyanhydride nanoparticles 
can reduce the high costs associated with antibody-related therapies. However, 
antibody instability leading to loss of biological activity upon encapsulation and release 
from these delivery vehicles is a formidable challenge in the design of effective 
antibody-based therapeutic formulations. The data presented herein demonstrate that 
amphiphilic polyanhydride nanoparticle-based delivery platforms can be used to provide 
sustained delivery of functional antibodies (i.e., polyclonal or monoclonal).  
Bioavailability and therapeutic indices for many therapeutic antibodies are strongly 
dependent on the circulating half-life3 and this can be altered by using controlled-release 
methods, based on the geometry, size and chemistry of the delivery devices, the 
appropriate antibody loading, and delivery route. The nanoparticle-based delivery 
system studied herein demonstrated polymer chemistry-dependent sustained release of 
antibodies for almost one month, as shown in Figure 5.1. In the present study, two 
specific polyanhydride chemistries (i.e., 20:80 CPH:SA and 50:50 CPTEG:CPH) were 
studied; however, we have previously demonstrated for several protein antigens that 
varying the co-monomer ratio, results in release profiles ranging from weeks to 
months17,20,25. 
While sustained release of antibodies over time results in longer circulating half-life, 
it is essential that the released protein is functional and bioactive. Formulations of 
antibodies in many polymer vehicles often require exposure to conditions that may be 
deleterious to protein structure and function37. In this work, the nanoparticle fabrication 
conditions utilized to encapsulate antibodies into polyanhydride nanoparticles (e.g., 
exposure to organic solvent, sonication, and vacuum drying) had no effect on the 
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structure, functionality, and bioactivity of both tetanus antitoxin and anti-TNF-α 
monoclonal antibodies (Figures 5.2, 5.3, 5.4 and 5.5). This is in agreement with similar 
results with other proteins exposed to these conditions17,18,20,21,25,34. 
Intravenous immunoglobulin (IVIg) is a FDA-approved therapeutic comprising of 
polyclonal antibodies pooled from serum donors and administered to patients3,5 for 
treatment of AIDS and toxin-mediated diseases5,6. However, since new developments 
allow for the production of unlimited types of monoclonal antibodies (mAbs), the use of 
therapeutic formulations based on mAbs have increased due to their high specificity3,5. 
Since therapies based on both polyclonal antibodies (i.e., tetanus antitoxin) and mAbs 
(i.e., anti-TNF-α) are currently in use, the present work included a detailed analysis of 
release and stability of both types of antibodies.  
As shown in Figures 5.2 and 5.3, the amphiphilic 50:50 CPTEG:CPH copolymer 
nanoparticles released stable tetanus antitoxin and preserved the functionality of the 
antitoxin. In contrast, tetanus antitoxin released from the hydrophobic 20:80 CPH:SA 
nanoparticles showed ~40% loss in antibody functionality (Figure 5.2). This detrimental 
effect of the hydrophobic 20:80 CPH:SA carrier on antibody functionality was shown to 
correlate with changes in the primary, secondary, and tertiary structures of the protein 
(Figure 5.3). Protein aggregation was observed when protein was released from both 
nanoparticle chemistries (Figure 5.3A), presumably due to the presence of the 
hydrophobic CPH17 in both copolymer systems; this behavior has been observed for 
other protein antigens19,20,34. In addition, a decrease in the β-sheet content was 
observed (i.e., left-shift of spectral minima as well as decrease of peak intensity at 200 
nm which is characteristic of β-sheet content35) for the protein released from 20:80 
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CPH:SA particles, as shown in Figure 5.3B. These changes in the secondary structure 
may lead to protein unfolding, as suggested by the fluorescence spectroscopy data 
(Figure 5.3C). 
Released monoclonal anti-TNF-α antibody from both polyanhydride nanoparticles 
chemistries showed a ~40% loss of functionality (Figure 5.4) that was also reflected in 
its biological activity (Figure 5.5). The results presented in Figure 5.5 also showed that 
exposure of antibody to polymer degradation products (e.g., cumulative release over 72 
h) had a detrimental effect on the biological activity of anti-TNF-α mAb. However, 
delivery of anti-TNF-α mAb by directly adding antibody-loaded nanoparticles to the 
assay wells improves the bioactivity of this mAb as reflected in the higher protection 
percentages (Figure 5.5) (i.e., higher neutralization) from the cytotoxic effect of TNF-α 
in L929 cells.  
Collectively, these results indicate that the amphiphilic 50:50 CPTEG:CPH 
nanoparticles provide sustained release of functional tetanus antitoxin and anti-TNF-α 
antibody. Similar results have been observed previously with this amphiphilic system 
when used as a delivery vehicle for other proteins including globular proteins17,20, acid-
stabilized proteins20, and Yersinia pestis antigens21.  
 
5.6 Conclusions 
One of the most difficult challenges to overcome in antibody-based therapies is to 
provide sustained delivery of therapeutic doses of bioactive antibodies. The studies 
reported herein demonstrate the potential use of amphiphilic polyanhydride 
nanoparticles as an effective antibody delivery platform. These nanoparticles provide 
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the ability to sustain antibody release kinetics for about four weeks, thus increasing 
antibody circulation half-life. Additionally, these particles are capable of preserving 
antibody functionality and bioactivity upon fabrication and release. Current studies are 
focused on investigating formulations based on these particles for in vivo neutralization 
of the inflammatory effect due to TNF-α after endotoxin challenge.  
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5.9 Supplemental data 
 
 
Supplemental Figure 5.1 Optimization of TNF-α cytotoxic dose and anti-TNF-α 
neutralization dose. A 500 pg/mL dose of TNF-α was sufficient to achieve around 95% 
of cytotoxicity in L929 cells, while 5 µg/mL of either anti-TNF-α antibody was necessary 
to protect close to 100% of cells. A) Titration of cytolytic activity of the recombinant TNF-
α, B) neutralization of TNF-α by different doses of antibody. The viability of the cells was 
quantified by MTT assay and represented as percentages against control cells cultured 
in the absence of TNF-α. Error bars represents standard deviation of three independent 
experiments performed in triplicate. 
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6.1 Abstract 
The in vitro adsorption of plasma proteins on polyanhydride microparticles based on 
sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was studied. Three model proteins from 
bovine serum (albumin (BSA), immunoglobulin G (IgG) and fibrinogen (Fg)) were used. 
The adsorption was studied using X-Ray Photoelectron Spectroscopy and gel 
electrophoresis. 2-D electrophoresis was used to study the adsorption of plasma 
proteins from bovine serum. Differences in the amount of protein adsorbed were 
detected as a function of: (i) copolymer composition and (ii) specific protein studied. A 
direct correlation between polymer hydrophobicity and protein adsorbed was observed 
and higher quantities of Fg and IgG were absorbed. In vitro release studies were 
performed with ovalbumin-encapsulated microparticles that were incubated with Fg; 
these studies showed a reduction in the amount of ovalbumin released from the 
microparticles when Fg is adsorbed on the surface. An understanding of protein 
adsorption patterns on parenteral delivery devices is valuable in optimizing their in vivo 
performance.  
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6.2 Introduction 
The use of biodegradable polymeric devices as drug carriers and adjuvants has 
promise because these materials can sustain the release of protein antigens over time 
in addition to exhibiting immunomodulatory properties that can be controlled by selecting 
the correct polymer chemistry.1,2 Polyester microparticles, specifically those composed 
of lactic acid and glycolic acid (e.g., poly (lactide-co-glycolide), PLGA), have been 
extensively studied and used as delivery devices for biomedical applications.3,4 Different 
proteins have been encapsulated into PLGA microparticles because they provide a 
sustained release for these proteins and their degradation products are easily absorbed 
by neighboring cells.5-7 However, these degradation products can create an acidic 
microenvironment that has been shown to perturb the structure of encapsulated 
proteins.5,7,8 In addition, PLGA is a bulk-eroding polymer that, in aqueous environments, 
can expose the encapsulated protein to a high moisture environment that may lead to 
aggregation.9,10  
In order to reduce moisture-induced aggregation, researchers have studied surface 
eroding polymers such as polyanhydrides.11,12 Many polyanhydride degradation 
products do not result in a decrease in the local pH that is as severe as that due to 
PLGA degradation (due to the lower solubility of polyanhydride degradation products in 
water). Thus, polyanhydrides provide a favorable environment for protein stabilization 
and release. In this regard, polyanhydrides have been shown to maintain the primary, 
secondary and tertiary structure of various proteins (i.e. ovalbumin, lysozyme, tetanus 
toxoid) as well as preserve their biological activity.13-15 Additionally, in vitro release 
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studies have shown that it is possible to control the release kinetics of proteins, ranging 
from days to months, by choosing the appropriate polyanhydride chemistry.11,13-15  
When these drug carriers are injected, their surface will be in contact with blood. It is 
well known that plasma proteins in the blood adsorb to these carriers within a few 
minutes after contact.16-19 The biodistribution and biocompatibility of these carriers, and 
therefore their effectiveness as vaccine adjuvants, can be influenced by the adsorption 
of these plasma proteins. For example, proteins adsorbed on polymer microparticles 
can determine the immunological recognition of these carriers by the mononuclear 
phagocytic system (MPS).17-19 Some plasma proteins can act as opsonins (e.g., 
immunoglobulin or complement factors) that can accelerate the recognition and 
elimination of drug carries by macrophages of the MPS.17,19 In case these opsonins are 
missing or other proteins such as albumins are adsorbed, a reduction in the uptake of 
these carriers by the MPS is observed, thus increasing their blood half-life.19,20 Other 
type of cells and immune pathways can be regulated by the presence of specific 
proteins; for example, adsorption of fibrinogen has shown to play an important role in 
the adhesion of platelets and neutrophils, and also this protein participate in the 
coagulation cascade.21-23 It is known that the particle surface properties (e.g., 
hydrophobicity and charge) and protein properties (e.g., hydrophobicity, charge, 
molecular mass, and conformational stability) play an important role in determining the 
amount of protein adsorbed on different types of material surfaces.16,20,24-26 Typically, the 
first protein layer formed on the specific surface will determine the subsequent 
interaction between proteins and the material surface. To describe the formation of 
these protein layers it is important to study both the protein-surface affinities and the 
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competitive or cooperative interactions between the different plasma proteins. In 
particular, it is known that abundant and rapidly adsorbed proteins can be displaced by 
trace proteins that arrive at the surface slowly (Vroman effect); this can affect the 
development of time-dependent competitive protein adsorption 27,28.  
Plasma protein adsorption on different material surfaces (e.g., modified silica) has 
been extensively studied for tissue engineering using films as model devices and 
focusing on non-degradable materials;22,29-32 but there are few systematic studies of 
protein adsorption phenomena on degradable materials. In this study, microparticles of 
polyanhydride copolymers based on sebacic acid (SA) and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) have been used.1,13,33 The hydrolytic degradation rates 
of polyanhydrides can be altered by simple changes in the polymer backbone by 
choosing appropriate monomers.34 For example, in order to enhance the hydrophilicity 
of the monomer to obtain a faster degradation rate, triethylene glycol (TEG) can be 
incorporated into the CPH backbone resulting in poly(1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane) (CPTEG), which when copolymerized with CPH results in a copolymer with 
amphiphilic properties.35 
The main purpose of this study was to determine how different degradable polymer 
chemistries affect protein adsorption. In this work, three model proteins from bovine 
serum were chosen for in vitro experiments: bovine serum albumin (BSA), which is the 
most abundant protein (60%) in plasma;22,30 immunoglobulin G (IgG), which is an 
opsonin and is the most abundant antibody in plasma;18,22,30 and fibrinogen (Fg), which 
in addition to its opsonization properties, is a “sticky” protein that adsorbs strongly on 
different surfaces.17,21,23 In order to study adsorption, X-Ray Photoelectron Spectroscopy 
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(XPS) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
using a fluorescent gel dye were used. To determine the effect of competitive 
adsorption, polyanhydride microparticles were incubated in bovine serum and 2-D 
electrophoresis was used to qualitatively determine the specific protein(s) adsorbed. 
Finally, in order to determine the effect of surface adsorption on protein release profiles, 
in vitro release studies were performed with ovalbumin (Ova)-encapsulated 
microparticles that were incubated with Fg, and the release kinetics was characterized 
with SDS-PAGE. 
 
6.3 Materials and methods 
6.3.1 Materials 
Chemicals needed for monomer synthesis and polymerization, sebacic acid (99%), 
p-carboxy benzoic acid (99+%), and 1-methyl-2-pyrrolidinone anhydrous (99+%), were 
purchased from Aldrich (Milwaukee, WI); 4-p-hydroxybenzoic acid, 1,6-dibromohexane, 
1-methyl-2 pyrrolidinone, and tri-ethylene glycol were purchased from Sigma Aldrich (St. 
Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
acetonitrile, acetic anhydride, methylene chloride, and petroleum ether were purchased 
from Fisher Scientific (Fairlawn, NJ). BSA and ovalbumin were purchased from Sigma 
Aldrich (St. Louis, MO); bovine IgG was purchased from Bethyl Corporation 
(Montgomery, TX); and bovine Fg and bovine serum were obtained from Aniara 
Corporation (Mason, OH). Materials for SDS-PAGE and 2-D electrophoresis, which 
included 12% Tris-Glycine pre-cast gels, unstained protein standards,  Flamingo gel 
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stain,11 cm Immobilized pH gradient (IPG) strips (pH 3-10, non-linear), and 4-15% 
polyacrylamide gels were purchased from BioRad Laboratories (Richmond, CA).  
 
6.3.2 Polymer synthesis and characterization 
CPH and CPTEG diacids were synthesized as previously described.36,37 SA and 
CPH prepolymers were synthesized by the methods described by Shen et al.38 and by 
Conix.36 Subsequently, CPH:SA and CPTEG:CPH copolymers were synthesized by 
melt polycondensation as respectively described by Kipper et al.39 and Torres et al.37 
The chemical structure of the polymers was characterized with 1H NMR and the 
molecular weight was determined using gel permeation chromatography (GPC). These 
methods were described in our previous work and the results are consistent with 
previous work.37,39 
 
6.3.3 Microparticle fabrication and characterization 
Microparticles of different polymer compositions were made using cryogenic 
atomization.40 Briefly, 100 mg of the polymer was weighed and dissolved in methylene 
chloride. The polymer solution was then pumped through an 8700–1200 MS ultrasonic 
atomizing nozzle (SonoTek Corporation, Milton, NY) into 200 mL of frozen ethanol (with 
an excess of liquid nitrogen). 50:50 CPH:SA and CPTEG-based copolymer 
compositions were fabricated at 4°C (inside a walk-in cooler) while the other polymers 
were fabricated at room temperature. All the compositions were stored at - 80 °C for 
three days. For CPTEG-based compositions, after the first 24 h, ~200 mL of cold 
ethanol was added to reduce aggregation; the solutions were stirred at 300 rpm for 15 
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min and placed back in the freezer at –80 °C. After three days, vacuum filtration was 
used to collect the microparticles and they were dried overnight under vacuum.15 
Microparticle samples were coated with an ultrathin layer of gold by low vacuum sputter 
coating and Scanning Electron Microscopy (SEM) (JEOL 840 A, JEOL Peabody, MA) 
was used to observe the morphology of the microparticles.  
 
6.3.4 Protein adsorption 
20% w/v suspensions of polymer microparticles were prepared in phosphate buffer 
saline (PBS) (0.1 M, pH 7.4). BSA, IgG, and Fg suspensions in PBS were prepared with 
a final concentration of 1 mg/mL. Then, 250 µL of the protein solutions were added to 
750 µL of the microparticle suspensions to obtain a final protein concentration of 250 
µg/mL. The solution was mildly vortexed for 1 min and incubated for 5 min at 37 °C. 
After incubation, the solution was centrifuged at 12000 x g for 10 min. Three washes 
with PBS were performed and the microparticles were dried under vacuum overnight.  
 
6.3.5 X-Ray Photoelectron Spectroscopy (XPS) 
XPS analysis was used to determine the amount of protein adsorbed on the surface 
of the microparticles. XPS data was acquired using a PHI 5500 Multi-technique system 
(Physical Electronics, Inc., Chanhassen, MN). Samples were mounted using 3M double-
sided Scotch tape. Standard aluminum source was used with carbon as reference for 
charge correction. Blank microparticles were used as controls. High-resolution C1s 
peaks were collected and fitted used CasaXPS software (RBD Instruments, Bend, OR). 
Binding energies were referenced to the aliphatic hydrocarbon peak at 285.0 eV.31,41 
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The total protein adsorbed is presented as µg of protein per area (cm2), which was 
obtained using the mean diameter of the microparticles. The area of the C1s peaks that 
contributes to the nitrogen content was divided by the total area of the carbon peak in 
order to determine the atomic concentration fraction that is related to the fraction of 
protein that is adsorbed on the microparticles. This was then used to estimate the total 
mass (µg) of protein adsorbed.  
 
6.3.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
To determine the amount of protein adsorbed and to corroborate the results obtained 
with XPS, SDS-PAGE was performed. In order to extract the protein adsorbed on the 
polymer microparticles, 600 µL of a non-reducing sample buffer (SDS (10% w/v), Tris-
HCl (1 M, pH 6.8), glycerol (3 mM), bromophenol blue (0.01% w/v)) were added to 20 
mg of microparticles. The samples were vortexed and heated for 5 min at 70 °C. After 
cooling at room temperature and centrifuging for 10 min at 12,000 x g, the supernatant 
was collected and each solution was filtered with 0.20 µm syringe filters to eliminate any 
remaining microparticles. The samples were loaded into 12% Tris-Glycine pre-cast gels 
and run for 90 minutes at 140V. 5 µL of unstained protein standard were used as 
reference to determine the molecular mass of the samples. The gels were incubated in 
fixative solution (40% ethanol, 10% acetic acid) at 4oC for 3 h. Next, they were stained 
with fluorescent flamingo gel overnight, after which the gels were washed with 0.01% 
Tween 20 solution to eliminate excess in the background. 
A Typhoon 8600 (GE Healthcare, Piscataway, NJ) fluorescence scanner with a 
green laser (532 nm) and a 555 nm longpass emission filter was used to obtain the 
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images of the gel and ImageQuantTL (GE Healthcare, Piscataway, NJ) software was 
used to quantify the intensity of the bands in the gels. In order to quantify the unknown 
samples, a standard curve with concentrations ranging from 2500 ng/mL to 10 ng/mL 
was obtained for the different proteins using the same SDS-PAGE protocol used for the 
unknown samples. The main characteristic bands for each of the proteins were used to 
obtain the standard curves, and the same bands were used for protein quantification. 
This fluorescence technique with the overnight staining protocol used in these 
experiments exhibits a limit of detection of 1 ng. Linear quantitation was obtained with 
the described protocol with correlation coefficients in the range of 0.97 to 0.99. The 
quantified adsorbed protein was normalized to the initial amount of protein used in the 
initial incubation. The total protein adsorbed is presented as µg protein per area (cm2). 
 
6.3.7 Qualitative identification of serum proteins by 2-D electrophoresis 
Microparticle suspensions (20% w/v) were prepared in PBS and 2.5 mL of bovine 
serum supplemented with bovine fibrinogen (10 µg/mL) was added. The samples were 
incubated at 37°C for 5 min with constant mixing (100 rpm). Three washing steps with 
PBS were performed as described in the Protein adsorption section. For protein 
desorption, a solution containing 10% (w/w) SDS and 2.3% (w/w) dithioerythritol was 
applied and samples were heated at 95 °C for 10 min.42 Particles were centrifuged for 
10 min at 12000 x g and the supernatant was applied for the 2-D electrophoresis 
analysis. 
The first dimension of the electrophoresis was done using 11 cm IPG strips (pH 3-
10). The first dimension separation was performed in the IPGPhor system (GE 
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Healthcare, Piscataway, NJ) following a slow voltage ramping protocol: 50 V for 10 h, 
500 V for 1 h, 1000 V for 1 h, and 8000 V for 4 h.42 For the second dimension of the 
separation analysis, strips were loaded in 4-15% polyacrylamide gels and run for 2 h at 
140 °C. Gels were fixed, stained and scanned as described in the SDS-PAGE section. A 
2-D separation was performed using bovine serum samples that were used as a control. 
A qualitative analysis was performed by comparing the gels of the desorbed proteins 
with those obtained from bovine serum and ImageQuantTL (GE Healthcare, 
Piscataway, NJ) software was used to identify the main bands on the gels. 
 
6.3.8 In vitro protein release 
The effect of protein adsorption on the release kinetics of protein-loaded polymer 
microparticles was studied. Ovalbumin (ca. 4 wt%) was encapsulated into polymer 
microparticles fabricated by cryogenic atomization as described previously.13,15,40 
Twenty mg of protein-loaded microparticles were incubated with fibrinogen at a final 
concentration of 10 µg/mL by the procedure described before. Ova-encapsulated 
microparticles not subjected to protein adsorption underwent the same wash protocol in 
order to be used as control and to obtain differences in the release profiles that are only 
caused by the presence of adsorbed protein on the surface.   
15 mg of Ova-encapsulated microparticles were suspended in 1 mL of phosphate 
buffer (0.1 M, pH 7.4) and incubated at 37°C and 100 rpm. Samples of 750 µL were 
taken at different intervals of time and replaced with fresh PBS. The release samples 
were stored at 4°C for measurements of protein concentration by SDS-PAGE as 
described before. The experiments were performed in triplicate. The cumulative release 
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was normalized by the total protein encapsulated, which was determined as previously 
described.15 
 
6.4 Results and discussion 
6.4.1 Microparticle fabrication and characterization 
Figure 6.1 shows SEM images of 10:90, 20:80 and 50:50 CPTEG:CPH and 
poly(SA) microparticles fabricated by cryogenic atomization. It was observed that the 
surface morphology of the microparticles varied with the polymer composition; 
Determan et al.13 suggested that this change in surface morphology is caused by 
hydrophobicity (i.e., the higher the CPH content, the smoother the surface of the 
microparticles). In Figure 6.1, we observe this trend with the different CPTEG:CPH 
compositions; the surface of the microparticles becomes smoother with increasing CPH 
content. The mean diameter for all the microparticles was 10-16 µm, which is consistent 
with previous work15,40. 
 
Table 6.1 XPS analysis of atomic concentrations and ratios of elements present on 
control blank polymer microspheres. 
Microsphere 
compositions 
C% N% O% O/C% N/C% 
Poly SA 76.23 0.00 23.77 0.31 0.00 
20:80 CPH:SA 77.54 0.00 22.42 0.29 0.00 
50:50 CPH:SA 76.37 0.00 23.18 0.30 0.00 
10:90 CPTEG:CPH 72.75 0.24 27.01 0.37 0.0033 
20:80 CPTEG:CPH 76.28 0.26 23.46 0.31 0.0034 
50:50 CPTEG:CPH 75.30 0.29 24.34 0.32 0.0039 
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Figure 6.1 SEM images of microparticles fabricated by cryogenic atomization: (a) 10:90 
CPTEG:CPH, (b) 50:50 CPTEG:CPH, (c) Poly(SA), and (d) 20:80 CPTEG:CPH. Scale 
bar: (a), (c), and (d) 50 µm, and (b) 10 µm. 
 
6.4.2 XPS analysis 
The detection of proteins at interfaces using XPS generally involves the detection of 
nitrogen in the proteins; when the substrate (i.e., polymer surface) contains the same 
atoms as the adsorbed proteins (but at different atomic concentrations), changes in the 
N/C ratio can be used to evaluate the adsorption of proteins.32 Blank polymer 
microparticles were used as controls in order to determine the presence of any nitrogen 
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atoms. Table 6.1 shows the elemental atomic concentration and elemental ratios on the 
surface of the blank microparticles. It was observed that microparticles containing 
CPTEG show the presence of nitrogen atoms at ca. 0.2% (atomic concentration), which 
was attributed to the chemicals used in the polymer synthesis.  
Incubation of microparticles with the three different model proteins was performed at 
37 °C for 5 min. This short incubation period is representative of in vivo conditions 
because it has been shown that the removal of up to 90% of intravenously applied 
devices from circulation in the blood stream occurs within a few minutes.22,43-45 
Therefore, the adsorption of plasma proteins should occur during this time. Incubation 
was also performed for 30 min (data not shown) and no difference in the amount of 
adsorbed protein was identified (by XPS analysis); these results are in agreement with 
literature models for protein adsorption.46  
Figure 6.2 shows XPS results (presented as µg of protein adsorbed per cm2) of (a) 
CPH:SA and (b) CPTEG:CPH microparticles for BSA, IgG and Fg. An increase in the 
nitrogen content is observed for all the polymer chemistries after incubation with protein 
providing evidence for the adsorption of protein on the microparticle surface. A direct 
correlation between the amount of protein adsorbed and the CPH content is present in 
both polymer systems. This trend correlates with the hydrophobicity of the polymer 
surface. Previous contact angle experiments performed by Lopac et al.40 have shown 
that the hydrophobicity of these systems increases when the CPH content increases. 
On the other hand, an increase in amphiphilicity (i.e., increasing CPTEG content from 
10-50%) results in a decrease in the amount of protein adsorbed by more than 50% in 
the case of IgG and Fg; these results are consistent with other studies that showed that 
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incorporation of PEG on different surfaces avoids plasma protein adsorption reducing 
macrophage uptake and increasing carrier blood half-life.16,18,20,47 From Figure 6.2, it is 
also clear that higher amounts of Fg (1.2 µg/cm2) and IgG (0.9 µg/cm2) are adsorbed on 
the different microparticle compositions; other plasma protein adsorption studies have 
shown similar trends after in vitro incubation with serum.18,31 This is important because 
in addition to the total amount of adsorbed protein, the type of protein adsorbed could 
affect the in vivo behavior of these drug carriers,18,22,30,47-49 Because of their opsonization 
properties, the adsorption of IgG and Fg can enhance phagocytosis by the MPS while 
the adsorption of BSA would reduce phagocytosis, thus increasing the blood circulation 
time of the microparticles.18,41,47-49 Long circulation time periods are desirable for protein 
delivery vehicles in order to allow uptake and presentation of the encapsulated protein 
by antigen presenting cells (APCs).  
 
Table 6.2 Quantification of components fitted to high-resolution C1s spectra.  
Protein-adsorbed microspheres Percentage area of C1s components 
  C1 C2 C3 C4 
10:90 CPTEG:CPH 
Blank 68.9 21.32 4.8 4.9 
BSA 64.7 22.0 6.9 6.3 
50:50 CPH:SA 
Blank 74.9 13.6 3.4 8.0 
IgG 64.3 20.7 10.0 4.9 
50:50 CPTEG:CPH 
Blank 64.8 24.2 6.6 4.4 
Fg 57.9 30.9 7.4 3.8 
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Figure 6.2 Total protein adsorbed (µg/cm2) on polyanhydride microparticles obtained 
from XPS analysis: (a) CPH:SA and (b) CPTEG:CPH. Error bars represent standard 
error of three different experiments with duplicate samples in each. * represent p-value < 
0.05 obtained from statistical student-t test.
 
High-resolution XPS analysis was used to probe the presence of proteins on the 
surface of the polymer microparticles. High-resolution C1s spectra were fitted with four 
main components according with their characteristic binding energy representing 
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aliphatic hydrocarbon at 285.0 eV (C1), ether and amine groups at 286.5 eV (C2), 
carbonyl and amide groups at 288.2 eV (C3), and ester and carboxylic acid groups at 
289.1 eV (C4).32,50-52 Analysis of C1s spectra allows for more direct comparison of 
protein adsorption based on increases in the amide and carboxylic acid groups (C3 and 
C4 components respectively).32,52 Both the C3 and the C4 components contribute to the 
identification of the adsorbed protein; however, the C3 component has been shown to 
be more significant.51 This is consistent with the XPS analysis of lyophilized proteins 
used as controls. Table 6.2 shows percentage areas obtained from high-resolution C1s 
fitted spectra for three different microparticle compositions as an example for each of 
the proteins studied. From inspection, there is a substantial increase in the C3 
component (from 3.4% to 10.0%) for 50:50 CPH:SA microparticles after adsorption of 
IgG. For 10:90 CPTEG:CPH microparticles, an increase in the C3 and C4 components 
is observed after incubation with BSA protein, from 4.8% and 5.0% to 6.9% and 6.3% 
respectively. It is instructive to note that for 10:90 CPTEG:CPH microparticles (which 
have the highest CPH content), the amount of BSA adsorbed is lower than that of IgG in 
50:50 CPH:SA, indicating that the adsorption of plasma proteins depends on the specific 
protein. For 50:50 CPTEG:CPH microparticles, a small increase of 0.8% is observed 
after incubation with Fg, which is the “stickiest” protein studied, confirming that the 
reduction of the CPH content (or the increase of CPTEG content) lowers the adsorption 
of plasma proteins.16,18,20,47,53 
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6.4.3 SDS-PAGE 
SDS-PAGE using a fluorescent gel stain dye was performed in order to confirm the 
results obtained by XPS analysis. Non-reducing conditions were used; bands at 66, 150 
and 330 kDa were expected for BSA, IgG and Fg respectively. The bands for each of 
the proteins appeared in the correct molecular weight (images not shown); lower 
molecular weight bands appeared for the CPH:SA system (especially for BSA) 
indicating that the proteins underwent hydrolysis. This phenomenon is attributed to the 
decrease in pH caused by the presence of SA in combination with the exposure to high 
temperatures during the incubation period and the sample preparation process; this 
observation is consistent with previous results.13,14 
Figure 6.3 shows the amounts of adsorbed protein per total surface area for (a) 
CPH:SA and (b) CPTEG:CPH microparticles. Once again, an adsorption pattern based 
on microparticle hydrophobicity is observed; the amount of protein adsorbed increases 
with CPH content and decreases with CPTEG or SA content. These results were 
confirmed statistically with a student-t test that showed significant differences (p < 0.05), 
especially between the microparticles containing a high fraction of CPH (i.e. 50:50 CPH: 
SA and 10:90 CPTEG:CPH) and those containing more SA or CPTEG (i.e., poly(SA) or 
50:50 CPTEG:CPH). These results are consistent with the XPS analysis (Figure 6.2). 
The SDS-PAGE results also confirm differences in the amount of protein adsorbed 
according to the type of protein studied. Consistent with the results shown in Figure 6.2, 
the data shown in Figure 6.3 indicated that BSA is the least adsorbed protein with an 
average mass of protein adsorbed of 0.3 µg/cm2 followed by IgG (1.1 µg/cm2 ) and Fg 
(1.8 µg/cm2). 
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Figure 6.3 Total protein adsorbed (µg/cm2) on polyanhydride microparticles obtained by 
SDS-PAGE of (a) CPH:SA, and (b) CPTEG:CPH. Error bars represent standard error of 
three different experiments with duplicate samples in each. * represent p-value < 0.05 
obtained from statistical student-t test.
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6.4.4 Competitive protein adsorption 
The three proteins used in this study are present in plasma at different 
concentrations and, as mentioned before, the type of protein adsorbed will have an 
effect on the biodistribution of these carriers. This makes it important to determine how 
these proteins adsorb in “competition”. In order to evaluate this “competitive effect”, 2-D 
electrophoresis was used to determine how proteins from bovine serum (Fg 
supplemented) competitively adsorbed on polymer microparticles. Figure 6.4 shows the 
2-D electrophoresis gels of proteins from bovine serum adsorbed on: (a) 50:50 CPH:SA 
and (b) 50:50 CPTEG:CPH microparticles. The strongly detectable proteins on the 2-D 
gels were albumin, immunoglobulin (light and heavy chains), IgM, antithrombin III, and 
fibrinogen. Some proteins (e.g., Apo E) were observed only for the most hydrophobic 
surface. From Figure 6.4, it is clear that for most of the proteins (e.g., IgG (light and 
heavy), albumin, IgM, fibrinogen) the bands present on gel (a) are more intense than the 
corresponding bands on gel (b); this is consistent with the results from the XPS and 
SDS-PAGE studies, indicating high protein adsorption on hydrophobic surfaces (i.e., 
50:50 CPH:SA). This study also corroborated the protein-rejection properties of PEG 
(i.e., 50:50 CPTEG:CPH) shown previously in this study and others.16,20 
Considering that albumin represents more than 60% of the total plasma proteins, 
one may expect this protein to be the most adsorbed; however, this is not the case for 
the two chemistries studied. In addition to protein-surface compatibility, this observation 
may be attributed to structural changes in albumin after adsorption on microparticle 
surfaces, as reported previously.25,53 This phenomena may also be a consequence of 
the Vroman effect in which displacement of abundant proteins by less abundant ones 
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occurs as well as the displacement of “sticky” proteins occurs by other trace proteins, 
explaining why fibrinogen was not found on the surface in high amounts even after it 
was supplemented back in the serum.27,28 Displacement often occurs within seconds 
after incubation47 and this is why we may be able to detect only the irreversibly 
adsorbed protein layer after 5 min of incubation.  
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Figure 6.4 2-D electrophoresis pattern of protein adsorbed on (a) 50:50 CPH:SA and (b) 
50:50 CPTEG:CPH microparticles after incubation with bovine plasma. 1: IgM; 2: 
albumin; 3: antithrombin III; 4: fibrinogen γ; 5: fibrinogen β; 6: IgG γ; 7: Apo E; 8: IgG 
light chains; 9: Apo A1. 
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6.4.5 In vitro protein release 
The adsorption of plasma proteins on the surface of polyanhydride microparticles 
may affect the release kinetics of protein-loaded microparticles. In order to study this 
effect, 50:50 CPTEG:CPH microparticles loaded with 4% ovalbumin (48 kDa) were 
fabricated and incubated with fibrinogen (330 kDa) as described before. An in vitro 
release study was performed for 28 days. SDS-PAGE was chosen to quantify the 
release kinetics because as fibrinogen desorbed over time, it was possible to 
differentiate between the two proteins. Figure 6.5 shows two representative gels from 
this study; samples taken after 2 h of release (lane 1) and from one to seven days (lane 
3 to lane 9) are shown for (a) Ova-encapsulated microparticles, and (b) Ova-
encapsulated microparticles that were incubated with Fg. It is important to observe that 
only a band at ca. 48 kDa (characteristic of Ova) is present in both gels indicating that 
desorption of Fg is not occurring, confirming that a short time of incubation is enough to 
obtain an irreversible layer of adsorbed protein and that the wash steps performed in the 
incubation process eliminated any reversible layers of adsorbed protein. 
Figure 6.5 also indicates a clear difference in the intensity of the characteristic band 
between gels (a) and (b), suggesting a reduced amount of released protein, caused by 
the presence of fibrinogen on the surface of the microparticles. Confirming these results, 
Figure 6.6 shows the cumulative Ova release profile from 50:50 CPTEG:CPH 
microparticles; the fraction of Ova released was obtained by normalizing the mass of 
released protein by the total amount of protein encapsulated. A decrease in the rate of 
Ova released is observed when Fg is adsorbed on the surface of the microparticles. The 
initial burst, which is 50% when no Fg is adsorbed to the surface, decreases to 26% 
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when Fg is adsorbed on the microparticle surface. Similar results were obtained from an 
in vitro release study for 50:50 CPH:SA microparticles (data not shown).  
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Figure 6.5 SDS-PAGE of 50:50 CPTEG:CPH microparticles: (a) Ova-encapsulated, and 
(b) Ova-encapsulated/Fg-adsorbed. Lane 1: sample after ~2 h of release; lane 2: MW 
standard ladder; lane 3 to lane 9: release samples at day 1 through day 7 respectively.  
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The release kinetics of proteins from polyanhydride microparticles is controlled by 
the degradation of the polymer,13,15 which in turn is dependent upon the hydrophobicity 
of the polymer. As we have shown in this work, the polymer hydrophobicity affects the 
adsorption/desorption kinetics of plasma proteins. In the case of bulk erodible polymers, 
as the erosion of the polymer progresses, more internal porous structures will be 
exposed, thus enlarging the available polymer surface area and providing additional 
sites (i.e., new porous walls) for protein adsorption;54 therefore the potential desorption 
of the adsorbed protein after water penetration is countered by the re-absorption of the 
protein on these new sites. Surface erodible materials are generally hydrophobic and 
prevent water penetration into the bulk. The interaction of plasma proteins is stronger 
with hydrophobic surfaces, leading to a higher adsorption/desorption ratio (i.e., higher 
net adsorption rate) as surface erosion progresses; this net adsorption of proteins on the 
“degraded” particle may lead to a slower release of encapsulated protein. Our 
experiments support this line of thought and the presence of plasma proteins on the 
surface of polymer microparticles does reduce the amount of protein released from 
biodegradable materials that are surface or bulk erodible. This may have positive 
implications if the desired rates of release of the protein are slower than what is 
observed without any surface adsorption of proteins, such as for vaccine delivery 
applications. However, caution must be exercised in that depending on the specific 
protein that is adsorbed, the microparticles could become less prone to phagocytosis. 
Our studies provide a systematic and rational framework to study these complex 
phenomena and will have value in the molecular design of adjuvants for vaccine delivery 
and of constructs and scaffolds for tissue engineering. 
 	  
193 
 
Figure 6.6 Ovalbumin protein released from 50:50 CPTEG:CPH microparticles. Error 
bars represent standard deviation of two different experiments with duplicate samples 
each. 
 
6.5 Conclusions 
The in vitro adsorption of three model plasma proteins on polyanhydride 
microparticles was studied. The adsorption of plasma proteins can affect the in vivo 
behavior of these polymeric devices in different ways. These studies demonstrated a 
direct correlation between polymer hydrophobicity and amount of protein adsorbed. The 
type of protein also plays an important role in the adsorption process. The release 
kinetics of protein from loaded microparticles is slowed down by the presence of 
adsorbed protein on the surface. The determination and knowledge of these patterns is 
important to understand the in vivo behavior of drug delivery devices. Therefore, these 
 	  
194 
studies provide a rational approach for the correct selection of polymer chemistry in 
order to design suitable carriers for therapeutic proteins and vaccine antigens.  
 
6.6 Acknowledgments 
The authors acknowledge financial support from NSF (EEC 0552584) and the Grow 
Iowa Values Fund. The authors thank Dr. Robert Doyle for his assistance with the use of 
the confocal microscope and Dr. Michael Wannemuehler and Dr. Maria Torres-
Gonzalez for discussions on the design and development of these experiments. We 
thank Elise Schiltz, an undergraduate at Iowa State University, who participated in this 
project.  
 
6.7 References 
 
 1.  Kipper M, Wilson JH, Wannemuehler MJ, Narasimhan B. Single dose vaccine 
based on biodegradable polyanhydride microspheres can modulate immune 
response mechanism. J Biomed Mater Res 2006;76A:798-810.  
2.  Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, 
Corradin G. Encapsulation of peptides in biodegradable microspheres prolongs 
their MHC class-I presentation by dendritic cells and macrophages in vitro. 
Vaccine 2003;21(11-12):1250-1255.  
3.  Alonso M, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres 
as controlled-release tetanus toxoid delivery systems. Vaccine 1994;12(4):299-
306.  
4.  Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable 
poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine 
antigens. Adv Drug Deliv Rev 2005;57(3):391-410.  
5.  Jiang W, Schwendeman SP. Stabilization of a model formalinized protein antigen 
encapsulated in poly(lactide-co-glycolide)-based microspheres. J Pharm Sci 
2001;90(10):1558-1569.  
6.  Gupta R, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine 
adjuvants and delivery systems. Dev Biol Stand 1998;12:63-78.  
7.  Crotts G, Park TG. Stability and release of bovine serum albumin encapsulated 
within poly(d,l-lactide-co-glycolide) microparticles. J Control Release 
1997;44:123-134.  
 	  
195 
8.  Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in 
injectable poly(lactide-co-glycolide). Nat Biotechnol 2000;18:52- 57.  
9.  Liu W, Langer R, Klibanov AM. Moisture-induced aggregation of lyophilized 
proteins in the solid state. Biotechnol Bioeng 1991;31:177- 184.  
10.  Costantino H, Langer R, Klibanov A. Solid-phase aggregation of proteins under 
pharmaceutically relevant conditions. J Pharm Sci 1994;83(12):1662-1669.  
11.  Göpferich A, Langer R. The influence of microstructure and monomer properties 
on the erosion mechanism of a class of polyanhydrides. J Polym Sci, A, Polym 
Chem 1993;31:2445- 2458.  
12.  Tamada J, Langer R. Erosion kinetics of hydrolytically degradable polymers. 
Proc Natl Acad Sci U S A 1993;90:552- 556.  
13.  Determan A, Trewyn BG, Lin VS-Y, Nilsen-Hamilton M, Narasimhan B. 
Encapsulation, stabilization, and release of BSA-FITC from polyanhydride 
microspheres. J Control Release 2004;100:97-109.  
14.  Determan A, Wilson JH, Kipper MJ, Wannemuehler MJ, Narasimhan B. Protein 
stability in the presence of polymer degradation products: consequences for 
controlled release formulations. Biomaterials 2006;27:3312–3320.  
15.  Torres M, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B. 
Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 
2007;28:108-116. 
16.  Freij-Larsson C, Nylander T, Jannasch P, Wesslen B. Adsorption behaviour of 
amphiphilic polymers at hydrophobic surfaces: effects on protein adsorption. 
Biomaterials 1996;17:2199-2207.  
17.  Soppimath K, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable 
polymeric nanoparticles as drug delivery devices. J Control Release 2000;70:1-
20.  
18.  Lück M, Paulke B-R, Schröder W, Blunk T, Müller RH. Analysis of plasma 
protein adsorption on polymeric nanoparticles with different surface 
characteristics. J Biomed Mater Res A 1997;39(3):478 -485.  
19.  Göppert T, Müller RH. Protein adsorption patterns on poloxamer- and 
poloxamine-stabilized solid lipid nanoparticles (SLN). European J Pharm 
Biopharm 2005;60(3):361–372.  
20.  Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. Protein 
encapsulation within poly(ethylene glycol)-coated nanospheres. II. Controlled 
release properties. J Biomed Mater Res B 1999;47(3):388 -395.  
21.  Chinn J, Horbett TA, Ratner BD. Baboon fibrinogen adsorption and platelet 
adhesion to polymeric materials. Thromb Haemostas 1991;65:608-617.  
22.  Horbett T. The role of adsorbed proteins in tissue response to biomaterials. In: B. 
D. Ratner ASH, F. Schoen, and J. E. Lemons, editor. Biomaterial science: an 
introduction to materials in medicine. San Diego, CA: ELSEVIER Academic 
Press; 2004. p 237-246.  
23.  Wu Y, Simonovsky FI, Ratner BD, Horbett TA. The role of adsorbed fibrinogen in 
platelet adhesion to polyurethane surfaces: a comparison of surface 
hydrophobicity, protein adsorption, monoclonal antibody binding, and platelet 
adhesion. J Biomed Mater Res 2005;A74(4):722-738.  
 	  
196 
24.  Norde W, Arai T, Shirahama H. Protein adsorption in model systems. Biofouling 
1991;4(1-3):37-51.  
25.  Norde W, Giacomelly CE. BSA structural changes during homomolecular 
exhange between the adsorbed and the dissolved states. Journal of 
Biotechnology 2000;79:259-268.  
26.  Norde W, Galistéo Gonzalez F, Haynes CA. Protein adsorption on polystyrene 
latex particles. Polym Adv Technol 2003;6(7):518-525.  
27.  Vroman L, Adams AL, Klings M. Interactions among human blood proteins at 
interfaces. Fed Proc 1971;30:1494.  
28.  Wojciechowski P, Brash, JL. The Vroman Efffect in Tube geometry: The 
Influence of Flow on Protein Adsorption Measurements. In: C.H. Bamford 
SLCaTT, editor. The Vroman Effect. Tokyo, Japan: VSP; 1990. p 95-108.  
29.  Horbett T. Principles underlying the role of adsorbed plasma proteins in blood 
interactions with foreign materials. Cardiovasc Pathol 1993;2:137S-148S.  
30.  Andrade J. Principles of protein adsorption. In: J. D. Andrade, editor. Surface and 
Interfacial Aspects of Biomedical Polymers. New York, NY: Plenum Press; 1985. 
p 1-80.  
31.  Thode K, Lück M, Semmler W, Müller RH, Kresse M. Determination of plasma 
protein adsorption on magnetic iron oxides: sample preparation. Pharma 
Research 1997;14(7):905-910. 
32.  Griesser H, McArthur SL, Wagner MS, Castner DG, Kingshott P, McLean KM. 
XPS, ToF-SIMS, and MALDI-MS for characterizing adsorbed protein films. 
Surfactant Sci 2003;110:641-669.  
33.  Kipper M, Seifert S, Thiyagarajan P, Narasimhan B. Understanding 
polyanhydride blend phase behavior using scattering, microscopy, and molecular 
simulations. Polymer 2004;45(10):3329-3340.  
34.  Uhrich K, Gupta A, Thomas TT, Laurencin CT, Langer R. Synthesis and 
characterization of degradable poly(anhydride-co-imides). Macromolecules 
1995:2184-2193.  
35.  Torres M, Determan AS, Mallapragada SK, and Narasimhan B. Polyanhydrides. 
In: In: Lee S aD, M., editor. Encyclopedia of Chemical Processing. New York, 
NY; 2006. p 2247-2257.  
36.  Conix A. Poly[1,3-bis(p-carboxyphenoxy)-propane anhydride]. Macro Synth 
1966;2:95–98.  
37.  Torres M, Vogel BM, Narasimhan B, Mallapragada SK. Synthesis and 
characterization of novel polyanhydrides with tailored erosion mechanisms. J 
Biomed Mater Res A 2005;76A(1):102 -110.  
38.  Shen E, Pizsczek R, Dziadul B, Narasimhan B. Microphase separation in 
bioerodible copolymers for drug delivery. Biomaterials 2001;22:201- 210.  
39.  Kipper M, Shen E, Determan A, Narasimhan B. Design of an injectable system 
based on bioerodible polyanhydride microspheres for sustained drug delivery. 
Biomaterials 2002;23:4405-4412.  
40.  Lopac S, Torres MP, Wilson-Welder JH, Wannemuehler MJ, Narasimhan B. 
Effect of polymer chemistry and fabrication method on protein release and 
stability from polyanhydride microspheres. J Biomed Mater Res Part B 
2009;91B:938-947.  
 	  
197 
41.  Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres 
composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater 
Res A 2004;22(10):837 -858.  
42.  Bjellquist B, Pasquali C, Ravier F, Sanchez J-C, Hochstrasser D. A nonlinear 
wide range immobilized pH gradient for two-dimensional electrophoresis and its 
definition in a relevant pH scale. Electrophoresis 1993;14:1357-65.  
43.  Muller M, Vörös J, Csúcs G, Walter E, Danuser G, Merkle HP, Spencer ND, 
Textor M. Surface Modification of PLGA microspheres. J Biomed Mater Res A 
2003;66A(1):55-61.  
44.  O'Mullane E, Artursson P, Tomlinson E. Biopharmaceutics of microparticulate 
drug carriers. Ann NY Acad Sci 1987;507:100-140.  
45.  Gessner A, Lieske A, Paulke B-R, Müller RH,. Functional groups on polystyrene 
model nanoparticles: influence on protein adsorption. J Biomed Mater Res A 
2003;65A(3):319-326.  
46.  Iordanskii A, Dmitriev EV, Kamaev PP, Zaikov GE. Desorption of human serum 
albumin and human fibrinogen from the poly(3-hydroxybutyrate) surface. J 
Applied Poly Sci 1999;74:595-600.  
47.  Allemann E, Gravel P, Leroux JC, Balant L, Gurny R. Kinetics of blood 
component adsorption on pol (D,L-lactic acid) nanoparticles: evidence of 
complement C3 component involvement. J Biomed Mater Res A 1997;37(2):229 
-234.  
48.  Peracchia M, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaekle 
D, D'Angelo J, Müller RH, Couvreur P. Visualization of in vitro protein-rejecting 
properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 
1999;20:1269-1275.  
49.  Lück M, Pistel K-F, Li Y-X, Blunk T, Müller RH, Kissel T. Plasma protein 
adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-
glycolide), poly(L-lactide) or ABA triblock copolymers containing 
poly(oxyethylene). Influence of production method and polymer composition. J 
Control Release 1998;5:107-120.  
50.  Briggs D, Beamson G. XPS studies of the oxygen 1s and 2s levels in a wide 
range of functional polymers. Anal Chem 1993;65:1517-1523.  
51.  Bomben K, Dev SB. Investigation of Poly(L-amino acids) by X-ray Photoelectron 
Spectroscopy. Anal Chem 1988;60:1393-1397.  
52.  Colea M, Thissenb H, Losica D, Voelcker NH. A new approach to the 
immobilisation of poly(ethylene oxide) for the reduction of non-specific protein 
adsorption on conductive substrates. Surface Sci 2007;601(7):1716-1725.  
53.  Giacomelli C, Norde W. The adsorption-desorption cycle. Reversibility of the 
BSA-silica system. J Colloid Interface Sci 2001;233:234-240.  
54.  Crotts G, Sah H, Park TG. Adsorption determines in-vitro protein release rate 
from biodegradable microspheres: quantitative analysis of surface area during 
degradation. J Control Release 1997;47:101-111. 
 
 
 
 
 	  
198 
CHAPTER 7 
 
Chemistry-Dependent Adsorption of 
Serum Proteins on Polyanhydride 
Microparticles Affects Uptake and 
Activation of Dendritic Cells: Identification 
of Complement Receptor 3-Mediated 
Particle Uptake 
 
A paper to be submitted for publication in Acta Biomaterialia, 2011 
 
Brenda Carrillo-Conde1, Amanda E. Ramer-Tait2, Michael J. 
Wannemuehler2, and Balaji Narasimhan1* 
 
 
 
Keywords: Polyanhydride, Microparticles, Serum Proteins, Adsorption, Dendritic Cells  
1Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 
50011 
2Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, 
Ames, IA 50011 
*To whom all correspondence should be addressed 
 	  
199 
7.1 Abstract 
The delivery of antigen-loaded microparticles to DCs may benefit by optimizing the 
surface of the microparticles themselves exploiting material properties and introducing 
signals that mimic pathogen properties. However, after being in contact with serum, 
proteins will quickly adsorb onto the surface of microparticles and considerably modify 
their surface characteristics. In this work, we described the chemistry-dependent serum 
protein adsorption patterns on polyanhydride particles and their implications in the 
molecular interactions with dendritic cells (DCs). The chemistry-dependent activation of 
DCs by non-serum coated particles was corroborated with the enhanced expression of 
MHC II and CD40 on DCs after incubation with 50:50 CPTEG:CPH particles, and the 
increased secretion of IL-6, TNF-α, and IL-12p40 by 50:50 CPH:SA particles. Presence 
of opsonins (i.e., complement component 3 (C3) and IgG) was able to trigger the 
adjuvant properties of these vaccine carriers by enhancing the properties that induce 
maturation of DCs (i.e., internalization, cell surface molecules expression and cytokine 
secretion) in a chemistry-dependent manner. Utilizing DCs derived from complement 
receptor 3 mice (CR3-/- mice), CR3 mediated-internalization of both non-serum- and 
serum-coated particles was identified.  These studies provide valuable insights into the 
rational design of targeted vaccine platforms to induce robust immune responses and 
improve vaccine efficacy. 
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7.2 Introduction 
The design of vaccine adjuvants capable of activating innate immunity is important 
for the induction of protective immune responses that will result in the production of 
efficacious vaccines 1, 2. A key step in the activation of the innate immune system is the 
recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition 
receptors (PRRs) on the surface of antigen presenting cells (APCs), including dendritic 
cells (DCs) 1-3. DCs can internalize and process soluble antigens, resulting in maturation 
and directing further interactions with other immune cells, including naïve T cells 2, 4, 5. 
The use of polymer particles to deliver antigen, either encapsulated or bound to the 
surface, has been shown to enhance antigen presentation compared to the 
administration of soluble antigen alone 6-8.  
The interaction of antigen-loaded microparticles with DCs may benefit from 
engineering the microparticle surface by exploiting material properties and introducing 
motifs that mimic the surface of pathogens 9. For example, it has been demonstrated 
that cationic surfaces greatly enhance uptake 10. On the other hand, the presence of 
ligands, which bind to specific cellular receptors, increases internalization 3, 4, 11. After 
contact with serum, microparticles may undergo significant changes in their surface 
properties due by the rapidly adsorption of serum proteins 12, 13.  
Polyanhydride microparticles have been shown to possess immunomodulatory 
properties 14, 15, which, when combined with their ability to stabilize and provide 
sustained release of protein antigens 16-20, make them excellent candidates as adjuvants 
for the design of single dose vaccine. Our previous work has shown that serum protein 
adsorption patterns on polyanhydrides microparticles are correlated to their surface 
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properties (i.e., hydrophobicity) suggesting that the adsorption of serum proteins can be 
tailored by controlling the particle surface chemistry 13. Proteins like IgG and 
complement factors (i.e., opsonins) have been identified at the surface of microparticles, 
which may influence recognition and uptake by APCs 9, 13, 21. Naturally, pathogens like 
Mycrobacterium tuberculosis, Legionella pneumophila, and M. leprae coat themselves 
with serum proteins, which facilitate phagocytosis by host cells by interaction with 
specific cell surface receptors such as complement, Fcγ, and mannose receptors 22-27. 
Therefore, understanding the biological consequences of serum protein adsorption to 
microparticles on the interaction of particles with APCs and APC activation may provide 
vital insights for the rational design of improved biomaterial-based adjuvants.   
This study was designed to evaluate the adsorption of mouse serum proteins on to 
the surface of polyanhydride microparticles and to understand their effect on 
microparticle uptake by DCs and DC activation. Polyanhydrides based on sebacic acid 
(SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) were evaluated in this study. The studies described herein 
identified the role of complement component C3 adsorbed on the surface of 
polyanhydride microparticles in receptor-mediated uptake and activation of DCs. 
 
7.3 Materials and Methods 
7.3.1 Materials 
Chemicals needed for monomer synthesis and polymerization, sebacic acid (99%), 
p-carboxy benzoic acid (99þ%), and 1-methyl-2-pyrrolidinone anhydrous (99%), were 
purchased from Aldrich (Milwaukee, WI); 4-p-hydroxybenzoic acid, 1,6-dibromohexane, 
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1-methyl-2 pyrrolidinone, and triethylene glycol were purchased from Sigma Aldrich (St. 
Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
acetonitrile, acetic anhydride, methylene chloride, and petroleum ether were purchased 
from Fisher Scientific (Fairlawn, NJ). Materials for SDS-PAGE and 2D electrophoresis, 
which included 12% tris-glycine precast gels, unstained protein standards, Flamingo gel 
stain, 11-cm immobilized pH gradient (IPG) strips (pH 3–10, nonlinear), and 4–15% 
polyacrylamide gels were purchased from BioRad Laboratories (Richmond, CA). 
Phosphatase substrate was purchased from Aldrich (St Louis, MO). β-mercaptoethanol, 
E. coli lipopolysaccharide (LPS) O111:B4, and rat immunoglobulin (rat IgG) were 
purchased from Sigma Aldrich. The materials required for the DC culture medium 
include: granulocyte macrophage colony stimulating factor (GM-CSF), purchased from 
PeproTech (Rocky Hill, NJ); HEPES buffer, RPMI 1640, penicillin-streptomycin, and L-
glutamine, purchased from Mediatech (Herndon, VA); and heat inactivated fetal calf 
serum, purchased from Atlanta Biologicals (Atlanta, GA). Materials used for flow 
cytometry included: intracellular (IC) fixation buffer, purchased from eBioscience (San 
Diego, CA); unlabeled anti-CD16/32 FcγR, purchased from Southern Biotech 
(Birmingham, AL); unlabeled hamster IgG, fluorescein isothiocyanate (FITC) conjugated 
anti-mouse MHC II (I-A/I-E) (clone M5/114.15.2), PE conjugated anti-mouse MHC Class 
I (H-2Kd/H-2Dd)(clone 34-1-2S), allophycocyanin (APC) anti-mouse CD40 (clone 1C10), 
phycoerythrin-Cy7 (PE/Cy7) anti-mouse CD86 (clone GL-1), Alexa Fluor® 700 anti-
mouse CD11c (clone N418); and corresponding isotypes: FITC-conjugated rat IgG2bκ; 
PE-conjugated rat IgG2a (clone eBR2a), APC rat IgG2aκ (clone eBR2a), PE/Cy7 
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conjugated rat IgG2b (clone KLH/G2b-1-2), Alexa Fluor® 700 conjugated Armenian 
hamster IgG (clone eBio299Arm). All of these reagents were purchased from 
eBioscience. Cadmium selenide quantum dots (QDs) (emission at 630nm) were a gift 
from Dr. Aaron Clapp at Iowa State University. 
 
7.3.2 Monomer and Polymer Synthesis 
Diacids of CPH and CPTEG were synthesized as described previously 28, 29. SA and 
CPH prepolymers were synthesized by the methods described by Shen et al 30. and 
Conix et al 28., respectively. Subsequently, 50:50 CPH:SA and 50:50 CPTEG:CPH 
copolymers were synthesized by melt polycondensation as respectively described by 
Kipper et al 31. and Torres et al 29. 1H NMR spectroscopy was used to characterize the 
polymer structure and the resultant spectra were consistent with previously published 
data 29, 31. The synthesized 50:50 CPH:SA copolymer had an average Mw of 12,000 
g/mol with a polydispersity index (PDI) of 2.0 while the 50:50 CPTEG:CPH copolymer 
had a Mw of 8,000 g/mol with a PDI of 1.8. These values were obtained from 1H NMR 
and corroborated with GPC and are consistent with previous work 8, 29, 31. 
 
7.3.3 Microparticle Fabrication and Characterization 
Cryogenic atomization was used to fabricate 50:50 CPH:SA and 50:50 CPTEG:CPH 
microparticles, as described elsewhere 13, 16, 19, 20. Briefly, 100 mg of the polymer was 
weighed and dissolved in methylene chloride. For QD-loaded microparticles, QDs were 
added to the dissolved polymer and dispersed by sonication at 40 Hz for 30 s. The 
polymer solution was then pumped through an 8700–1200 MS ultrasonic atomizing 
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nozzle (SonoTek Corporation, Milton, NY) into 200 mL of frozen ethanol (with an excess 
of liquid nitrogen). Microparticles were fabricated at 4 ºC. Compositions were stored at -
80 ºC for 3 days. For 50:50 CPTEG:CPH, after the first 24 h, 200 mL of cold ethanol 
was added to reduce aggregation; the solutions were stirred at 300 rpm for 15 min and 
placed back in the freezer at - 80 ºC. After 3 days, vacuum filtration was used to collect 
the microparticles and they were dried overnight under vacuum. Scanning electron 
microscopy (SEM) (JEOL 840 A, JEOL Peabody, MA) was used to observe the 
morphology of the microparticles. The particle size distribution was obtained from SEM 
images using ImageJ image analysis software (National Institutes of Health, Bethesda, 
MD) 13, 16, 19, 20. An average of 200 particles per image was analyzed. Quasi-elastic light 
scattering (QELS) was used to determine the ζ-potential of the particles, as described 
previously 3. Particle morphology and size were consistent with previous work 14, 16-20. An 
average size of 6 ± 4 µm and 5 ± 3 µm was calculated for 50:50 CPH:SA and 50:50 
CPTEG:CPH particles, respectively. 
 
7.3.4 Mice 
C57BL/6 mice were purchased from Harlan Sprague Dawley (Indianapolis, IN) and 
CR3-/- mice (C57BL/6 background) were obtained as a generous gift from Dr. Mary Ann 
McDowell (University of Notre Dame). All mice were housed under specific pathogen-
free conditions where all bedding, caging, and feed were sterilized prior to use. All 
animal procedures were conducted with the approval of the Iowa State University 
Institutional Animal Care and Use Committee.   
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7.3.5 Adsorption of Mouse Serum onto Microparticles 
13.3% w/v suspensions of polymer microparticles were prepared in phosphate 
buffered saline (PBS) (0.1 M, pH 7.4). Mouse serum was obtained from cardiac 
puncture of euthanized C57BL/6 mice and storage in aliquots at -20 ºC until use. 
Particle suspensions were incubated with fresh mouse serum to a 1:4 final volume ratio 
of particle suspension to serum. The suspension was mildly vortexed for 1 min and 
incubated for 30 min at 37 ºC. After incubation, the particle suspension was centrifuged 
at 12,000 x g for 10 min to pellet the particle-protein complexes. The pellet was re-
suspended in PBS, transferred to a new vial, and centrifuged again (at the same 
conditions) to pellet the particle-protein complexes; this procedure was repeated three 
times. After the third washing step the supernatant did not contain any detectable 
amount of proteins based on BCA protein detection assay and SDS-PAGE analysis. 
Microparticles were dried under vacuum overnight for at least 2 h.  
 
7.3.6 Determination of Protein Adsorption Patterns 
Proteins were eluted from the particles by applying a solution containing 10% (w/w) 
SDS and 2.3% (w/w) dithioerythritol for 2-D electrophoresis analysis and reducing 
sample buffer (SDS (10% w/v), Tris-HCl (1M, pH 6.8), glycerol (3 mM), bromophenol 
blue (0.01% w/v)) for SDS-PAGE analysis. Samples were heated at 95 ºC for 10 min 
and particles were centrifuged for 10 min at 12,000 x g and the supernatant was used to 
perform SDS-PAGE and 2D electrophoretic analysis 13, 16.  
2D electrophoresis was used to qualitatively and semi-quantitatively identify the type 
of proteins adsorbed to polyanhydride particles. The first dimensional separation was 
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performed in the IPGPhor system (GE Healthcare, Piscataway, NJ) using 11-cm IPG 
strips (pH 3–10) following a slow voltage ramping protocol: 50 V for 10 h, 500 V for 1 h, 
1000 V for 1 h, and 8000 V for 4 h 13, 32. For the second dimension of the separation 
analysis, IPG strips were loaded in 4–15% polyacrylamide gels and run for 2 h at 140 V. 
The gels were incubated in fixative solution (40% ethanol, 10% acetic acid) at 4oC for 3 
h. Next, they were stained with fluorescent flamingo gel stain (BioRad Laboratories, 
Richmond, CA) overnight, and washed with a 0.01% Tween 20 solution to reduce non-
specific fluorescence 13, 16. A Typhoon 8600 (GE Healthcare, Piscataway, NJ) 
fluorescence scanner was used to obtain the images of the gels. Experiments were 
performed in triplicates. A qualitative analysis was performed by comparing the gels of 
the desorbed proteins with those obtained from mouse sera and Progenesis SameSpots 
(Nonlinear Dynamics Inc., Durahm, NC) software was used to identify the main bands 
on the gels by comparison on their molecular weight and isoelectric point position on the 
gel. The fluorescence volume of each protein spot was quantified using ImageQuantTL 
(GE Healthcare, Piscataway, NJ) and normalized with the total fluorescence volume of 
the gel. Data for each protein spot is presented as percentage of fluorescence volume.   
 
7.3.7 Identification of Complement Component C3 and C3a  
Sandwich ELISA was used for identification of specific components in the protein 
mix recovered from microparticle surfaces. A mouse complement component C3 ELISA 
kit from Kamiya Biomedical Company (Seattle, WA) was utilized for quantitative 
determination of C3 in samples recovered from particle surfaces. Protocol was followed 
exactly as described by the company.  
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Complement activation was assessed by measuring the concentration of C3a in the 
serum supernatants after incubation with the polyanhydride particles. A mouse 
complement component 3a (C3a) ELISA kit from Kamiya Biomedical Company was 
utilized for this purpose.  
 
7.3.8 DC Culture and Stimulation 
DCs were grown as described previously 3, 14, 33 and stimulated with either 200 ng/mL 
lipopolysaccharide (LPS; a positive control), 125 µg/mL of QD-loaded or blank 50:50 
CPH:SA and 50:50 CPTEG:CPH microparticles or left untreated (NS; non-simulated, 
negative control). Treatments were applied to the DCs incubated in DC culture medium 
(RPMI containing 1% L-glutamine, 1% penicillin–streptomycin solution, 2% HEPES, 
0.5% gentamicin, 0.1% b-mercaptoethanol, and 10% heat inactivated fetal bovine serum 
(FBS) supplemented with GMCSF (10 ng/mL)) on day nine post-harvest and incubated 
for 48 h. DCs were >90% positive for DC marker CD11c. For internalization studies, a 
released QD control was subtracted from each treatment group to account for QD 
release due to particle degradation 34. For this control, after 48 h of particle incubation in 
DC culture medium, particles were centrifuged and the supernatants containing the 
released QDs were added to DCs for 48 h to account for any fluorescence caused by 
the uptake of released QDs as opposed to internalization of QD-loaded particles [34]. 
FluoSpheres® carboxylate-modified polystyrene microspheres (PS, 2µm, 580/605 nm, 
Invitrogen, Carlsbad, CA) were used as controls for internalization experiments. 
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7.3.9 Flow Cytometry Analysis 
Flow cytometric analysis of surface molecule expression was performed to assess 
for the expression of MHC I, MHC II, CD40, and CD86 as previously described 3, 14, 33, 34. 
 
7.3.10 Cytokine Assays 
 After stimulation for 48 h with nanoparticles, cell-free supernatants were assayed 
for IL-1β, IL-10, TNF-α, IL-6, and IL-12p40 using a multiplex cytokine assay in 
conjunction with a Bio-Plex System (BioRad, Hercules, CA). 
 
7.3.11Statistical Analysis 
The statistical software JMP®7 was used to analyze the cell surface marker, 
cytokine, and internalization data. One-way ANOVA and Tukey’s HSD were used to 
determine statistical significance among treatments and p-values < 0.05 were 
considered significant. 
 
7.4 Results 
7.4.1 Chemistry-dependent protein adsorption patterns: immunoglobulin G (IgG) 
and complement component C3 adsorption on polyanhydride particles surface 
 It is well known that cationic particles show greater adhesion with cell membranes 
and therefore it is important to determine the surface charge of polymeric particles since 
this property could influence their uptake. Measurements of ζ-potential using QELS 
resulted in similar values (-22 ± 5.5 mV) for both particle chemistries and is consistent 
with previous work 3. The presence of deprotonated carboxylic groups may account for 
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the negative surface charge of the polyanhydride particles. After incubation with mouse 
serum, the average ζ-potential was -5 ± 6 mV, which is an indication of the presence of 
serum proteins on the surface. This value for the ζ-potential is consistent with other work 
in which BSA adsorbed on the surface of negatively charged polystyrene particles 
reduced their highly negative ζ-potential 9.  
 SDS-PAGE and BCA protein quantification assay were used to determine 
quantitatively the adsorption of serum proteins onto polyanhydride microparticles. From 
SDS-PAGE results (data not shown), more intense bands are observed for 50:50 
CPH:SA gels, which is indicative of a higher amount of proteins adsorbed on the surface 
of these microparticles. This pattern, corroborated with BCA assay, is consistent with 
previous work that showed that the hydrophobic nature of the CPH:SA system results in 
increased adsorption of specific proteins 13. In contrast, the presence of ethylene glycol 
motifs in the CPTEG:CPH system lead to a reduced protein adsorption from mouse 
serum 13, 35. This repulsive effect of formulations containing poly(ethylene glycol) has 
been demonstrated previously and showed the reduction of opsonin (i.e., IgG and C3) 
adsorption 35. Figures 7.1A and 7.1B show representative images of 2D gels for 
proteins eluted from 50:50 CPH:SA and 50:50 CPTEG:CPH particles, respectively. In 
order to identify the main proteins adsorbed on microparticles, gels obtained from eluted 
proteins from particles were compared with reference map and databases of mouse 
serum 36. From Figures 7.1A and 7.1B, the main proteins identified on the surface of 
both 50:50 CPH:SA and 50:50 CPTEG:CPH particles were albumin and IgG; however, 
complement component C3 is mainly present on the surface of 50:50 CPH:SA particles. 
Table 7.1 shows a detailed analysis of the main proteins identified on polyanhydride 
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microparticles and it is presented as percentage of overall protein amount adsorbed to 
the particles (this analysis was made based on fluorescence volume). While opsonins 
were the predominant type of protein bound to 50:50 CPH:SA particles, other proteins 
including apolipoproteins were present on 50:50 CPTEG:CPH particles. 
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Figure 7.1. Chemistry-dependent protein adsorption patterns: immunoglobulin G (IgG) 
and complement component C3 adsorption on polyanhydride particles surface. 
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Representative 2-D gels of proteins adsorbed on 50:50 CPH:SA (A) and 50:50 
CPTEG:CPH (B) particles. (C) Complement component C3 was adsorbed on the 
surface of 50:50 CPH:SA microparticles, as measured through an anti-mouse 
complement C3 ELISA. Data is presented as µg of C3/cm2 . Values are the mean of 
three independent experiments; error bars correspond to standard error of means. * 
represents p-value ≤ 0.05, as obtained from a student t-test. (D) 50:50 CPH:SA 
microparticles induced C3 cleavage (i.e., complement activation) as measured by the 
appearance of C3a in mouse serum supernatant after incubation with microparticles. 
Data is normalized with control serum that was similarly incubated in the absence of any 
particles (negative control). Values are means of three independent experiments; error 
bars correspond to standard error of mean. * represents p-values ≤ 0.05.  
 
 It has been shown that encapsulation of different payloads can change surface 
properties (i.e., ζ-potential) of polyanhydride particles depending on the nature of the 
payload and how it distributes inside the particle 17. The effect of antigen encapsulation 
on the patterns of serum proteins adsorbed on polyanhydride particles was evaluated by 
using ovalbumin (Ova) as a model antigen. Encapsulation of Ova did not change the 
chemistry-dependent pattern of proteins adsorbed to the microparticles (data not 
shown). 
 The amount of C3 adsorbed to the microparticles was quantified in the samples 
of eluted proteins (Figure 7.1C). An average of 0.12 µg/cm2 and 0.38 µg/cm2 were 
calculated for C3 adsorption on 50:50 CPH:SA and 50:50 CPTEG:CPH particles, 
respectively. Cleavage of C3 was evaluated by assessing the presence of C3a in serum 
supernatant after incubation with polyanhydride particles. The data presented in Figure 
7.1D shows that higher amounts of C3a were generated after incubation of 50:50 
CPH:SA particles in mouse serum. 
 	  
212 
Table 7.1. Representative percentages of the most abundant protein species adsorbed 
on 50:50 CPH:SA and 50:50 CPTEG:CPH particlesa,b.  
Adsorbed protein 50:50 CPH:SA 50:50 CPTEG:CPH 
   
Albumin 23.2 28.7 
IgG γ chain 32.5 25.4 
IgG light chain 4.1 5.3 
IgM  7.2 10.4 
Complement component C3 25 7.9 
Apolipoprotein A-I 1.4 2.5 
Apolipoprotein E 0.3 3.8 
Apolipoprotein H 0.0 8.5 
Transferrin 0.0 2.3 
 
a Data for each protein spot is presented as percentage of fluorescence volume. The 
fluorescence volume of each protein spot was quantified using ImageQuantTL and 
normalized with the total fluorescence volume of the gel, which include all protein spots.  
b Data is representative of three independent experiments. 
 
7.4.2 Internalization of non-serum and serum+ polyanhydride particles is mediated 
by complement receptor 3 
The ability of the polyanhydride particles to be internalized by DCs was tested in 
order to determine the effect of adsorbed proteins to enhance particle internalization. 
When 50:50 CPH:SA particles were incubated with DCs, ~20% of cells were observed 
to contain particles, while incubation of 50:50 CPTEG:CPH particles with DCs resulted 
in less than 10% particle-positive cells (Figure 7.2). The low internalization observed for 
the amphiphillic 50:50 CPTEG:CPH microparticles was consistent with previous work 
from our laboratories 34, 37. The effect of serum protein adsorption on particle 
internalization was assessed. When serum-coated microparticles were added to the DC 
cultures, it was observed that 20 % more DCs had internalized   50:50 CPH:SA particles 
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which may be a consequence of the interaction of opsonins (i.e., IgG and C3) with 
cellular receptor like FcR and C3 receptors 6, 38. To evaluate this hypothesis, 
internalization of sham-coated and serum-coated particles by DCs deficient in CR3 was 
tested. Strikingly, internalization of both sham-coated and serum-coated polyanhydride 
particles was significantly reduced independent of particle chemistry. Similar levels of 
internalization of polystyrene particles by WT and CR3-/- DCs were observed (Figure 
7.2). 
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Figure 7.2. Internalization of  polyanhydride particles is mediated by complement 
receptor 3. Percentages of DCs with internalized microparticles after incubation with 
sham-coated and and serum-coated 50:50 CPH:SA and 50:50 CPTEG:CPH particles 
was measured by flow cytometry. Data is represented as mean ± standard error of three 
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independent experiments performed in triplicate. * indicates significant differences 
between WT and CR3-/- within a group, while # indicates significant differences between 
sham-coated and serum-coated particles within a chemistry.  
 
7.4.3 Serum proteins adsorbed on particle surfaces influence the expression of 
MHC II and co-stimulatory molecules on DCs in a chemistry dependent manner 
We have previously demonstrated the chemistry-dependent activation of DCs by 
polyanhydride particles 14, 34. The results shown in Figure 7.3A corroborate these 
findings with enhanced expression of MHC II when DCs are incubated with 50:50 
CPTEG:CPH particles compared to that obtained with 50:50 CPH:SA particles. Both 
polymer chemistries equally enhanced the surface expression of the co-stimulatory 
molecules CD86 and CD40 (Figures 7.3B and 7.3C). Interestingly, the increase in 
internalization observed for serum-coated 50:50 CPH:SA particles results in the up-
regulation of both MHC II and CD40 (Figures 7.3A and 7.3C).  
Analysis of particle+ and particle- populations of DCs from WT mice showed a direct 
correlation between particle internalization and the surface expression of CD40 was 
observed. In contrast, enhancement of MHC II and CD86 surface expression on DCs 
was not dependent on nanoparticle internalization, as evidenced by no significant 
difference in expression levels between particle- and particle+ populations 
(Supplemental Figure 7.1). These observations are consistent with previous work 
showing the relationship between polyanhydride nanoparticle internalization and 
activation of murine DCs 34. 
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Figure 7.3. Serum proteins adsorbed on particles influence the expression of MHC II 
and co-stimulatory molecules on DCs in a polymer chemistry-dependent manner. After 
stimulation with either non-serum or serum+ microparticles for 48 h, DCs were harvested 
from WT mice and analyzed by flow cytometry for surface expression of (A) MHC II, (B) 
CD86, (C) CD40. LPS and non-stimulated cells (NS) were used as positive and negative 
controls, respectively. Data are expressed as the mean ± standard error of three 
independent experiments performed in triplicate. * represents significant difference 
compared to the NS group at p-value ≤ 0.05, while # represents significant difference 
between sham-coated and  serum-coated particles  within a group at p-value ≤ 0.05. 
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7.4.4 Reduced internalization of non-serum and serum adsorbed particles by CR3 
-/- DCs results in reduction in the expression of MHC II and CD40 molecules 
Results showed in Figure 7.4 demonstrates that the reduction in particle 
internalization by CR3-/- DCs results in changes in DC activation profiles. A significant 
decrease in the expression of MHC II and CD40 was also observed (Figures 7.4A and 
7.4C). Expression of CD86 on CR3-/- DCs was not statistically significant from that 
observed in WT DCs for all the particle groups, indicating that its expression is 
independent of CR3-mediated internalization (Figure 7.4B).  
 
7.4.5 Serum proteins adsorbed on 50:50 CPTEG:CPH microparticles enhance 
secretion of pro-inflammatory cytokines (i.e., IL-6 and TNF-α) and IL-12p40 
In addition to antigen presentation and T cell activation, DCs also modulate immune 
responses via the cytokines they secrete. After 48 h of incubation with particles of either 
chemistry, enhanced secretion of IL-1β was observed (Figure 7.5A). However, only 
50:50 CPH:SA particles increased the secretion of IL-6, IL-12p40, and TNF-α in 
comparison with the non-stimulated cells (Figures 7.5B, 7.5C, and 7.5D). This is in 
agreement with previous work that showed that the hydrophobic 50:50 CPH:SA particles 
significantly influenced DC cytokine production 14, 33. Moreover, the secretion of IL-6, IL-
12p40 and TNF-α by DCs incubated with serum-coated 50:50 CPTEG:CPH particles 
was significantly elevated (Figures 7.5B, 7.5C, and 7.5D).  
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Figure 7.4. Reduced internalization of non-serum and serum adsorbed particles by CR3 
-/- DCs results in reduction in the expression of MHC II and CD40 molecules. After 
stimulation with either non-serum or serum+ microparticles for 48 h, DCs were harvested 
from WT and CR3 -/- mice and analyzed by flow cytometry for surface expression of (A) 
MHC II, (B) CD86, (C) CD40. LPS and non-stimulated cells (NS) were used as positive 
and negative controls, respectively. Data are expressed as the mean ± standard error of 
three independent experiments performed in triplicate. * represents significant difference 
between non-serum and serum+ within a group at p-value ≤ 0.05, while # represents 
significant difference between WT and CR3-/- within a group at p-value ≤ 0.05. 
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In general, no differences in the amounts of secreted cytokines by WT and CR3-/- 
DCs were observed. The only exception was a decrease in the production of IL-12p40 
by CR3-/- DCs when cultured with serum-coated 50:50 CPH:SA particles (Supplemental 
Figure 7.2). It has been previously shown that secretion of IL-12p40 is enhanced by 
particle internalization 34; as the internalization of 50:50 CPH:SA particles is 
considerably reduced by CR3-/- DCs, the reduction in secretion of IL-12p40 after 
incubation with this particles may be related with this decrease in internalization. 
  
7.5 Discussion 
 Biodegradable polymeric particles have been extensively studied as carriers for the 
delivery of antigens and drugs 1, 14, 15, 39, 40. APCs are cells that would encounter and 
engage with polymeric nanoparticles in a manner involving the interaction of polymeric 
structures on the surface of the particle with membrane receptors on the APC. This 
interaction will initiate particle uptake and influence the magnitude and polarity of the 
immune resultant response 1, 2. Adsorption of specific serum proteins to the surface of 
polymeric particles alters their recognition and uptake by APCs 12, 13, 41. The data 
presented herein demonstrate that the chemistry-dependent adsorption of serum 
proteins on polyanhydride particles (Figure 7.1) influences their internalization and the 
activation of murine DCs (Figures 7.2, 7.3, 7.4 and 7.5 and Supplemental Figures 7.1 
and 7.2).  
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Figure 7.5. Serum proteins adsorbed on 50:50 CPTEG:CPH microparticles enhance 
secretion of IL-6, TNF-α and IL-12p40. After stimulation with either non-serum or serum+ 
microparticles for 48 h, supernatants were harvested and assayed for (A) IL-1β, (B) IL-6, 
(C) IL-12p40, and (D) TNF-α. Data is represented as mean concentration of cytokines ± 
standard error of three independent experiments performed in triplicate. LPS was used 
as a positive control stimulant with mean values of 1,041 pg/mL for IL-1β, 44,329 pg/mL 
for IL-6, > 50,000 pg/mL for IL-12p40 and TNF-α. * represents significant difference 
compared to the NS group at p-value ≤ 0.05, while # represents significant difference 
between non-serum and serum+ within a group at p-value ≤ 0.05. 
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Particle chemistry and hydrophobicity play an integral role in particle internalization 
by DCs, as well as DC activation profiles (i.e., cell surface marker expression and 
cytokine production) 3, 8, 14, 33, 34. These properties also determine patterns of serum 
protein adsorption on polyanhydride particles. While the hydrophobic 50:50 CPH:SA 
particles adsorb higher amounts of serum proteins, including IgG and complement 
component C3, the presence of ethylene glycol in the amphiphillic 50:50 CPTEG:CPH 
reduced serum protein adsorption (Figure 7.1). Identification of C3 coating on 
polyanhydride particles is important since is known to mediate cellular uptake of 
particles via complement receptor-mediated mechanisms 35, 42. The inhibitory effect of 
EG-containing particles on protein adsorption has been previously observed and is 
related to longer particle circulation times 9, 35, 42, 43.   
Identification of C3 is of special interest because of the potential of using the 
complement cascade as a danger signal of innate immunity, which is a desirable goal in 
the design of adjuvants 44. Complement can also promote antigen-specific immune 
responses enhancing both humoral 45 and T cell immunity 46. Just like on pathogen 
surfaces, instantaneous complement activation by the alternative pathway can be 
achieved by deposition of C3 on the surface of polymer particles that can promote 
cleavage to form C3a and C3b fragments, which have biological functions 44, 47. In this 
study, we demonstrate that polyanhydride chemistries (i.e., 50:50 CPH:SA and 50:50 
CPTEG:CPH) activate complement, as shown in Figure 7.1D in which the presence of 
the C3a fragment was identified in serum after incubation with polyanhydride particles.  
The molecular mechanisms and interactions of these particulate adjuvants with 
dendritic cells have been an area of study in our laboratories 3, 14, 33, 34, 37 and we have 
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identified polymer-associated molecular patterns and descriptors responsible for the 
“pathogen-mimicking” activation of DCs 34, 37; however, there is a value to study the 
effect of serum protein adsorption and its consequent outcomes (i.e., complement 
activation) on the molecular interactions with DCs . Non-serum coated 50:50 CPH:SA 
and 50:50 CPTEG:CPH particles were internalized by DCs but a higher percentage of 
cells with internalized particels (~22%) was identified when cells were co-cultured with 
50:50 CPH:SA particles (Figure 7.2). These observations of chemistry-dependent 
internalization of polyanhydride particles are consistent with previous work 8, 14, 34. 
Serum-coated 50:50 CPH:SA particles were internalized at higher levels by DCs (~42% 
of particle+ cells) and is hypothesized to be a consequence of greater adsorption of 
opsonins (i.e., IgG and C3) that could interact with Fcγ and complement receptors (i.e., 
CR3 and CR1), respectively, resulting in higher particle uptake 4, 38. It is known that CR3 
binds to C3bi, an inactive form of the C3b cleavage product of C3, fixed on particle 
surfaces, but CR3 may also cooperate with CR1, which binds to C3b or Fcγ receptors to 
facilitate antibody-dependent phagocytosis [48, 49]. Our data indicates that binding of 
C3 on the surface of 50:50 CPH:SA allows for cleavage of C3 into C3a and C3b 
fragments (Figure 7.1D), which suggest a role of CR3 receptor on the internalization of 
serum-coated particles. Using CR3-/- DCs a 90% reduction in particle+ cells was 
observed, for this serum-coated particles. This data is consistent with previous work that 
demonstrated the role of CR3 receptor in the recognition of opsonized bacteria and 
zymosan particles 22, 50, 51.  
However, a similar inability to uptake non-serum coated particles for both 
polyanhydride chemistries was observed in CR3-/- DCs, demonstrating a CR3 receptor-
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mediated uptake pathway for non-serum coated particles (Figure 7.2). This outcome 
demonstrates that C3 receptor plays a critical role in the internalization of polyanhydride 
particles. These observations are consistent with the pathogen-mimicking characteristics 
of polyanhydride particles since certain domains (i.e., lectin site) of the CR3 receptor 
have been related to the binding and phagocytosis of non-opsonic Mycobacterium 
tuberculosis, LPS, Leishmania lipophosphoglycan (LPG), and various particulate 
saccharides that include β-glucan and zymosan 22, 48, 50, 52. Detailed studies in our 
laboratories have previously demonstrated the similar DC activation properties between 
polyanhydride particles and LPS identifying hydroxyl end group and oxygen backbone 
moieties as some of the important pathogen-mimicking structural descriptors 34, 37. 
These structural descriptors may be also dictating the CR3-mediated internalization of 
polyanhydride particles described in this study, which appears to be specific for these 
chemistries as demonstrated by the high uptake levels of non-serum and serum-coated 
polystyrene particles by CR3-/- DCs (Figure 7.2). The biodegradable nature of 
polyanhydride particles that allows the exposure of molecular patterns seems to be 
detrimental to dictate interactions with specific DC receptors (i.e., CR3) compare to 
those initiated by PS particles, which may be internalized by a different mechanism.  
 Besides particle internalization, the up-regulation of antigen presentation machinery 
and T cell co-stimulatory molecules as well as cytokine secretion by DCs are important 
and desirable characteristics of vaccine adjuvants in order to efficiently activate naïve T 
cells and promote the differentiation of B cells 1, 2. A polymer chemistry-dependent 
enhancement in the expression of MHC II and co-stimulatory molecules (i.e., CD40 and 
CD86) and secretion of cytokines was observed in this study (Figures 7.3, 7.4 and 7.5) 
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and is consistent with previous observations 14, 33, 34, 37. While 50:50 CPTEG:CPH 
particles enhanced the expression of MHC II, CD86 and CD40, 50:50 CPH:SA particles 
increased the secretion of IL-6, IL12-p40 and TNF-α. However, adsorption of serum 
proteins on the hydrophobic 50:50 CPH:SA particles resulted in higher expression of 
MHC II and CD40 (Figures 7.3 and 7.4). While the enhanced expression of CD40 was 
identified to be directly dependent on particle internalization, as shown in Figure 7.4 and 
in previous work 34, the expression of MHC II was independent of particle internalization, 
but may be induced by CD40 triggering 53. On the other hand, serum protein adsorption 
on the amphiphilic 50:50 CPTEG:CPH particles increased the secretion of pro-
inflammatory cytokines (i.e., IL-6 and TNF-α) and IL-12p40 in comparison to non-serum-
coated particles (Figure 7.5). The non-serum-coated particles did not induce the 
production of these cytokines, which is detrimental for the initiation of danger signals to 
trigger an adaptive immune response. Therefore, chemistry-dependent adsorption of 
serum proteins influences the expression of key surface markers and production of 
cytokines that are involved in DC maturation and antigen presentation.  
Together, these results indicate that polyanhydride particles are capable of inducing 
DC activation and that polymer chemistry can be rationally designed to induce this 
mature DC phenotype; for example, the intrinsic characteristics of the amphiphilic 50:50 
CPTEG:CPH (e.g., presentation of oxygen-rich molecular patterns to cells) particles can 
induce DC maturation (i.e., enhancement in MHC II, CD86, and CD40 expression) while 
the hydrophobicity of 50:50 CPH:SA particles can direct specific protein adsorption 
patterns that will also enhance its adjuvant properties. The specific interactions of 
particles with serum proteins and their consequences in the molecular interaction with 
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DCs documented in this study presents an intriguing opportunity for the rational design 
of vaccines possessing the capacity to induce diverse immune responses tailored for a 
target disease. 
 
7.6 Conclusions 
In this study, mouse serum protein adsorption patterns on the activation of DCs by 
polyanhydride particles were dictated by polymer chemistry. The polymer chemistry-
dependent activation of DCs by non-serum coated particles was confirmed and the 
ability of adsorbed serum proteins to trigger the adjuvant properties of these particles 
was identified. The data indicates that complement receptor C3-mediated pathways are 
involved in the internalization of both non-serum- and serum-coated polyanhydride 
particles by DCs, highlighting the pathogen-mimicking characteristics of these partcles. 
The receptor-mediated endocytosis induced by the direct interaction of adsorbed 
opsonins or intrinsic pathogen-mimicking patterns of polyanhydride particles with the 
complement receptor C3 may be exploited to design efficacious vaccines.  
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Supplemental Figure 7.1. Expression of CD40 is directly related to particle 
internalization by WT DCs but not the expression of MHC II or CD86. Percent of DC 
populations that internalized (particle+) or did not internalize (particle-) 50:50 CPH:SA 
and 50:50 CPTEG:CPH with or without serum proteins adsorbed on their surface that 
were also positive for (A) MHC II, (B) CD86, and (C) CD40. Data are represented as the 
mean ± standard error of three independent experiments each of which was performed 
in triplicate. * represents a statistically significant difference between nanoparticle+ and 
nanoparticle- groups within a group at p-value < 0.05. 
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Supplemental Figure 7.2. Cytokine secretion profiles from CR3-/- DCs were consistent 
with those observed from WT DCs. After stimulation with either non-serum or serum+ 
microparticles for 48 h, supernatants were harvested and assayed for (A) IL-1β, (B) IL-6, 
(C) IL-12p40, and (D) TNF-α. Data is represented as mean concentration of cytokines ± 
standard error of three independent experiments performed in triplicate. LPS was used 
as a positive control stimulant with mean values of 1,041 pg/mL for IL-1β, 44,329 pg/mL 
for IL-6, > 50,000 pg/mL for IL-12p40 and TNF-α. * represents significant difference 
compared to the NS group at p-value ≤ 0.05, while # represents significant difference 
between non-serum and serum+ within a group at p-value ≤ 0.05. 
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CHAPTER 8 
 
Mannose-Functionalized “Pathogen-Like” 
Polyanhydride Nanoparticles Target C-
Type Lectin Receptors on Dendritic Cells 
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8.1 Abstract 
Targeting pathogen recognition receptors on dendritic cells (DCs) offers the 
advantage of triggering specific signalling pathways to induce a tailored and robust 
immune response. In this work, we describe a novel approach to targeted antigen 
delivery by decorating the surface of polyanhydride nanoparticles with specific 
carbohydrates to provide “pathogen-like” properties that ensure nanoparticle engage C-
type lectin receptors on DCs. The surface of polyanhydride nanoparticles was 
functionalized by covalent linkage of di-mannose and lactose residues using an amine-
carboxylic acid coupling reaction. Co-culture of functionalized nanoparticles with bone 
marrow-derived DCs significantly increased cell surface expression of MHC II, the T cell 
co-stimulatory molecules CD86 and CD40, the C-type lectin receptor CIRE and the 
mannose receptor CD206 over the non-functionalized nanoparticles. Both non-
functionalized and functionalized nanoparticles were efficiently internalized by DCs, 
indicating that internalization of functionalized nanoparticles was necessary but not 
sufficient to activate DCs. Blocking the mannose and CIRE receptors prior to the 
addition of functionalized nanoparticles to the culture inhibited the increased surface 
expression of MHC II, CD40 and CD86. Together, these data indicate that engagement 
of CIRE and the mannose receptor is a key mechanism by which functionalized 
nanoparticles activate DCs. These studies provide valuable insights into the rational 
design of targeted nanovaccine platforms to induce robust immune responses and 
improve vaccine efficacy. 
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8.2 Introduction 
The use of vaccine adjuvants to activate the innate immune system is crucial to 
vaccine effectiveness1. Adjuvants can be used to enhance the efficacy of single dose 
vaccines and reduce the required antigen dose. The use of biodegradable polymer 
nanoparticles as vaccine delivery vehicles allows for effective delivery of payloads by 
parental or mucosal administration by protecting the antigen from harsh physiological 
conditions and enabling transport across biological barriers (e.g., mucus membranes) 2. 
Polyanhydride nanoparticles have shown excellent potential as vaccine carriers3-6. 
Encapsulation of protein antigens into polyanhydride particles stabilizes them and 
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provides sustained antigen release4,7; these particles also enhance the immune 
response by acting as an adjuvant3. 
Dendritic cells (DCs) are antigen presenting cells (APCs) that play a major role in 
connecting the innate and adaptive immune systems, a key step to inducing protective 
immunity8. DCs can sense and internalize antigen by a variety of mechanisms that 
trigger DC maturation and direct further interactions with other immune cells, including 
naïve T cells1,9,10. Pattern recognition receptors (PRRs) on DCs detect the presence of a 
potential threat by interacting with pathogen-associated molecular patterns (PAMPs) 
10,11. In particular, C-type lectin receptors (CLRs) are PRRs with highly conserved 
carbohydrate-recognition domains that bind sugar moieties (e.g., mannose, fucose, and 
glucan) on the surface of certain pathogens (e.g., Candida albicans, Mycobacterium 
tuberculosis, and Mycobacterium leprae) in a calcium-dependent manner12,13. Ligand 
recognition by Toll-like receptors, a type of PRR, promotes a cascade of intracellular 
signaling events 14 . In addition, ligand recognition by CLRs leads to pathogen 
internalization via receptor mediated endocytosis and subsequent degradation and 
presentation of the pathogen as antigen to T cells in the context of MHC I or MHC II, or 
both13,15. Engagement of CLR-associated signaling processes can induce diverse 
immune responses depending upon the type of carbohydrate ligand bound, the type of 
responding APC and the engagement of other PRRs on the APC12. Thus, the targeting 
to and the activation of signaling pathways associated with CLRs (e.g., activation of NF-
κB signaling pathway) can be a powerful strategy to tailor the immune response11,13,14 
Previous studies have demonstrated the potential of targeting CLRs to induce DC 
maturation and activation; these studies focused on the use mannoproteins from 
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pathogens16 or the conjugation of glycans directly to the antigen17. Limited studies have 
explored the use of carbohydrate-functionalized vaccine carriers as targeting vehicles, 
with most studies using antibodies as ligands18. This study outlines a novel approach to 
target the mannose receptor (CD206) and CIRE (CD209) on murine DCs by mimicking 
carbohydrate moieties found on the surface of pathogens19. Polyanhydride nanoparticle 
surfaces were functionalized with di-mannose in order to study specific interactions with 
both CLRs known to recognize mannose residues10,13. The polyanhydride system used 
in this study is an amphiphilic copolymer of 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG). The studies described herein 
demonstrate that mannose-functionalized polyanhydride nanoparticles induce receptor-
mediated activation of DCs that may be exploited to enhance the adjuvanticity of this 
targeted delivery platform.  
 
8.3 Materials and Methods 
8.3.1 Materials 
Chemicals needed for monomer synthesis and polymerization, as well as for 
nanoparticle fabrication, including sebacic acid (99%), p-carboxy benzoic acid (99+%), 
and 1-methyl-2-pyrrolidinone, anhydrous (99+%), were purchased from Aldrich 
(Milwaukee, WI); 4-p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2 
pyrrolidinone, and tri-ethylene glycol were purchased from Sigma Aldrich (St. Louis, 
MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
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acetonitrile, acetic anhydride, methylene chloride, pentane, and petroleum ether were 
purchased from Fisher Scientific (Fairlawn, NJ).  
  
8.3.2 Monomer and Polymer Synthesis 
CPTEG:CPH copolymers were synthesized by melt polycondensation as described 
previously20. The chemical structure was characterized with 1H NMR and the molecular 
mass was determined using gel permeation chromatography (GPC) 20. 
 
8.3.3 Nanoparticle Fabrication 
An anti-solvent nanoencapsulation method recently published by Ulery et al.21 was 
used to fabricate nanoparticles based on a 50:50 molar ratio of CPTEG:CPH 
copolymers (50:50 CPTEG:CPH). Briefly, polymer was dissolved in methylene chloride 
(15 mg/mL) held at 4ºC. The polymer solution was rapidly poured into a bath of pentane 
held at -40ºC at an anti-solvent to solvent ratio of 1:150. Particles were collected by 
filtration and dried under vacuum for 2 h. For fluorescence microscopy studies, FITC-
dextran (1% (w/w)) was suspended and homogenized by sonication in the polymer 
solution prior to precipitation. 
 
8.3.4 Nanoparticle Surface Functionalization 
8.3.4.1 Synthesis of Carboxylated-Lactose and Di-mannose 
β-1-O-allylated lactose22 was prepared through mercury (II)-catalyzed allylation23 of 
penta-O-acetyl-lactosylbromide. As expected, using excess amounts of NaIO4 (8 
equivalents) under ruthenium-catalyzed Sharpless conditions24,25 produced the desired 
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acid in 91% yield. Subsequent deacetylation under mild condition using K2CO3 provided 
the desired fully deprotected disaccharide (Figure 8.1A).  
To obtain the dimannoside, the iterative synthesis of linear α-1,2-linked dimannose  
with a fluorous allyl group using fluorous-solid phase extraction (FSPE) served as the 
model26-28. Carboxylmethyl- di-mannose was obtained by ozonolysis of the alkene29, 
followed by further oxidation with Jones reagent26. Global deprotection under Birch 
reduction30 furnished the fully deprotected α-1,2-linked di-mannose (Figure 8.1B). 
 
 
Figure 8.1. Schematic representation of the synthesis of (A) carboxy-functionalized 
lactose and (B) carboxy-functionalized di-mannose. 
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8.3.4.2 Surface Functionalization 
Lactose and di-mannose were conjugated on the surface of polyanhydride 
nanoparticles by an amine-carboxylic acid coupling reaction28,30,31. Lactose, a neutral 
sugar with the same molecular weight as di-mannose, was chosen as a control sugar 
because of its different stereochemical configuration compared to di-mannoside. 
Particles with glycolic acid groups on the surface (linker groups) and non-functionalized 
(NF) particles were used as controls. An average concentration of 9.6 x 10-4 mmol 
COOH/mg of NF nanoparticles was calculated by a theoretical approach using the end 
groups obtained from 1H NMR spectra and by deconvolution analysis of the C1s high-
resolution spectra obtained from X-Ray Photoelectron Spectroscopy (XPS). The 
conjugation reaction was performed by incubating a nanoparticle suspension (100 
mg/mL) with 10 equivalents of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC), 12 equivalents of N-hydroxysuccinimide (NHS), and 10 
equivalents of ethylene diamine in distilled water. This first incubation was carried out at 
room temperature for 12 h at a constant agitation of 350 rpm. After the incubation 
period, particles were centrifuged at 10,000 rpm for 10 min and the supernatant was 
removed. A new incubation was performed with 12 eq. of EDC, 12 eq. of NHS and 10 
eq. of the corresponding saccharide (i.e., lactose or di-mannose) in distilled water, using 
constant agitation at 350 rpm for 12 h at room temperature. Particles were sonicated 
before and after each incubation period to break aggregates. After the reaction was 
completed, nanoparticles were collected by centrifugation (10,000 rpm, 10 min) and 
dried under vacuum overnight.   
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8.3.4.3 Characterization of Functionalized Nanoparticles 
The morphology and size of functionalized and non-functionalized nanoparticles 
were characterized by scanning electron microscopy (SEM, JEOL 840A, JEOL Ltd., 
Tokyo, Japan) and quasi-elastic light scattering (QELS, Zetasizer Nano, Malvern 
Instruments Ltd., Worchester, UK), respectively. For SEM, samples were vacuum dried 
and coated with gold before imaging with the electron microscope. The nanoparticles 
were suspended in cold water and sonicated for one minute before QELS readings were 
performed. QELS was also used to determine the ζ-potential of non-functionalized and 
functionalized nanoparticles in order to determine the presence of the disaccharides. 
XPS (PHI 5500 Multi-technique system, Physical Electronics, Inc., Chanhassen, MN) 
was used to determine the presence of lactose and di-mannose on the surface of 
polyanhydride nanoparticles. Binding energies were referenced to the aliphatic 
hydrocarbon peak at 285.0 eV32. High-resolution C1s peaks were collected and fitted 
using CasaXPS software (RBS Instruments, Bend, OR). Finally, a modified and 
optimized high throughput version of a phenol-sulfuric acid assay33 was used to quantify 
the amount of sugar attached to the nanoparticles. The modified assay was performed 
directly in 96-well plates and the incubation time was increased to 30 min to allow for 
equal reduction of the different sugars used to link to the nanoparticles. Non-
functionalized nanoparticles were used as controls to account for polymer interference 
with the assay. A microplate reader was used to obtain the absorbance of standards 
and unknown samples using a wavelength of 490 nm. The total amount of sugar 
(µg/mg) was calculated by normalization with the nanoparticle mass. 
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8.3.5 In vitro DC Uptake and Activation 
8.3.5.1 Mice 
C57BL/6 (B6) mice were purchased from Harlan Sprague Dawley (Indianapolis, IN). 
All mice were housed under specific pathogen-free conditions where all bedding, 
caging, and feed were sterilized prior to use. All animal procedures were conducted with 
the approval of the Iowa State University Institutional Animal Care and Use Committee.   
 
8.3.5.2 DC Culture and Stimulation 
Dendritic cells were derived from the bone marrow precursor cells recovered from 
the femurs and tibias of B6 mice according to a previously published protocol34,35. DCs 
were >90% positive for DC marker CD11c. For flow cytometry analysis, non-stimulated 
(NS) DCs and Escherichia coli lipopolysaccharide (LPS) (200 ng/mL) (Sigma Aldrich, St. 
Louis, MO) treated DCs were used as negative and positive controls, respectively. On 
day 9 of the culture, non-functionalized or functionalized nanoparticles were incubated 
with DCs for 48 h at a concentration of 0.125 mg/mL, a concentration chosen based on 
previously published studies35. In order to investigate the role of mannose receptor 
engagement in DC activation by di-mannose-functionalized polyanhydride 
nanoparticles, DCs were incubated with anti-CD206 (Clone 310301, R&D Systems, 
Minneapolis, MN) and/or anti-CD209 (Clone LWC06, eBioscience, San Diego, CA) 
antibodies either individually or in combination at a final concentration of 10 µg/mL for 
15 min at room temperature prior to addition of stimulants. Pre-incubation with anti-
CD206 and/or anti-CD209 blocked the cross-linking of the mannose and/or CIRE 
receptors by sugar-functionalized nanoparticles. This treatment tested the hypothesis 
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that functionalized nanoparticles enhance DC activation via increased mannose and/or 
CIRE receptor-mediated endocytosis. 
 
8.3.5.3 Flow Cytometric Analysis 
Flow cytometric analysis of surface molecule expression was performed as 
previously described34. Additional antibodies used in this study include FITC anti-mouse 
CD206 (MMR, clone MR5D3) and the isotype-specific control antibody FITC rat IgG2a κ 
(clone RTK2748) purchased from BioLegend (San Diego, CA), and biotin anti-mouse 
CD209 (CIRE, clone 5H10) purchased from eBioscience (San Diego, CA). As noted, the 
two antibodies used for FACS analysis are different from the antibodies used to block 
CLRs, thus preventing false negatives due to unavailable binding sites following 
treatment with the blocking antibody. Samples were acquired on a Becton-Dickinson 
FACSCantoTM flow cytometer (San Jose, CA) and the data analyzed using FlowJo 
(TreeStar Inc., Ashland, OR). Percentage of cells expressing each cell surface marker 
were obtained by quantifying the peak shift from their respective isotype controls and 
the intensity of the expression was reported as mean fluorescence intensity (MFI). 
 
8.3.5.4 Cytokine Assays 
 After stimulation for 48 h with non-functionalized or functionalized nanoparticles, cell-
free supernatants were assayed for IL-1β, IL-10, TNF-α, IL-6, and IL-12p40 using a 
multiplex cytokine assay in conjunction with a Luminex 100 System (Flowmetrics, 
Austin, TX) as described elsewhere34,35. 
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8.3.5.5 Fluorescence Microscopy Analysis of Nanoparticle Uptake by DCs 
 To visualize nanoparticle interactions with DCs, a previously described experimental 
protocol for co-incubation, immunofluorescence preparation and microscopic 
observation was followed21. In these experiments, an equivalent amount (200 µg/mL) of 
either non-functionalized or functionalized 1% FITC-dextran loaded nanoparticles were 
incubated with DCs, then washed repeatedly three times with pH 7.4 PBS to remove 
extracellular and non-adherent particles. DCs co-incubated with nanoparticles for 30 min 
were fixed and analyzed 2 h post uptake. At the indicated times, cultures were fixed for 
20 min with 4% paraformaldehyde in pH 7.4 PBS, washed and incubated with 5 µg/mL 
tetramethylrhodamine-wheat germ agglutinin (WGA) for 10 min at 37o C. Stained and 
washed coverslips were mounted on glass slides using Pro-Long w/DAPI mountant 
(Invitrogen, Carlsbad, CA). Epifluorescence microscopy was performed using an 
Olympus IX-71 inverted microscope with blue, green, and red filter sets with a cooled 
CCD camera. Final image preparation along with morphometric analysis was performed 
as described previously by us employing threshholding and particle counting algorithms 
of ImageJ v1.36b (NIH, Bethesda, MD)21. Binary data was extracted from grayscale 
images collected from the FITC bandpass filter set using equivalent exposure settings 
from fixed samples of DCs various nanoparticle modifications. For each sample, images 
from 5 fields of view (FOV) were collected and compiled with all grayscale images, 
including the the 5 FOVs from the various nanoparticle formulations. The compiled 
image set was then batch treated for background subtraction and thresholding using 
parameters set according to negative (no particle) control cultures that were performed 
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in parallel for each experiment and time point. Results presented are compiled from 
three separate biological replicates. 
 
8.3.5.6 Statistical Analysis 
The statistical software JMP®7 was used to analyze the cell surface marker, 
cytokine, and internalization data. One-way ANOVA and Tukey’s HSD were used to 
determine statistical significance among treatments and p-values < 0.05 were 
considered significant. 
 
8.4 Results 
8.4.1 Polymer Synthesis 
A 50:50 molar ratio copolymer of CPTEG and CPH was synthesized as previously 
described20. This formulation was chosen for these studies because previous studies 
have shown that it preserves protein structure and antigenicity in addition to exhibiting 
adjuvant properties4,5,7,34. 1H NMR spectroscopy was used to characterize the polymer 
structure and the spectra were consistent with previously published data20. The 
synthesized 50:50 CPTEG:CPH copolymer had a Mw of 8,500 g/mol with a 
polydispersity index (PDI) of 1.7. These values are consistent with previous work7,20.   
 
8.4.2 Characterization of Functionalized Nanoparticles 
 Particle morphology and size of both non-functionalized and functionalized-
nanoparticles were analyzed by SEM (data not shown). Some aggregation was 
observed after surface functionalization, which was attributed to the reaction conditions. 
 	  
244 
The aggregation was disrupted by sonicating the nanoparticles before use, as indicated 
by the size distribution profiles of the sonicated nanoparticles obtained by QELS (Table 
8.1). No significant differences were observed between the size of the functionalized 
and the non-functionalized nanoparticles. 
 
Table 8.1. Nanoparticle characterization. Non-functionalized and functionalized were 
characterized by QELS and zeta potential measurements. Particle size data represent 
the mean value ± standard deviation (SD) of dynamic light scattering data collected in 
three independent experiments. Zeta potential data represent the mean value ± SD of 
three independent readings. Change in zeta potential clearly indicates that sugar were 
efficiently conjugated to the 50:50 CPTEG:CPH nanoparticles surface. Sugar density on 
nanoparticles surface was determined by a colorimetric phenol-sulfuric acid assay. 
Amount of sugar was determined relative to standard curves; data is presented as mean 
± SD of four independent experiments. 
Nanoparticle type Average Particle 
Diameter (nm) 
Average Particle 
ζ-Potential (mV) 
 Sugar Density 
(µg/mg of particle) 
Non-functionalized 162 ± 43 -20 ± 0.6  ---- 
Linker 231 ± 52 21 ± 1.5  ---- 
Lactose 266 ± 44 26 ± 2.4  10.9 ± 6.8 
Di-mannose 278 ± 32 28 ± 3.2  12.4 ± 5.5 
 
Measurements of ζ-potential using QELS were employed to characterize the 
nanoparticle surface functionalization (Table 8.1). The non-functionalized nanoparticles 
exhibited a ζ-potential of -20 mV. In contrast, the various functionalized nanoparticles 
resulted in a positively charged ζ-potential (ranging from 20-26 mV). The positive charge 
observed after functionalization is attributed to the presence of the diamine linker on the 
surface of the particles; this was corroborated by analyzing the ζ-potential of 
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nanoparticles that were only reacted with the ethylene diamine linker but without glycolic 
acid or sugar. This control showed a slightly more positive ζ-potential in comparison to 
the linker and sugar modified particles. As expected, the reaction yield of sugar 
attachment to the linker is not 100%. Since the di-mannoside is a neutral sugar, the free 
amine groups present on the surface of the particles are responsible for the positive 
charge observed.  
 
Table 8.2. An increase in the nitrogen content of functionalized nanoparticles correlates 
with the presence of the amine linker used in the amine-carboxylic acid reaction. X-ray 
photoelectron spectroscopy (XPS) analysis of atomic percentages and ratios of 
elements present on non-functionalized and functionalized 50:50 CPTEG:CPH 
nanoparticles. 
Nanoparticle type % Ca % Na % Oa O/Cb N/Cb 
Non-functionalized 74.9 ± 1.5 1.2 ± 0.1 23.9 ± 2.3 0.320 0.016 
Linker 65.5 ± 0.9 4.4 ± 0.5 18.1 ± 1.9 0.276 0.067 
Lactose 76.3 ± 2.1 5.1 ± 0.4 20.9 ± 1.1 0.274 0.067 
Di-mannose 73.9 ± 1.1 5.3 ± 0.7 23.3 ± 1.5 0.315 0.072 
 
aData reported as mean ± standard deviation of four independent experiments 
performed in triplicate. 
bRatio of the two elements as indicated. 
 
The functionalized nanoparticles were characterized using XPS36 to quantitatively 
determine successful linker and sugar conjugation to the nanoparticle surface. Table 8.2 
shows the surface elemental atomic percentages and elemental ratios of non-
functionalized and functionalized nanoparticles. Clear differences in the N/C ratio were 
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observed, showing a significant increase in nitrogen content (i.e., 0.01 in the non-
functionalized particles to almost 0.07 in the functionalized particles). This increase in 
nitrogen content is directly related to the presence of the amine linker. The presence of 
nitrogen groups on the surface makes the surface composition of these particles similar 
to that of pathogens, which are known to have a high content of amine-containing 
compounds37.  
High-resolution C1s spectra were fitted with four main components according to their 
characteristic binding energies representing aliphatic hydrocarbon at 285.0 eV (C1), 
ether and amine groups at 286.5 eV (C2), carbonyl and amide groups at 288.2 eV (C3), 
and ester and carboxylic acid groups at 289.1 eV (C4)32. Analysis of C1s spectra allows 
for more direct comparison of sugar attachment based on increases in the ether and 
amine groups (C2). Ether groups are characteristic of carbohydrate structures while the 
amine groups are indicative of the presence of the amine linker used for surface 
modification. Table 8.3 shows the average percentage areas obtained from high-
resolution C1s fitted spectra. These data indicate a clear increase in the C2 component 
in the functionalized-nanoparticle groups, especially those functionalized with lactose 
and di-mannose. The C2 component percentage for the non-functionalized 50:50 
CPTEG:CPH nanoparticles is ~22%, while that of the sugar-functionalized nanoparticles 
is ~30%. It is known that the outer surface of bacterial pathogens are comprised of 
various constituents bearing amine and hydroxyl groups (e.g., peptidoglycan, 
lipopolysaccharide, lipoproteins, and flagella)37. Analysis of C1s (Table 8.3) and O1s 
(data not shown) spectra of functionalized nanoparticles showed a clear increase of 
amine, ether, and hydroxyl groups, resulting in a surface composition that is similar to 
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that of pathogens37. The total amount of sugar attached to the nanoparticle surface was 
quantified by the phenol-sulfuric acid assay. The results showed that similar amounts 
(12.6 ± 6.4 µg/mg of particle) of lactose and di-mannose were attached to the 50:50 
CPTEG:CPH nanoparticles (Table 8.1). 
 
Table 8.3. Increased surface presence of ether, amine and hydroxyl groups 
corroborated nanoparticle functionalization. Average percentage areas of aliphatic 
hydrocarbon (C1), ether and amine groups (C2), carbonyl and amide groups (C3), and 
ester and carboxylic acid groups (C4) were obtained from XPS high-resolution C1s fitted 
spectra.   
 Percentage area of C1s componentsa 
Nanoparticle type C1 C2 C3 C4 
Non-functionalized 59.7 ± 1.2 22.3 ± 0.7 8.7 ± 0.6 1.4 ± 0.1 
Linker 58.3 ± 1.7 26.6 ± 0.7 7.1 ± 0.3 0.1 ± 0.2  
Lactose 58.2 ± 0.8 30.1 ± 1.2 6.6 ± 0.6 0.6 ± 0.1 
Di-mannose 58.1 ± 1.9 29.6 ± 1.0 6.9 ± 0.5 0.4 ± 0.1 
a Data reported as mean ± standard deviation of four independent experiments 
performed in triplicate. 
 
8.4.3 Di-mannose-functionalized nanoparticles enhanced DC expression of MHC 
II, co-stimulatory molecules and CLRs 
 Flow cytometry was used to determine if functionalized nanoparticles enhanced the 
activation status of DCs. In general, the results indicate that di-mannose functionalized 
nanoparticles significantly enhanced the expression of key surface markers that are 
associated with DC maturation and antigen presentation (i.e., MHC II, CD86, and CD40) 
and concomitantly increased the surface expression of CLRs (i.e., CD206 and CIRE) as 
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compared to non-functionalized nanoparticles (Figure 8.2). Another interesting 
observation from these studies is that the di-mannose functionalized nanoparticles 
induced higher expression of both CD206 and CIRE as compared to lactose-
functionalized particles, confirming the specificity of both CIRE and CD206 for mannose 
residues as observed previously13.   
 
 
Figure 8.2. Di-mannose-functionalized nanoparticles enhanced DC expression of MHC 
II, co-stimulatory molecules and C-type lectin receptors (CLRs). After stimulation with 
either non-functionalized (NF) or functionalized nanoparticles for 48 h, DCs were 
harvested and analyzed by flow cytometry for surface expression of (A) MHC II, (B) 
CD86, (C) CD40, (D) CIRE, or (E) CD206. LPS and non-stimulated cells (NS) were used 
as positive and negative controls, respectively. Data are expressed as the mean ± the 
SEM of four independent experiments performed in triplicate. * and # represent groups 
that are statistically significant (p ≤ 0.05) compared to the NS and NF groups, 
respectively. MFI = mean fluorescence intensity. 
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 Soluble lactose and di-mannose and non-functionalized nanoparticles plus soluble 
sugar were used as controls to probe the benefit of the covalent linkage of the sugars to 
the nanoparticle surface. The addition of soluble sugars (i.e., lactose and di-mannose) 
to cultures of DCs with non-functionalized nanoparticles did not significantly change cell 
surface marker expression from levels induced by the non-functionalized nanoparticles 
alone (Supplemental Figure 8.1).  
 
8.4.4 Stimulation with functionalized nanoparticles enhanced pro-inflammatory 
cytokine secretion 
Although stimulation of DCs with either non-functionalized or functionalized 
nanoparticles modestly increased the secretion of IL-6 in comparison to the non-
stimulated controls, the greatest amounts of IL-6 were produced by DCs stimulated with 
linker-modified nanoparticles (black bars in Figure 8.3). Elevated levels of TNF-α were 
secreted (gray bars in Figure 8.3) upon stimulation with the linker-functionalized 
particles. Neither IL-10 nor IL-1β was detected in the culture supernatants (data not 
shown). This observation is consistent with previously published work with other 
polyanhydride chemistries35 and different particle sizes34. The level of IL-12p40 secreted 
into the culture medium by DCs stimulated with either non-functionalized or 
functionalized nanoparticles was not statistically different from the non-stimulated 
controls (data not shown). 
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Figure 8.3. Stimulation with functionalized nanoparticles enhanced secretion of pro-
inflammatory cytokines from DCs. After stimulation with non-functionalized (NF) and 
functionalized nanoparticles for 48 h, supernatants were harvested and assayed for IL-6 
(   ) and TNF-α (   ). Data is represented as mean concentration of cytokines ± the SEM 
of four independent experiments performed in triplicate. LPS was used as a positive 
control stimulant (> 50,000 pg/mL for IL-6 and 6,861 pg/mL for TNF-α) and non-
stimulated cells (NS) were used as a negative control. * and # represent groups that are 
statistically significant (p ≤ 0.05) compared to the NS and NF groups, respectively. 
 
8.4.5 Both non-functionalized and functionalized nanoparticles were efficiently 
internalized by DCs  
Microscopic analyses were performed to determine if the enhanced activation of 
DCs by functionalized nanoparticles was associated with enhanced internalization. 
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Interestingly, all the functionalized nanoparticle groups were efficiently internalized 
following 30 min of co-incubation with DCs (Figure 8.4A). These qualitative findings 
were corroborated by morphometric analysis of the epifluorescent images of the FITC-
loaded nanoparticles, which is presented as the total area (µm2) of internalized 
nanoparticles. This metric allowed us to perform biologically relavent comparisons 
among all treatments. The morphometric analysis revealed that higher amounts of 
functionalized nanoparticles were internalized by DCs when compared to non-
functionalized nanoparticles (Figure 8.4B).     
 
 
Figure 8.4. Both non-functionalized and functionalized nanoparticles (green) were 
efficiently internalized by DCs after co-incubation for 30 min. Monolayers incubated for 2 
h post-internalization with FITC-loaded nanoparticles were stained with WGA 
conjugated with tetramethylrhodamine to delineate the plasma membrane. (A) 
 	  
252 
Epifluorescent microscopy demonstrated that nanoparticle functionalization enhanced 
internalization when compared to non-functionalized (NF) nanoparticles. Representative 
epifluorescent images were captured and processed using identical exposure and 
ImageJ settings. (B) Quantitative morphometric analysis measuring nanoparticle uptake 
per field of view (FOV). Data is reported as the total area of fluorescence detected within 
each FOV (* represents groups that are statistically significant (p ≤ 0.05) compared to 
the NF group). Images shown are representative of four fields of view analyzed for each 
group and consistently observed over three independent experiments. Scale bar = 20 
µm. 
 
8.4.6 Mannose receptor-mediated activation of DCs by di-mannose functionalized 
nanoparticles 
To test the specificity of the di-mannose functionalization for binding to CLRs, 
monoclonal antibodies were used to inhibit activation of the mannose receptor and CIRE 
on DCs stimulated with non-functionalized and di-mannose-functionalized nanoparticles 
(Figure 8.5). For all the surface markers evaluated (i.e., MHC II, CD40, CD86, CD209, 
and CD206), the mean fluorescence intensity (MFI) values for the non-stimulated DCs 
did not change over that of the controls when the monoclonal antibodies against the 
CLRs were added, indicating that no additional stimulation was provided by the 
antibodies used as blocking agents. After blocking with anti-CD209 or anti-CD206, a 
reduction in the expression of CIRE and CD206, respectively, was observed after 
stimulation with di-mannose-functionalized nanoparticles (as shown in Figures 8.5D 
and E). This result demonstrates that the use of specific monoclonal antibodies can 
block the up-regulation of the mannose and CIRE receptors induced by di-mannose-
functionalized particles. Furthermore, when the anti-CD206 monoclonal antibody was 
used, the increased surface expression of MHC II, CD40, and CD86 was inhibited 
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(Figures 8.5A, B, and C). This outcome demonstrates that mannose receptor 
engagement by the functionalized nanoparticles plays a critical role in their adjuvant 
effect. In these experiments, the linker and lactose-functionalized particles were also 
added to separate DC cultures to control for the specificity of the blocking antibodies. 
After pre-treatment with the anti-CD206 monoclonal antibody, there was no significant 
inhibition in the expression of MHC II, CD40, and CD86 (Supplemental Figure 8.2), 
further corroborating the specificity of the mannose receptor mediating DC activation by 
the di-mannose-functionalized nanoparticles. 
 
 
Figure 8.5. Mannose receptor-mediated activation of DCs by di-mannose functionalized 
nanoparticles is inhibited by receptor-specific monoclonal antibodies. DC cultures were 
incubated for 15 min with either α-CD206, α-CD209 or α-CD206 + α-CD209, or media 
(control, NS) and then were stimulated with either non-functionalized (NF) or di-
mannose-functionalized nanoparticles for 48 h. DCs were harvested and analyzed via 
flow cytometry for changes in surface expression of (A) MHC II, (B) CD86, (C) CD40, 
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(D) CIRE, or (E) CD206. MFI (mean fluorescence intensity) ± the SEM of each of the 
markers of two independent experiments performed in triplicate is presented. * 
represents groups that are statistically significant (p ≤ 0.05) compared to the control 
treatment. 
 
8.5 Discussion 
Engineering nanoparticles that are targeted to specific receptors on APCs offers a 
novel approach for the rational design of effective vaccine adjuvants. The covalent 
linkage of specific carbohydrates to the surface of nanoparticles allows for the targeting 
of CLRs and activation of complex signaling pathways including crosstalk with other 
PRRs (e.g., TLRs and Fc receptors) that can direct the immune response. The data 
presented herein demonstrate the design and fabrication of novel di-mannose-
functionalized polyanhydride nanoparticles that possess characteristically similar 
chemical compositions as that of pathogen surfaces. These “pathogen-like” 
nanoparticles were efficiently internalized by DCs (Figure 8.4) and concomitantly 
activated DCs (Figures 8.2 and 8.3) in vitro by specific interactions with the mannose 
receptor (Figure 8.5).  
 All the particles (i.e., non-functionalized and linker, lactose, and di-mannose-
functionalized) enhanced the expression of MHC II, CD40, and CIRE (Figures 8.2A, 
8.2C and 8.2D) when compared to non-stimulated DCs. While non-functionalized 50:50 
CPTEG:CPH nanoparticles demonstrated moderate DC activation, di-mannose 
functionalization of the nanoparticles induced greater expression of MHC II, CD40, and 
CD86. MHC II, CD40, and CD86 play an important role in the induction of adaptive 
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immunity through activation of CD4+ T cells, and it would be beneficial for an effective 
adjuvant to enhance the expression of MHC II and co-stimulatory molecules1,9,34.  
CIRE and the mannose receptor play an important role in antigen uptake, as well as 
in DC migration and initial interaction with T cells9-11,13. As mentioned before, the 
activation of CLR-induced signalling processes can result in the induction of diverse 
immune responses12. As shown in Figures 8.5D and 8.5E, by chemically conjugating di-
mannose to the surface of polyanhydride nanoparticles, effective cross-linking of CLRs 
on DCs was achieved, resulting not only in a higher expression of both CIRE and 
CD206, but also in higher expression of other DC maturation markers (i.e., MHC II, 
CD40, and CD86) compared to the non-functionalized particles. High affinity binding of 
CLRs to their ligands is known to result in increased expression of the receptor on the 
cell surface38. Additionally, the results presented in Supplemental Figure 8.1 
demonstrate that the sugars must be covalently attached to the nanoparticles to 
enhance the activation of the DCs. Finally, the data presented in Supplemental Figure 
8.2 further corroborates the binding of the di-mannose-functionalized nanoparticles to 
the mannose receptor in order to enhance the activation of DCs. 
The expression of MHC II, CD86 and CD40 is essential for antigen presentation and 
activation of naïve T cells; however, it is not sufficient to induce an effective T cell 
response. In the context of a robust immune response, DCs need to secrete an 
appropriate profile of cytokines to enhance CD4+ T cell activation. The data presented in 
Figure 8.3 demonstrate that DCs secreted IL-6 after stimulation with both non-
functionalized and functionalized nanoparticles. IL-6 is important to both innate and 
adaptive immune response, as it contributes to systemic inflammation1 and promotes 
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humoral immune responses39. Linker-functionalized nanoparticles also induced the 
secretion of TNF-α. This cytokine is important in early DC maturation and further 
induction of T cell differentiation and, therefore, even small amounts can influence the 
bias and magnitude of an immune response. Production of these two cytokines by DCs 
has been previously associated with CLR-induced signaling events12,16.  
The observed enhancement in surface molecule expression (Figure 8.2) and IL-6 
secretion (Figure 8.3) by DCs after stimulation with di-mannose functionalized 
nanoparticles was hypothesized to be related to an increase in particle internalization40. 
However, as shown in Figure 8.4, all functionalized nanoparticles were efficiently 
internalized by DCs. In particular, both linker and di-mannose-functionalized 
nanoparticles were present in higher numbers inside the DCs than non-functionalized 
and lactose functionalized nanoparticles. These data indicate that particle internalization 
is necessary but not sufficient for enhanced DC activation. Previous work from our 
laboratories has demonstrated enhanced internalization of soluble antigen by 
monocytes when delivered with non-functionalized polyanhydride nanoparticles21. 
Therefore, the results presented in Figure 8.4 suggest that the functionalized 
nanoparticles would also provide efficient antigen delivery.  
The specific interaction of functionalized nanoparticles with CLRs documented in this 
study presents an intriguing opportunity for the rational design of nanovaccines 
possessing the capacity to induce diverse immune responses tailored for a target 
disease. While the increased activation of DCs with di-mannose functionalized particles 
was directly correlated with a receptor-ligand interaction, the enhanced internalization of 
linker-functionalized nanoparticles represents a non-specific interaction that may be 
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dictated by the positive charge of the functionalized particles. It is well known that 
cationic particles show greater adhesion with cell membranes41 and, therefore, may be 
an explanation for the enhanced cellular uptake of the linker-functionalized 
nanoparticles observed in this study. In addition, the non-specific interaction due to the 
linker-functionalized nanoparticles may closely mimic the interaction between DCs and 
endogenous danger signals. Indeed, cellular recognition of endogenous (e.g., hyaluronic 
acid, uric acid crystals) and exogenous (e.g., LPS, lipoteichoic acid) hydrophobic 
moieties is an important component of the danger hypothesis describing activation of 
innate immune responses42,43. Non-functionalized polyanhydride nanoparticles present a 
hydrophobic surface to DCs in much the same manner as would apoptotic cells or 
endogenous stressors compared to the more robust responses induced by microbial 
PAMPs. Endogenous danger signals are known to stimulate a robust adaptive immune 
response in the absence of deleterious inflammatory responses42, an attribute that 
would be valuable to replicate when developing safe and effective vaccines. 
Collectively, these results indicate that polyanhydride nanoparticles can be rationally 
functionalized to effectively enhance activation of APCs and lead to the design of 
efficacious targeted vaccine delivery platforms. 
 
8.6 Conclusions 
In this study, novel “pathogen-like” particles were fabricated by functionalizing the 
surface of polyanhydride nanoparticles with sugar residues. The ability of these novel 
particles to induce and enhance DC activation by specific interactions with the mannose 
receptor was demonstrated. Targeting CLRs on DCs with ligands covalently linked to 
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polyanhydride nanoparticles has the potential to efficiently deliver antigens to DCs for 
effective processing and presentation to T cells. A specific ligand-receptor interaction 
(i.e., di-mannose-CD206) was identified by blocking the mannose receptor on DCs, 
which resulted in the inhibition of DC activation. This data indicates that mannose 
receptor signaling pathways are involved in the expression of surface molecules 
required for antigen presentation and T cell co-stimulation. The receptor-mediated 
endocytosis induced by the direct interaction of mannose residues with the mannose 
receptor may be exploited to design efficacious nanovaccines. The initial interactions of 
these novel di-mannose functionalized nanoparticles with CLRs on DCs have been 
demonstrated in these studies; however, the biological consequences of these 
interactions still need to be evaluated and are a continued area of investigation in our 
laboratories. 
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8.9 Supplemental data 
 
 
Supplemental Figure 8.1. Covalent attachment of sugars to nanoparticles is necessary 
to enhance activation of DCs. After stimulation with either soluble lactose or di-mannose 
or soluble sugars plus non-functionalized (NF) nanoparticles for 48 h, DCs were 
harvested and analyzed by flow cytometry for surface expression of (A) MHC II, CD86, 
and CD40, and (B) CIRE and CD206. LPS and non-stimulated cells (NS) were used as 
positive and negative controls, respectively. Data are expressed as the mean ± the SEM 
of three independent experiments performed in duplicate. * represents groups that are 
statistically significant (p ≤ 0.05) compared to the NS group. MFI = mean fluorescence 
intensity. 
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Supplemental Figure 8.2. Expression of DC activation markers by linker and lactose-
functionalized nanoparticles is not inhibited by receptor-specific monoclonal antibodies . 
DC cultures were incubated for 15 min with either α-CD206, α-CD209 or α-CD206 + α-
CD209, or media (control, NS) and then were stimulated with either linker-functionalized 
(NF) or lactose-functionalized nanoparticles for 48 h. DCs were harvested and analyzed 
via flow cytometry for changes in surface expression of (A) MHC II, (B) CD86, (C) CD40, 
(D) CIRE, or (E) CD206. MFI (mean fluorescence intensity) ± the SEM of each of the 
markers of two independent experiments performed in triplicate is presented. * 
represents groups that are statistically significant (p ≤ 0.05) compared to the control 
treatment. 
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9.1 Abstract 
Innovative vaccine platforms are needed in order to develop effective single-dose 
vaccines to control new and re-emerging diseases. These platforms should be able to 
direct antigen internalization and promote immunogenic responses by antigen 
presenting cells, as well as prevent rapid degradation of antigen, all these in order to 
augment, modulate and extend immune responses. In this work a transdisciplinary 
approach was utilized to rationally design efficacious vaccines against Yersinia pestis by 
combining two novel platforms, αGal-modification of the vaccine antigen (i.e., F1-V) and 
use of polyanhydride nanoparticles as vaccine delivery vehicles, which results in the 
induction of a robust immune response. High antibody titers with high avidity and with 
the ability to recognize epitopes that have been identified as protective were elicited by 
vaccine regimes containing soluble αGal-F1-V and encapsulated αGal-F1-V or F1-V. 
Using peptides arrays in combination with informatics tools we have introduced a novel 
strategy in understanding antigen-antibody interactions, generating information that 
allows for the rational selection of antigen (i.e., αGal-modification)- and adjuvant (i.e., 
polyanhydride nanoparticles)-based platforms for the design of efficacious vaccines. 
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9.2 Introduction 
Yersinia pestis, the causative agent of pneumonic plague, is an antibiotic-resistant 
organism1,2, easy to weaponize, and can significantly affect susceptible populations3, 
making the development of an effective vaccine highly desirable. Previous studies have 
shown that immunization with the fusion protein, F1-V, provides protection in mice4 and 
cynomolgus macaques5; however, this antigen failed to produce sufficient levels of 
protection in other non-human and human trials6,7.  
Despite the promising possibilities of the F1-V antigen, there remains a major hurdle 
in the treatment against plague and alternatives have been explored in order to improve 
vaccine efficacy and induce long-term, protective immunity. In this regard, targeting 
antigen presenting cells (APCs) offers an option capable of eliciting combined humoral 
and cellular responses, and has been applied to Y. pestis, showing protection in mice8. 
Targeting Fcγ receptors (FcγR) present on a variety of APCs (i.e., dendritic cells, 
Langerhans cells, and macrophages) is considered the most effective mechanism by 
which APCs identify and internalize antigens to induce an effective immune response9. 
Antigen opsonization (i.e., formation of immune complexes) allows for the Fc portion of 
the antigen-bound antibodies to interact with FcγR9-12 and has been shown to increase 
immunogenicity of several antigens (e.g., tetanus toxoid, hepatitis B antigen, etc)10-12.  
Anti-αGal is the most abundant natural antibody in humans, constituting ~1% of 
serum IgG and interacts with the carbohydrate epitope Gal-α(1-3)-Gal-β(1,4)-GlcNAc-R 
(αGal) found on glycolipids and glycoproteins of most animals13,14. This αGal epitope is 
synthesized in other animals by the glycosylation enzyme α1,3galactosyltransferase 
(α1,3GT); however, the α1,3GT gene was inactivated in humans and therefore human 
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cells are completely devoid of αGal epitopes, leading to the recognition of αGal antigens 
as foreign13,14. As a result, any soluble antigen that has αGal epitopes will form immune 
complexes with anti-αGal and will be targeted for effective uptake by APCs15-18. αGal 
modification has been shown to substantially increase the immunogenicity of proteins as 
diverse as bovine serum albumin (BSA)19, viral hemagglutinin16, and HIV gp12018. 
Exploiting the natural occurring anti-αGal immune response to enhance immunity of the 
F1-V antigen is a strategy that may lead to reduced antigen dose and more efficacious 
immunization protocols resulting in cost-effective vaccines. 
The use of vaccine adjuvants is another alternative to improve vaccine 
immunogenicity by providing pro-inflammatory signals and prolonging the persistence of 
vaccine antigens, which is of special importance to induce affinity maturation of B 
cells20. Sustained exposure to antigen can be achieved by utilizing nanoparticle-based 
platforms; in fact, several biodegradable polymers have been studied as vaccine 
delivery vehicles 20. In particular, polyanhydride particles have demonstrated the ability 
to provide sustained release of stable protein antigens and to activate antigen 
presenting cells and modulate immune responses21-31. Moreover, amphiphilic 
polyanhydride particles made of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were able to stabilize the F1-V antigen21 
and a vaccine formulation based on this copolymer provided long-term protection 
against Y. pestis challenge in mice32.  
This study outlines a novel approach to design an effective single-dose vaccine 
against Y. pestis by combining the polyanhydride nanoparticle-based platform with 
antigenically modified F1-V protein. It is hypothesized that the combination of these two 
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approaches will augment and accelerate antigen-specific immunity leading to the 
development of a cost-effective plague vaccine that can reduce the need for multiple 
injections and result in greater patient compliance. In this work, the F1-V antigen was 
modified with αGal epitopes and to mimic the relevant human immune characteristics to 
the αGal pathway, an α1,3GT gene knockout (KO) mouse model, which lacks αGal 
epitopes and can produce anti-αGal similarly to humans, was used to evaluate the 
efficacy of the proposed vaccine formulations. Peptide array and informatics analysis 
tools were used to identify immunodominant epitopes recognized by the antibodies 
elicited by the various vaccine regimens. The studies described herein demonstrate the 
importance of integrating concepts from material science, protein chemistry, 
immunology and computational analysis to rationally design the next generation of 
adjuvants and vaccines for emerging and re-emerging diseases.  
 
9.3 Materials and Methods 
9.3.1 Materials 
Chemicals needed for monomer synthesis and polymerization, as well as for 
nanoparticle fabrication, including sebacic acid (99%), p-carboxy benzoic acid (99+%), 
and 1-methyl-2-pyrrolidinone, anhydrous (99+%), were purchased from Aldrich 
(Milwaukee, WI); 4-p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2 
pyrrolidinone, and tri-ethylene glycol were purchased from Sigma Aldrich (St. Louis, 
MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
acetonitrile, acetic anhydride, methylene chloride, pentane, and petroleum ether were 
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purchased from Fisher Scientific (Fairlawn, NJ). Goat anti-mouse IgG (H+L)-AP was 
purchased from Jackson ImmunoResearch (West Grove, PA). Phosphatase substrate 
was purchased from Aldrich (St Louis, MO). Polyacrylamide 4–20% Tris–HCl pre-cast 
gradient gels, unstained protein standards, pre-stained broad range molecular weight 
standards, and Flamingo Gel Stain were purchased from Bio-Rad Laboratories 
(Richmond CA). Bicinchoninic acid (BCA) and micro-BCA protein assay kits was 
obtained from Pierce Biotechnology Inc. (Rockford, IL). 
 
9.3.2 Antigenic Modification of F1-V 
Recombinant F1-V obtained from NIH Biodefense and Emerging Infections 
Research Resources Repository (BEI, Manassas, VA) was antigenically modified by 
chemical addition of αGal epitopes at lysine residues. Chemical addition of αGal 
epitopes to this vaccine antigen was performed at BioProtection Systems, Inc. (Ames, 
IA) using an efficient chemo-enzymatic synthesis of the αGal trisaccharide and 
conjugation33. The modified F1-V was characterized by SDS-PAGE and western blot 
using either F1-V hyperimmunized mice sera, which were obtained from repeated 
injections of F1-V antigen to adult female C57BL/6 mice, or αGal (+) sera from α1,3GT 
KO mice, which were obtained after three intraperitoneal injections with rabbit red blood 
cells to induce production of anti-αGal antibodies.  
 
9.3.3 Polymer Synthesis and Characterization 
Synthesis of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) diacids was performed as described 
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previously34. 1H NMR and gel permeation chromatography (GPC) were utilized to 
confirm polymer chemical structure and to measure molecular weight, respectively. The 
50:50 CPTEG:CPH copolymer had a Mn of 8,500 Da and a PDI of 1.70, consistent with 
previous work21,22,29,34. 
 
9.3.4 Nanoparticle Fabrication and Characterization 
Both F1-V and αGal-modified F1-V (αGal-F1-V) encapsulated nanoparticles were 
fabricated by the anti-solvent nanoencapsulation method reported previously31,32. 
Nanoparticle recovery was >70% and antigen encapsulation efficiency was >95%. 
Scanning electron microscopy (SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan) and quasi-
elastic light scattering (QELS, Zetasizer Nano, Malvern Instruments Ltd., Worchester, 
UK) were employed to investigate particle morphology and size, respectively.   
 
9.3.5 In vitro Antigen Release Kinetics 
F1-V and αGal-F1-V loaded nanoparticles were incubated with 0.1 mM phosphate 
buffer saline (PBS, pH 7.6) in microcentrifuge tubes. Samples were sonicated to 
uniformly distribute the nanoparticles and placed an incubator at 37 ºC with constant 
agitation. Supernatants were sampled over time to determine the amount of released 
antigen using a microBCA protein assay. The removed volumes were replaced with 
fresh PBS following supernatant removal to maintain perfect sink conditions. Data is 
presented as cumulative fraction of released antigen, which was determined by dividing 
the amount released at each time point by the total amount of encapsulated protein into 
the nanoparticles21,26,29.  
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9.3.6 Mice 
The α1,3GT gene knockout (KO) mouse model was used to stimulate immunity to 
αGal and mimic human immunity to this epitope. Mice were obtained from BioProtection 
Systems, Inc. and housed under specific pathogen-free conditions where all bedding, 
caging, and feed were sterilized prior to use. All animal procedures were conducted with 
the approval of the Iowa State University Institutional Animal Care and Use Committee. 
An intraperitoneal injection regimen of rabbit red blood cells (RRBCs) was performed 
prior to immunization to induce production of anti-αGal antibodies. Animals received 
three injections of RRBCs (3 x 109 RRBCs/injection) at 14-day intervals. Seven days 
after the final RRBC injection, whole blood was collected from mice via the saphenous 
vein and serum was assessed for anti-αGal specific antibodies. Only mice whose sera 
showed optical density values (OD405nm) higher than 5x background (PBS) were used in 
the study and animals were distributed randomly across the different immunization 
groups.  
 
9.3.7 Vaccinations  
Mice were vaccinated subcutaneously with the regimens described in Table 9.1 by 
suspension in pyrogen-free saline in a volume of 100 µL. Nanoparticles were sonicated 
briefly to disperse clumps prior to immunization using a 23 gauge needle. Control 
animals received 100 µL of saline alone. A booster dose of 5 µg of F1-V was 
subcutaneously administered to all mice 37 days after immunization. Blood samples 
were collected from the left saphenous vein prior to immunization, prior to boosting (pre-
boost) at day 36, and five days after boosting (post-boost). Serum was collected by 
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centrifugation and stored at -20°C and assayed for anti-F1-V specific antibodies. These 
experiments were conducted in duplicate with a different batch of nanoparticles used for 
each experiment.    
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9.3.8 F1-V and LcrV Specific Enzyme-Linked Immunosorbent Assay (ELISA) 
High protein binding 96-well Costar microtiter plates (Corning Life Sciences, Lowell, 
MA) were coated overnight with 100 µl of phosphate buffer saline (PBS) at a pH of 7.4 
containing 0.5 µg/mL of F1-V or LcrV (BEI, Manassas, VA). PBS containing 0.05% 
Tween 20 (PBS-T) and 2% (w/v) gelatin as a non-specific blocking agent (BD 
Biosciences, San Jose, CA) was used to block plates for at least 2 h at room 
temperature. After the blocking period, plates were heated at 60 ºC for 10 min in a dry 
oven to melt gelatin, and rinsed three times to remove any unbound blocking reagent. 
Sera samples were diluted 1:100, then serially diluted two-fold in PBS-T with 1% (v/v) 
normal goat serum (NGS), and incubated overnight at 4ºC. PBS-T was used to wash the 
plates three times followed by the addition of 100 µL of PBS-T (1% (v/v) NGS) 
containing alkaline phosphatase (AP)-conjugated goat anti-mouse IgG(H&L) at a 1:1000 
dilution. After 2 h of incubation at room temperature, the plates were washed four times 
with PBS-T and 100 µL of sodium carbonate (50 mM) and magnesium chloride (2 mM) 
buffer (pH 9.3) containing 1 mg/mL of phosphatase substrate was added. The plates 
were allowed to react for 20 min at room temperature. Optical density (OD) of each well 
was measured at 405 nm using a Spectramax 190 Plate Reader (Molecular Devices, 
Sunnyvale, CA). Endpoint titers were defined as the highest dilution with an OD value of 
at least 0.2, which was at least three times the background OD value. To determine the 
antibody isotype induced by the various immunization regimens, OD was determined by 
the same ELISA protocol as described before. Sera samples were diluted at 1:500 and 
alkaline phosphatase-conjugated goat anti-mouse IgG1, IgG2a, IgG2c, IgG3, and IgM 
(Jackson ImmunoResearch Laboratories, West Grove, PA) were used.  
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9.3.9 Antibody Avidity Assay 
Antibody avidity analysis was performed as described previously25,32. Briefly, ELISA 
plates were coated overnight with 0.5 µg/mL F1-V. Plates were washed with PBS-T and 
blocked for two hours with 2% gelatin in PBS-T. Serum samples were diluted 1:500 in 
1% NGS-PBS-T and incubated overnight at 4ºC. Plates were washed with PBS-T and 
5M NaSCN diluted in 0.1M NaH2PO4 buffer was added to the first column and two-fold 
serially diluted to 9.76 mM leaving two columns containing 0M NaSCN. The NaSCN was 
incubated for 15 min and the plates were washed five times with PBS-T. AP-conjugated 
goat anti-mouse IgG (H&L) diluted 1:1000 in 1% normal goat serum in PBS-T was 
incubated for 2 h. Plates were washed and phosphatase substrate (1 mg/mL) in 
carbonate buffer (pH 9.3) was added. Changes in OD were measured at 405 nm using a 
spectrophotometer. Avidity index was defined as the concentration of NaSCN necessary 
to reduce the OD by 50% compared to the wells treated with 0.1 M sodium phosphate.  
 
9.3.10 Epitope Mapping by Peptide Arrays 
For analysis of the binding specificity of the produced immune sera to F1 or V 
antigenic peptides, an ELISA assay was performed following a similar protocol to the 
one described previously. Two sets of overlapping peptides, one panel covering the full 
length of the F1 antigen (27 peptides) and the other covering the full length of the V 
antigen (53 peptides), were obtained from BEI. Immunlon 2HB 96-well plates were 
incubated with the peptides (5 µg/mL) and incubated overnight at 4ºC. Plates were 
blocked for 2 h at room temperature with 2.5% skim milk in PBS-T. Sera samples were 
incubated at 1:200 dilution overnight at 4ºC and after three washing steps with PBS-T 
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AP-conjugated goat anti-mouse IgG(H&L) at a 1:1000 dilution was added. Plates were 
allowed to react for 2 h with the phosphatase substrate buffer described before and 
changes in OD were determined at 405 nm.  
  
9.3.11 Statistical Analysis 
JMP® software (SAS Institute, Cary, NC) was used to make comparisons between 
the various vaccine regimens using one-way ANOVA and Tukey’s HSD and p-values < 
0.05 were considered significant. 
 
9.3.12 Informatics Analysis 
9.3.12.1 Clustering Analysis of Peptide Array Data 
Cluster analysis was performed in order to identify antigenic peptides under the 
different treatment conditions which are significant for induction of robust immune 
response and to compare the immunization groups under study. In this hierarchical 
clustering method, the similarity between observations is assessed according to their 
relative proximity in the data space. Starting from the separate data points in the 
parameter space, RN (N=10 for the comparison of 80 peptides, and N=80 for 10 different 
immunization groups), the Euclidean distance, dE, is calculated to classify clusters. This 
distance in the N-dimensional space is calculated according to the following equation. 
 
The color coding of the peptide maps indicates the relative distance among the data, 
and the tree structures, which are referred to as dendrograms, show the hierarchical 
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grouping. Note that the order of the rows and columns were rearranged through the 
clustering. 
 
9.4 Results 
9.4.1 αGal modification of F1-V 
Chemical addition of αGal epitopes to the F1-V antigen was performed using an 
efficient chemo-enzymatic synthesis of the αGal trisaccharide. SDS-PAGE was initially 
used to characterize the αGal-F1-V and compare it with the unmodified F1-V. Figure 
9.1A shows a representative gel comparing the unmodified F1-V and the αGal-F1-V. 
While the unmodified F1-V lane shows a main band at ~53 kDa, which is consistent with 
previous work21, a higher molecular weight band was identified for the αGal-F1-V 
together with some less intense bands at 100 kDa. This slight increase in the antigen 
molecular weight is the indicative of successful attachment of αGal epitopes. Western 
blot analysis was performed to corroborate the modification of the F1-V antigen. When 
hyperimmunized F1-V sera were used to react with both proteins (Figure 9.1B), 
consistent bands similar to those observed in the SDS-PAGE gel were observed. These 
findings demonstrate that the αGal-modified F1-V conserved its primary structure after 
the modification process. On the other hand, when the blot was reacted against αGal(+) 
serum, the only bands observed were those that corresponded to the αGal-F1-V protein 
(Figure 9.1C), further confirming the successful attachment of αGal epitopes.  
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Figure 9.1 Electrophoretic and western blot analysis of the F1-V and αGal-F1-V 
antigens confirms attachment of αGal epitopes. A) Flamingo fluorescence stained gel; 
B) and C) immunoblots developed with anti-F1-V hyperimmunized serum and anti-αGal 
(+), respectively.  
 
9.4.2 Nanoparticle Characterization and In vitro Antigen Release 
Scanning electron photomicrographs of F1-V and αGal-F1-V loaded 50:50 
CPTEG:CPH nanoparticles are shown in Figure 9.2. Particles showed similar spherical 
morphology and size (147 nm for F1-V loaded particles versus 169 nm for αGal-F1-V 
loaded particles), which was consistent with QELS analysis and with particle 
morphology and sizes observed in previous studies22,28,32.  The release kinetics of both 
antigens was monitored for more than 30 days and quantified using the micro-BCA 
assay. A higher initial burst was observed for the αGal-F1-V antigen (~2%) during the 
first two days resulting in ~75% of total protein released in 33 days compared to 68% of 
F1-V antigen in the same time period (Figure 9.2).  
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Figure 9.2 Slight faster release kinetics was observed for αGal-F1-V compared to the 
release of unmodified F1-V. (top) Scanning electron microphotographs of F1-V and 
αGal-F1-V-loaded 50:50 CPTEG:CPH nanoparticles. Scale bar: 5 µm. (bottom) 
Cumulative release fraction of ( ) F1-V and ( ) αGal-F1-V antigens released from 
50:50 CPTEG:CPH  nanoparticles. Error bars are representative of two independent 
experiments performed in duplicate.  
 
9.4.3 Nanovaccine formulations that include soluble and/or encapsulated αGal-F1-
V induce enhanced antibody production with high avidity 
Previous work has shown that αGal modification substantially increased the 
immunogenicity of diverse proteins like BSA19, viral hemagglutinin16, and HIV gp12018.  
Therefore, it is hypothesized that αGal-modification of the F1-V antigen will generate a 
robust immune response. It has also been shown that high antibody titers correlate with 
protection against Y. pestis challenge4,35. Based on this, the quantity and quality of 
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antibodies produced after immunization with different vaccine formulations combining 
two platforms (i.e., αGal-modification of the antigen and amphiphilic polyanhydride 
nanoparticles as vaccine delivery vehicles) were assessed.  
Prior to application of an antigen boosting dose, higher anti-F1-V antibody titers were 
obtained when 5 µg of αGal-F1-V was delivered solubly (SαGal-F1-V) compared to the 
same dose of unmodified F1-V (SF1-V) (Figure 9.3A). However, after boosting, no 
significant differences were observed in anti-F1-V titers between the two antigens. On 
the other hand, delivery of 100% of the antigen encapsulated in 50:50 CPTEG:CPH 
nanoparticles failed to induce antibody production since titers were below those of the 
soluble dose groups. When vaccine formulations comprised of 50% of the antigenic 
dose (2.5 µg) soluble together with 50% encapsulated into polyanhydride nanoparticles, 
high antibody titers were induced to the same level or higher than the 100% soluble 
groups. From this data, it is clear that the combination of encapsulated and soluble 
antigen is critical to the induction of high antibody titers, which is consistent with 
previous published data that used the same nanoparticle platform to deliver F1-V 
intranasally32. Different antigen combinations were used to evaluate the effect of 
delivering either αGal-F1-V or unmodified F1-V soluble and/or encapsulated. Figure 
9.3A shows that formulations containing soluble αGal-F1-V and unmodified F1-V or 
αGal-F1-V encapsulated (SαGal-F1-V + EF1-V and SαGal-F1-V + E αGal-F1-V) showed higher anti-
F1-V antibody titers that were statistically significant when compared to the soluble F1-V 
formulation.  
Since it has been previously shown that the LcrV protein (V antigen) is the causative 
agent of plague4,8,35, anti-LcrV-specific ELISAs were carried out to determine if 
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antibodies produced after immunization with the various vaccine regimens recognize the 
V antigen. Results shown in Figure 9.3B demonstrated that all the vaccine formulations 
evaluated induced similar levels of anti-LcrV antibodies production with the exception of 
the 100% unmodified F1-V encapsulated group (EF1-V). Serum analysis demonstrated 
that IgG1 was the dominant serum antibody isotype produced (Figure 9.3D).  
 
Figure 9.3 Nanovaccine formulations that include αGal-F1-V soluble and/or 
encapsulated stimulate enhanced antibody production with high avidity. (A) and (B) Anti-
F1-V and anti-LcrV IgG antibody titers, respectively. Titers were determined by end-
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point ELISAs 36 days post-vaccination (pre-boost) and post-boost (42 days after 
vaccination). (C) IgG antibody avidity pre and post-boosting dose. (D) Antibody isotype 
induced by various immunization regimens. Both avidity and optical density for isotypes 
were determined via ELISA at a 1:500 dilution. Data is presented as the mean ± SEM 
representative of two independent experiments. * = p ≤ 0.005 within the pre-boosting 
groups compared with the SF1-V regimen, and # = p ≤ 0.05 within the post-boosting 
groups compared with the SF1-V regimen. 
 
In addition to antibody titer, the quality of the antigen-specific antibody, including 
avidity, also determines vaccine efficacy36. In the present study, mice immunized with 
vaccine regimens containing αGal-F1-V antigen developed a high avidity F1-V-specific 
IgG response (Figure 9.3C). The formulation comprised of soluble and encapsulated 
αGal-modified F1-V (SαGal-F1-V + E αGal-F1-V) showed the highest avidity index 36 days 
post-vaccination after the boost. In contrast, mice vaccinated with SF1-V and EF1-V 
generated a low avidity anti-F1-V specific IgG antibody.  
 
9.4.4 Use of informatics analysis to identify optimal vaccine formulation 
components 
Principal component analysis (PCA) was used to analyze the anti-F1-V and anti-
LcrV titers and avidity indices data and to draw inferences about the contribution of each 
vaccine formulation component to the generated immune response. PCA enabled the 
simultaneous investigation of the relationship between the multiple variables of the 
vaccine regimens used in this study, including αGal modification of the F1-V, use of 
50:50 CPTEG:CPH nanoparticles as adjuvants, and amount of soluble versus 
encapsulated protein.  
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Figure 9.4A depicts the vaccine formulations assessed with PCA. In this figure, the 
distance along the red line between the perpendicular blue line and the control 
describes similarity. Soluble formulations and combination of soluble plus encapsulated 
antigen are clustered together far away from the control, which indicate that those 
regimens induced higher antibody titers with high avidity. The fully encapsulated antigen 
in polyanhydride nanoparticle groups were located closer to the control, corroborating 
previous observations affirming the need for a combination between soluble and 
encapsulated antigen. Among the clustered groups, the three groups containing αGal-
F1-V in a soluble form (SαGal-F1-V, SαGal-F1-V + EF1-V, SαGal-F1-V + E αGal-F1-V) were the 
regimens that showed the largest difference compared to the unmodified F1-V soluble 
group (represented by the green square and circle that are highlighted by a blue circle, 
and the gray diamond, which is closer to these two groups).  
Figure 9.4B shows the different variables that were grouped in the axis of the 
previous PCA biplot (Figure 9.4A). When related with the distribution of the various 
vaccine regimens in the two-dimensional space of the PCA plot, it was demonstrated 
that having the αGal-modification of the F1-V at the front end of the vaccine formulation 
stimulates a primary immune response, resulting in an enhanced initial (i.e., before 
administration of the antigen booting dose) production of high F1-V-specific IgG 
antibody titers with high avidity.  
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Figure 9.4 Informatics analysis to identify optimal vaccine formulations. (A) PCA biplot 
of various vaccine regimens. The plot maps out high dimensional correlations permitting 
one to track the relative influences of varying the vaccine formulation. Distance along 
red line between perpendicular blue and the control describe similarity. (B) Variables 
that define the axis values of the previous PCA biplot. Proximity between points defines 
similarity.  
 
9.4.5 Epitope Mapping Using Peptide Arrays 
To further characterize the binding of the anti-sera obtained after immunization with 
the various vaccine regimens to the F1 and V antigens respectively, we examined the 
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binding of the generated antibodies to two separate panels of overlapping peptides. One 
panel covered the full-length of the F1 antigen (27 peptides) and the other panel 
covered the full length of the V antigen (53 peptides). The peptide sequences used for 
this study are presented in Figure 9.5A. To facilitate visualization of the peptide array 
data, a colored map of the data matrix was generated and is presented in Figure 9.5B. 
Peptides showing higher immune responses are represented as red, yellow, or light 
blue. From a visual analysis of the peptide map, two responsive peptides were identified 
for the F1-antigen (i.e., F1-1 and F1-18), while four responsive regions were observed 
for the V antigen (V-1, V-2, V-14, V-19, V-20, V-27, and V-44).  
 
Figure 9.5 Differential epitope-recognition by antibodies elicited during immunization 
with the various vaccine formulations. α1,3GT KO mice were immunized with vaccine 
regimes presented in Table 1 and boosted 37 days post-vaccination. Sera collected five 
days after boosting was assayed for epitope recognition using a peptide array for both 
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the F1- and V-antigens. (A) depicts the sequence of the 80 individual peptides that were 
evaluated by ELISA. Peptides that showed higher response are boxed. (B) Heat map of 
the responses of the 80 peptides is shown, beginning at the top with the amino-terminal 
peptide and then moving down sequentially through the F1-V protein. Peptides which 
show higher immune response for specific immunization groups are presented with red, 
yellow, or light blue color and vaccination groups are represented by numbers 
identifying each of the columns for the heat map. Data are the average measurements 
for three pulled serum samples per vaccination group (samples from three or four mice 
were pulled).  
 
Implementation of clustering analysis (i.e., hierarchical clustering) allows for 
grouping of similar peptides under the different treatment conditions, and rapid 
identification of the more responsive peptides. Two main peptide clusters were observed 
from this analysis (Figure 9.6). Peptides that were shown to be immunodominant 
segments are F1-1, F1-18, V-1, V-2, V-14, V-19, V-20, V-27, and V-44. Similarly, in the 
PC space, the same peptides were identified as outliers (Supplemental Figure 9.1). 
From Figure 9.6, a comparison of the immunization groups based on the clustering 
among different treatments in terms of their proximity in the data space was performed. 
From visual analysis, the vaccine formulation group containing soluble αGal-F1-V 
together with encapsulated F1-V (SαGal-F1-V + EF1-V) showed recognition of a diverse 
number of peptides mainly from the V antigen. From clustering analysis of the 
immunization groups, the vaccine regimen SαGal-F1-V + E αGal-F1-V was shown to be closer 
to the SαGal-F1-V + EF1-V group. The soluble unmodified F1-V dose (SF1-V) was in close 
proximity to the control (i.e., saline) groups with a limited number of low intensity 
epitopes.  
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Figure 9.6 Peptide with significant response were identified by hierarchical clustering 
analysis Implementation of clustering analysis allows for grouping of similar peptides 
under the different treatment conditions, and the peptides which show relatively higher 
response than others. The two main peptide clusters identified are circled in red. 
Similarity between vaccinations regimes in terms of the proximity in the data space are 
highlighted in a red box, similar groups are connected by blue brackets.  
 
9.5 Discussion 
The efficacy of vaccines to induce protective immune responses relies on their ability 
to mimic the immune pathways initiated by natural infections, including signaling to the 
innate immune system20,28. Directing antigen internalization and promoting immunogenic 
responses by APCs, as well as preventing rapid degradation of antigen are key steps to 
 	  
287 
augment and extend immune stimulation20,37. The data presented herein demonstrated 
the success of using transdisciplinary approaches to rationally design efficacious 
vaccines against Y. pestis by combining two platforms, αGal-modification of the vaccine 
antigen (i.e., F1-V) and polyanhydride nanoparticles as vaccine delivery vehicles, which 
results in the induction of a robust immune response. 
Characterization by SDS-PAGE and western blot analysis demonstrated successful 
attachment of αGal-epitopes to the F1-V antigen (Figure 9.1); moreover, the different 
release profile obtained for the αal-F1-V in comparison with non-modified F1-V (Figure 
9.2) is also indicative of this modification. The release profile observed for the αGal-F1-V 
antigen may be attributed to a non-uniform protein distribution within the nanoparticles 
caused by a change in the protein hydrophobicity with the addition of the αGal epitopes. 
Addition of carbohydrate epitopes may reduce protein hydrophobicity, distributing the 
antigen closer to the particle surface and resulting in a higher initial burst. 
The presence of high-titer anti-αGal antibodies provides an endogenous adjuvant for 
induction of robust immune responses to αGal-expressing pathogens13,16. This triggers 
several mechanisms that facilitate antigen uptake and presentation by APCs, including 
complement activation and FcγR-mediated endocytosis17,18,37. Subsequent antigen 
processing and presentation by APCs may lead to the induction of a potent and specific 
immune response. Experimental testing of this hypothesis showed that vaccine 
regimens containing αGal-F1-V induced higher antibody production as indicated by 
antibody titers prior to boosting (Figure 9.2A).  
Polyanhydride nanoparticles activate DCs in a chemistry-dependent manner in 
vitro22,27,28 and identification of the polymer properties that direct particle interaction with 
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DCs has been well studied in our laboratories. These studies identified the molecular 
attributes that confer “pathogen-mimicking” properties to the amphiphilic 50:50 
CPTEG:CPH nanoparticles28,38. In the present study, vaccine formulations containing 
encapsulated antigen in polyanhydride nanoparticles were able to induce equal or 
higher F1-V-specific antibody titers with the exception of 100% antigen-encapsulated 
nanoparticles. The adjuvant properties of polyanhydride nanoparticles observed in vitro 
may translate in vivo allowing for DC migration to the draining lymph node where they 
can facilitate the induction of an adaptive immune response36,37. However, the presence 
of soluble antigen is important during the initiation of a primary immune response, which 
may explain the efficacy of vaccines that combine soluble and encapsulated antigens in 
comparison to those formulations that contain 100% encapsulated antigen. The efficacy 
of vaccine regimes that include both soluble and encapsulated F1-V to induce protection 
after intranasal administration has been previously demonstrated32. Higher production of 
antibodies with high avidity was especially achieved when soluble αGal-F1-V was 
delivered together with encapsulated F1-V or αGal-F1-V (Figures 9.3A and 9.3C). 
These observations demonstrate the efficacy of having the αGal-modified antigen at the 
“front end” of the vaccine formulation, which can be related to an enhanced initial 
antigen uptake by APCs mediated via FcγRs and induction of a primary immune 
response that is αGal-dependent followed by an antigen-specific response provided by 
the continuous antigen exposure controlled by nanoparticle degradation.   
The production of antigen-specific antibodies with high avidity is also important for 
the induction of a robust immune response that may lead to protection32,39. High 
antibody avidity is usually achieved by continuous antigen exposure and is associated 
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with affinity maturation of B cells39. Antibodies with higher avidity were produced after 
immunization with vaccine formulations containing soluble plus encapsulated antigen 
(Figure 9.3C). Previous work from our laboratories has shown that the amphiphilic 
50:50 CPTEG:CPH nanoparticles are internalized by APCs at a slower rate than 
hydrophobic nanoparticles28,38. Moreover, the amphiphilic nanoparticles persist within 
the body after subcutaneous administration acting as a depot (data not shown), which 
when combined with the slow antigen release dictated by nanoparticle degradation, 
allows for extended presence of antigen resulting in more avid antibodies. The avidity of 
an antibody for its antigen is dependent on the affinity of individual antigen-binding sites 
for the epitopes on the antigen40. Differentiation of B cells with specificity for diverse 
epitopes on the same antigen into plasma cells induce secretion of antibodies with 
binding capacities for the same multiple epitopes that elicit proliferation in the first 
place40. In the data presented herein, the use of hierarchical clustering analysis allowed 
for identification of vaccine regimes that are similar in the data space and that were able 
to induce the production of antibodies that recognize several epitopes from both the F1 
and V antigens (Figure 9.6). Tellingly, these vaccine formulations (i.e., SαGal-F1-V + EF1-V, 
SαGal-F1-V + EαGal-F1-V, SF1-V + EF1-V, SαGal-F1-V, and SF1-V + EαGal-F1-V) elicited production of 
antibodies with higher avidity (Figure 9.3C).  
Conservation of antigen epitopes during vaccine delivery is an important aspect for 
protection. In this regard, the amphiphilic 50:50 CPTEG:CPH polyanhydride particles 
are effective delivery vehicles that have shown to stabilize the F1-V antigen, maintaining 
its primary, secondary, and tertiary structure in vitro21, which may translate into 
conservation of linear and conformational epitopes in vivo. Peptide arrays with the 
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application of informatics analysis tools (i.e. PCA analysis, and clustering analysis) were 
used in this study to identify immunodominant segments. In the case of the F1 antigen, 
the F1-1 and F1-18 peptides were identified as immunodominant. An amino acid region 
in the F1 antigen that has been related with protection in passive immunotherapy is 
located at the amine-terminal end of the F1 antigen41. The F1-1 peptide that was 
recognized by the antibodies elicited by most of the immunization groups in this study 
may be part of this protective sequence identified at the N-terminus of the F1 antigen. 
Other immunogenic F1 segments have been identified as linear B and T cell epitopes in 
the F1 antigen. The sections encoded by amino acids 145-162 and 123-137 have been 
recognize as B and T cells epitopes, respectively42,43. However, from our peptide array 
data, the immunization groups did not elicit antibodies against those specific epitopes, 
with the exception of the SαGal-F1-V + EF1-V group that showed a weak response to these 
regions (Figures 9.5 and 9.6).  
It is well known that the V antigen is an effector protein and some of its epitopes 
have been identified as responsible for the contact-dependent Type III secretion system 
during infection6,35,44-47. Therefore, designing vaccine formulations capable of inducing 
IgG antibodies capable of recognize the V epitopes responsible for infection is of great 
importance. In this sense, visualization of the peptide array map allows for identification 
of vaccine formulations that induce production of epitope-specific IgG antibodies45-47. 
Even though the distribution of linear and conformational epitopes for F1-V is not 
completely known, the presence of a linear section in the F1 segment and a section 
dominated by α-helix conformations in the V antigen suggests that conformational 
epitopes are mainly present in the V region44. Specifically, V-1, V-2, V-14, V-19, V-20, V-
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27, and V-44 were identified as immonodominant sequences in our analysis (Figures 
9.5 and 9.6). Two sequences in the V antigen have been previously identified to contain 
one or multiple protective epitopes - the main sequence is encoded by amino acids 168 
to 27545,48 and the peptides V-27 and V-44, which were identified as immunodominant in 
this study, are located in this protective region. These peptides were mainly recognized 
by antibodies elicited after immunization with vaccine regimens that combined the αGa-
F1-V and polyanhydride nanoparticle platforms. A second protective region has been 
identified at the N-terminus of the V antigen (2 to 135)45,46,48,49, which is partially 
encoded by amino acids within the peptides V-1, V-2, V-14, V-19 and V-20. These 
peptides were also shown to be immunodominant by the same vaccine regimens. Some 
of those epitopes were related to recognition by CD4 T cells (i.e., 71-86, 101-116, and 
166-178), which are partially encoded by the V-14, V-19 and V-20 peptides46,49.  
Identification of protective B and T cell determinants is necessary in order to develop 
such sequences as vaccine immunogens or to design appropriate antigen delivery 
vehicles that can protect specific epitopes during the delivery process. Collectively, 
these results indicate that the combination of αGal-modification and amphiphilic 
polyanhydride nanoparticles in a vaccine regimen against Y. pestis enhanced the 
production of F1-V-specific IgG antibodies with high avidity, with recognition of 
protective epitopes, which suggests its potential to induce protection. Using peptide 
arrays in combination with informatics tools, we have developed a new toolbox in 
understanding antigen-antibody interactions, generating information that allows for the 
rational selection of antigen (i.e., αGal-modification) and adjuvant (i.e., amphiphilic 
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polyanhydride nanoparticles) based platforms for the design of efficacious single dose 
vaccines. 
 
9.6 Conclusions 
A transdisciplinary approach that combined concepts from material science, protein 
chemistry, immunology, and computational analysis, was applied to rationally design a 
vaccine for Y. pestis capable of inducing a robust immune response. This vaccine 
formulation combines two platforms, αGal-modification of the F1-V antigen and 
amphiphilic polyanhydride nanoparticles as vaccine delivery vehicles and adjuvants, in 
order to direct and enhance the immune response previously obtained by vaccines 
based on the F1-V antigen and other adjuvants (e.g., liposomes, flagellin, cytokines). 
High antibody titers with high avidity and with the ability to recognize protective epitopes 
were elicited by vaccine regimes containing soluble αGal-F1-V and encapsulated αGal-
F1-V or F1-V. The αGal-modification of antigen and amphiphilic polyanhydride 
nanoparticles technologies can function in tandem to design efficacious vaccine 
platforms for a wide range of pathogens.  
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9.9 Supplemental data  
 
Supplemental Figure 9.1 Principal component analysis (PCA) of peptide arrays 
corroborates as outliers the same set of peptides identified by clustering analysis. The 
plot maps out high dimensional correlations permitting identification of significance 
responder from the peptide array data.  
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CHAPTER 10 
Conclusions 
Innovative and safe vaccine platforms are needed to design efficacious prophylactic 
and therapeutic vaccines to protect humans from new and re-emerging infectious 
diseases. Ideally, new vaccine regimens would provide protection from disease 
following a single immunization. Therefore, the need to design novel drug and vaccine 
delivery methods is urgent and it requires the use of complementary strategies to 
stimulate both the innate and adaptive immune systems. This work has focused on the 
design of targeted drug and vaccine platforms based on amphiphilic polyanhydride 
particles that can result in the generation of robust immune responses. A 
transdisciplinary approach that combines concepts from biomaterials, nanotechnology, 
carbohydrate and protein chemistry, molecular biology, immunology and computational 
analysis was applied to rationally design and engineer novel vaccine platforms that 
encompass passive and active targeting strategies. Yersinia pestis, the causative agent 
of bubonic and pneumonic plague, was the disease of interest in this project; however, 
the platforms developed can be applied to different diseases.  
Passive targeting strategies for the design of delivery vehicles based on 
polyanhydride particles were explored in the chapters 4 and 5 of this thesis. Polymer 
chemistry was selected as the main variable to control antigen stabilization and release. 
The importance of selecting the appropriate polymer chemistry to maintain structural 
integrity resulting in a biologically stable protein (e.g., antigen and antibodies) was 
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demonstrated in Chapters 4 and 5. Particles based on amphiphilic 50:50 CPTEG:CPH 
preserved antigenicity of recombinant proteins and the biological function of antibodies, 
suggesting that these polymers are promising carriers for Y. pestis antigens as well as 
for the delivery of functional antibodies for passive immunotherapy.   
The surface chemistry of the particle may also dictate interactions of the particles 
with soluble and cellular components of the immune system. The exposure of these 
particles to serum generally results in the adsorption of specific proteins to their surfaces 
and alters their recognition by immune cells and their biodistribution. In Chapter 6, the 
variables guiding protein adsorption phenomena were identified by studying the in vitro 
adsorption of model plasma proteins. These studies demonstrated a direct correlation 
between polymer hydrophobicity and amount of protein adsorbed. This analysis was 
expanded upon in Chapter 7 when the effect of the chemistry-dependent adsorption of 
serum proteins on the uptake and activation of antigen presenting cells (i.e., dendritic 
cells or DCs) was evaluated. This work revealed changes in particle uptake and 
activation phenotype of DCs as a consequence of surface adsorption of opsonins (i.e., 
immunoglobulin G and complement component C3) and provided important insights into 
the mechanisms mediating polyanhydride particle uptake (i.e., complement receptor-
mediated uptake). 
The insights obtained with respect to how particle surface chemistry may be 
important in their interactions with immune cells led to the design and development of 
active targeting strategies to improve and direct the adjuvant properties of polyanhydride 
particles. In Chapter 8, a novel approach to targeted antigen delivery was developed by 
functionalizing the surface of polyanhydride nanoparticles with specific carbohydrates to 
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provide “pathogen-like” properties that ensure nanoparticle recognition by C-type lectin 
receptors on DCs. The ability of these novel particles to induce and enhance DC 
activation by specific interactions with the mannose receptor was demonstrated. The 
receptor-mediated endocytosis induced by the direct interaction of mannose residues 
with the mannose receptor may be exploited to design efficacious nanovaccines.  
Continuing with the development of innovative vaccine platforms based on active 
targeting strategies, a novel approach was adopted by combining amphiphilic 
polyanhydride particles as delivery vehicles with the αGal-modification of vaccine 
antigens trying to target the endogenous pathways (i.e., FcγR-mediated endocytosis) 
activated by the αGal motifs (Chapter 8). Yersinia pestis was used as a target pathogen 
to test the proposed vaccine regimes in vivo. The amphiphilic 50:50 CPTEG:CPH 
nanoparticles were used to deliver the Y. pestis antigens based on results from Chapter 
4 that showed its ability to stabilize these antigens. Results showed that high antibody 
titers with high avidity and with the ability to recognize protective epitopes were elicited 
by vaccine regimens containing soluble αGal-F1-V and encapsulated αGal-F1-V or F1-
V. The data presented herein demonstrated the success of using transdisciplinary 
approaches to rationally design efficacious vaccines against Y. pestis by combining two 
platforms, which results in the induction of robust immune responses. 
Taken together, these studies demonstrated the promise of amphiphilic 
polyanhydride particles as drug delivery devices and vaccine adjuvants, and provided 
key insights into the rational design of targeted platforms to enhance the induction of 
antigen-specific immune responses and to facilitate the design of protective targeted 
therapeutic treatments and vaccines. 
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CHAPTER 11 
Ongoing and Future Work 
 
 The research described in this thesis has demonstrated the versatility and promise 
of biodegradable polyanhydride particles as a platform for targeted vaccine delivery. The 
ability to incorporate passive and active targeting strategies into these vehicles and 
combine them with other platforms (i.e., antigen modification) to improve vaccine 
efficacy provides a basis for future research. While polymer chemistry was the main 
variable investigated for passive targeting, showing its potential to provide controlled 
release and antigen stabilization and serum protein adsorption and interactions with 
antigen presenting cells (APCs), the investigation of other variables like particle size and 
shape and their effect on interactions with APCs may help design vaccine delivery 
vehicles that mimic pathogens. On the other hand, the active targeting strategies 
described herein can be expanded by incorporating different ligands (i.e., peptides, 
antibodies, haptens) to target other receptors on APCs (i.e., Toll-like receptors, TLRs). A 
pictorial summary representing the passive and active strategies utilized in this research 
and proposed as future work is shown in Figure 11.1. While the studies described in 
Chapter 6 and the proposed incorporation of other ligands provide key insights on the 
targeting capabilities of the functionalized particles, the downstream mechanisms of 
antigen processing and presentation initiated by these targeted vaccine adjuvants need 
to be studied and described. This can be performed by utilizing receptor knockout mice 
and a combination of individual cell-based and cell population-based methods. It is also 
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important to relate the results obtained by the mechanistic in vitro experiments to the 
evaluation of the in vivo targeting capabilities of the functionalized polyanhydride 
particles. Applying these studies to the target disease utilized in the present work (i.e., 
Yersinia pestis) could result in optimization of the vaccine formulation with dose sparing 
and immunity against knockout strains of bacteria designed to function as bioterrorism 
weapons. Finally, future work combining the broad database of knowledge and 
platforms gathered through these investigations could be utilized to design single-dose, 
targeted vaccine strategies for other diseases such as influenza and HIV.  
 
 
Figure 11.1 Pictorial summary of passive and active strategies discussed in this work. 
Particle size and shape may direct particle internalization through different uptake 
mechanisms (i.e., phagocytosis, endocytosis, or micropinocytosis). Particle chemistry 
and incorporation of TLR ligands target initiation of molecular danger signals that may 
enhance APC activation. Finally, incorporation of other ligands (i.e., carbohydrates) on 
the particle surface can target particle internalization through receptor-mediated 
endocytosis, which can direct the generated immune response.  
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11.1 Evaluation of Polyanhydride Particle Size and Shape Effects on the 
Internalization and Activation of APCs  
While the work described in Chapters 4 and 5 demonstrated that tailoring 
polyanhydride chemistry can be used as a passive targeting strategy for the stability and 
controlled release of vaccine antigens (i.e., Y. pestis antigens and antibodies for passive 
immunotherapy)1,2, chemistry-dependent serum protein adsorption patterns were also 
identified3 and their influence on particle uptake by APCs (i.e., DCs) and activation of 
these immune cells was demonstrated (in Chapters 6 and 7)4. These findings provided 
adequate information for the transition from passive targeting to the incorporation of 
molecules for active targeting; however, there are other physical characteristics of 
polymeric particles such as size and shape that have the potential of targeting specific 
mechanisms of particle internalization by APCs 5-18. The mechanism by which DCs 
uptake and internalize particles will determine the subsequent processing and 
presentation pathway (i.e., MHC class I, MHC class II, or cross-presentation 
pathways)15,18-20. Particle size appears to be a key determinant for the uptake and 
internalization of particles. Particles having a size range between 0.5 to 10 µm (i.e., 
microparticles and large nanoparticles) are optimally taken up by phagocytosis, particles 
<500 nm but > 200 nm are internalized through endocytosis and are trafficked to early 
endosomal compartments15,21 and macropinocytosis is the uptake mechanism that DCs 
use for small nanoparticles (<50 nm)16,17,20. Particle size is also an option to target a 
specific and desirable delivery route; for example, for mucosal delivery it is known that 
particles between 100 and 500 nm in size are preferred because they can pass through 
the nasal cavity into the lungs22. Additionally, internalization of both opsonized and non-
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opsonized PS and PLGA devices with different shapes exhibited a strong dependence 
on local particle shape from the perspective of the phagocyte11,12,14. This work 
demonstrated similarities between bacteria and particles with the same shape14.  
Previously developed methods to fabricate monodisperse particles23 and particles of 
different shapes11,12,14 can be applied to the copolymer systems used in this research 
(i.e., CPH:SA and CPTEG:CPH). We have performed preliminary studies to determine 
the effect of particle shape on the activation of DCs and initial results showed that DCs 
stimulated with PS and PLGA rods show differential expression of co-stimulatory 
molecules (i.e., CD40) and secretion of cytokines (i.e., IL12-p40) compared with 
spheres from these chemistries (Figure 11.2). Based on this work, controlling 
polyanhydride particle size and shape together with the already generated information 
on the effect of polymer chemistry upon immune activation may be of great advantage 
for the rational design of targeted vaccine platforms.  
 
Figure 11.2 Dendritic cells stimulated with PS and PLGA rods show different expression 
of co-stimulatory molecule CD40 (A) and secretion of cytokine IL12-p40 (B) compared 
with spheres from these chemistries. After stimulation with either spheres or rods made 
of PS or PLGA for 48 h, supernatants were harvested and assayed for cytokine 
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secretion and then DCs were harvested and analyzed by flow cytometry for surface 
expression. Data is presented in mean fluorescence intensity (MFI) for cell surface 
marker expression and concentration (pg/mL) for cytokine production, and is 
representative of one experiment performed in triplicate. 
 
11.2 Functionalized Polyanhydride Particles to Target TLRs on APCs  
The ability of carbohydrate-functionalized polyanhydride particles to be internalized 
by DCs and enhancement of their activation mediated by the mannose receptor was 
demonstrated in Chapter 86. The design of protocols to fabricate these carbohydrate-
functionalized particles ensures the targeting of C-type lectin receptors (CLRs), which 
have the potential to efficiently deliver antigens to DCs for processing and presentation 
to T cells19,24,25. However, it is known that engagement of other pattern recognition 
receptors (PRRs) on APCs may lead to the initiation of different signaling events and 
moreover, that signaling through a combination of PRRs may also benefit the generation 
of robust immune responses26,27. The most well studied PPRs have been TLRs and 
eleven of these receptors have been identified in humans28-30. TLR signaling plays an 
important role in determining the quality of the T cell response. For example, the use of 
lipopolysaccharide (LPS), which is a TLR4 ligand, leads to a preferential cell-mediated 
response (TH1)31,32. The role of TLRs in the initiation of innate immune responses 
makes them potential targets for vaccines by using them as vaccine adjuvants 
combined with the polyanhydride particle platform.  
We performed preliminary studies on the targeting of TLRs by translating the 
protocols developed to attach carbohydrate residues to modify the surface of 
polyanhydride nanoparticles with poly I:C, a TLR3 ligand. Encapsulation of this ligand 
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was also tested and the activation of bone marrow derived macrophages with these 
functionalized particles was evaluated. Initial results (Figure 11.3) demonstrated that 
pathogen-associated molecular patterns (PAMPs), i.e., poly I:C, embedded within the 
particle through encapsulation or attached to the particle surface mimic the structure of 
pathogens leading to increased secretion of inflammatory cytokine. Initiation of 
inflammatory cytokines by inclusion of PAMPs could help drive more robust adaptive 
immune responses towards antigens loaded within the nanoparticles. Therefore, using 
TLRs is an active targeting approach with great potential and it should continue to be an 
area of investigation to improve the adjuvant properties of polyanhydride particles.  
 
 
Figure 11.3 Maximum stimulation of macrophages occurs when nanoparticles 
encapsulating Poly I:C are phagocytosed. 20 µM cytochalasin D in PBS or PBS alone 
were administered to the cells for 15 min prior to administration of the nanoparticle 
treatments. Cell free supernatant samples were collected at 24 h to measure IL-1β, IL-6, 
IL-10, IL-12 p40 and TNF-α using Luminex® Multiplex assay. Significant differences 
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between treatment groups are identified by different letters above the histograms (p < 
0.05, n=6) as determined by one-way ANOVA with Tukey post-test. * indicates statistical 
differences of cytochalasin D treatment from PBS via Mann-Whitney U test (p < 0.05, 
n=6).  
 
11.3 In Vitro and In Vivo Mechanistic Evaluation of Functionalized Polyanhydride 
Particles  
As mentioned before, the in vitro targeting properties of the carbohydrate-
functionalized particles were demonstrated by the increased expression of CD206 and 
CD209 with an accompanying increased expression of MHC II and CD86 on DCs 
(Chapter 6)6. However, more studies are needed in order to better comprehend the 
adjuvanticity and targeting potential of these materials. The next step should be to 
evaluate the effect that sugar modification and the subsequent targeting of specific 
receptors on APCs will have on the mechanisms of particle internalization and 
processing. To accomplish this, the utilization of CLR knockout (KO) mice is proposed to 
determine the role of CLR engagement on the internalization of functionalized particles 
by APCs and their activation profile. To further elucidate the mechanisms which 
nanoparticles exploit to propagate antigen presentation a combination of cell-based and 
cell population-based methods (i.e., fluorescence microscopy methods and Image 
Stream, and flow cytometry and Bioplex® analysis, respectively) can be used4,6-9,33. 
Preliminary studies using DCs derived from the bone marrow of mannose receptor 
(MMR)-KO mice and combining ImageStream and flow cytometric analysis corroborated 
the role of engagement of this receptor by di-mannose-functionalized particles on the 
activation of DCs. From Figure 11.4, it can be observed that while MMR-KO DCs 
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internalized functionalized particles at similar rates than wild type (WT) DCs, the levels 
of expression of major histocompatibility complex II (MHC II) and co-stimulatory 
molecules (i.e., CD40 and CD84) were lower for MMR-KO DCs, indicating that 
engagement of the mannose receptor is necessary for the activation of DCs. The 
methods used with these KO mice can be applied to other mice models (i.e., SIGNR3 
KO mice) to expand the evaluation of the interactions of sugars with specific CLRs.  
 
 
Figure 11.4 (A) MMR-KO DCs internalized functionalized-particles at similar rates than 
wild type (WT) DCs, and (B) expression of MHC II and co-stimulatory molecules CD40 
and CD84 after stimulation with mannose-functionalized 50:50 CPTEG:CPH 
nanoparticles was lower for MMR-KO DCs, indicating that engagement of the mannose 
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receptor is necessary for the activation of DCs. Particle internalization was determined 
using ImageStream at 30 min, 2 and 48 h, and data is presented as percent of particle 
positive cells and is the mean of three independent experiments. Flow cytometric 
analysis was used to determine expression of surface molecules after stimulation with 
either non-functionalized or functionalized 50:50 CPTEG:CPH nanoparticles. Data is 
presented as mean fluorescence intensity (MFI) and is the average of three independent 
experiments performed in triplicate. Error bars represent standard error.  
 
Furthermore, it is necessary to evaluate the in vivo performance of carbohydrate-
modified particles. In order to do this, the design and performance of in vivo studies in 
animal models is proposed to evaluate the adjuvant properties of these materials. 
Initially, the in vivo distribution of these particles following either intranasal (IN) or 
subcutaneous (SC) administration to mice can be studied by using a Kodak In Vivo 
Multispectral Imaging System. The ability to assess particle distribution in real time 
combined with mechanistic internalization studies will provide insights into how the 
adjuvant properties of functionalized polyanhydride particles can be used to target the 
vaccine to the desired tissues to enhance and modulate the subsequent immune 
response in the presence of antigen.  
 
11.4 Optimization of Yersinia pestis Vaccine by Use of Functionalized 
Polyanhydride Particles 
While single administration of a vaccine formulation of soluble F1-V co-delivered with 
F1-V loaded 50:50 CPTEG:CPH nanoparticles provided complete protection against 
lethal Y. pestis challenge and induced a long-lived, high-titer, high-avidity antibody 
response34 and the αGal-modification of the F1-V antigen studied in Chapter 9 is an 
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option to improve the efficacy of a Y. pestis vaccine, optimization of different parameters 
is still necessary. Vaccine formulations combining soluble F1-V together with 
encapsulated F1-V showed superior performance when delivered intranasally or 
subcutaneously when compared with 100% of encapsulated antigen or 100% soluble 
antigen. However, only two ratios of soluble to encapsulated antigens were studied (by 
using different immunization routes) - 80:20 (i.e., intranasally) and 50:50 (i.e., 
subcutaneously). There may be an optimal ratio of soluble to encapsulated antigen that 
may convey protection with robust antibody responses. Determination of this optimal 
total antigen dose will allow for utilization of the lowest antigenic dose thereby reducing 
cost. A three step experimental design is proposed to achieve the fabrication of a 
vaccine with dose sparing capabilities. The first two steps involve the reduction of the 
total antigen dose, while the third step includes the utilization of functionalized 
polyanhydride particles to enhance and extend the generated immune response. In the 
first experiment, the encapsulated antigen dose could be maintained at 10 µg of F1-V 
(same encapsulated dose as that utilized in the studies that resulted in protection), while 
the soluble antigen dose could be reduced until getting to a final dose eight times lower 
than that used in the intranasal studies. Figure 11.5 shows F1-V-specific IgG1 antibody 
titers through 6 weeks post vaccination, and the data indicate that the vaccine regimens 
are comparable with a formulation containing MPLA and even when this adjuvant was 
able to elicit higher antibody titers during the initial weeks of the study, at week six these 
titers start falling which is consistent with previous data9,34. In the first six weeks of the 
study, it was not possible to observe clear differences between the immunization groups 
combining different doses of soluble antigen with encapsulated F1-V; this study is still 
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ongoing. After completing this first experiment, the next step will be to reduce the 
encapsulated dose in order to find an optimal dose that will result in similar antibody 
titers to those elicited by the total antigen dose that have previously provided protection.  
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Figure 11.5 Kinetics of IgG1 antibody titer for 6 weeks post-vaccination. Soluble antigen 
dose (S) was reduced from 50 µg following two-fold dilutions to 5 µg of F1-V, while the 
encapsulated dose of antigen in 50:50 CPTEG:CPH nanoparticles was kept constant 
(10 µg of F1-V).  
 
Current research has analyzed the vaccine adjuvant and delivery capacity of 
particles composed of a specific polymer chemistry without the inclusion of any targeting 
agent on the surface of these carriers 5,7-9,33,34. A logical next step, after their success in 
in vitro studies, is to investigate the efficacy of carbohydrate-functionalized 
polyanhydride particles in generating a robust immune response that compensates for 
the reduction of antigen dose and that can result in protection. It may be possible for the 
optimal vaccine formulation to be a cocktail vaccine in which a combination of non-
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functionalized and functionalized (with different ligands) particles, and particles with 
different sizes and administration through different routes may provide protection.  
 
11.5 Functionalized-Polyanhydride Particles for the Single-Dose, Targeted 
Vaccination against Other Infectious Diseases  
The transdisciplinary approach proposed in this research for the rational design of 
efficacious targeted vaccines showed success in the design of a single-dose, dose 
sparing targeted vaccine for Yersinia pestis; however, this platform approach can be 
applied to other respiratory and non-respiratory diseases that may find an advantage in 
using the passive and active targeting strategies designed in this work. A first step may 
be to translate this approach for the design of targeted vaccines for other respiratory 
diseases such as influenza. It is hypothesized that the development of a single-dose 
targeted vaccine based on the use of carbohydrate-functionalized polyanhydride 
nanoparticles administered intranasally may result in the induction of robust immune 
responses due to the fact that both the administration route and the targeted receptor-
mediated endocytosis pathway mimic the way the influenza virus enters the body and 
how it is recognized by the innate immune system (i.e., macrophages)35. It is known that 
the influenza A virus uses the mannose receptor on macrophages (i.e., alveolar 
macrophages) for viral entry35; therefore the use of mannose-functionalized particles to 
deliver influenza antigens may target the same entrance pathway of the pathogen 
increasing the possibilities of this platform for success. However, other CLRs (i.e., 
galactose-type lectin receptor) have been also identified as an entry receptor for this 
virus, which is targeted by the sugar galactose. There is a need for the development of 
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rapid strategies for the fabrication of these novel particles. Currently in our laboratories 
in combination with our collaborators from the ISU Chemistry Department (Dr. Pohl’s 
research group) whose expertise is in the synthesis of different sugars for particle-
attachment, a high-throughput system for the fabrication and evaluation of 
carbohydrate-functionalized particles has been designed. Preliminary studies 
demonstrate the ability of this high-throughput set up to attach three different sugars on 
polyanhydride particles within the same experiment. These particles were evaluated for 
their capacity of activate alveolar macrophages in vitro and preliminary results 
demonstrated that both mannose- and galactose-functionalized particles enhanced the 
activation of macrophages (Figure 11. 6). Although these results demonstrated the 
potential of the high-throughput approach to accelerate and improve the design of 
functionalized particles, there are still several variables that should be tested (e.g., 
particle size, particle chemistry, sugar quantity) to maximize the value from this 
technique.  
 
Figure 11.6 Alveolar macrophages stimulated with di-mannose- or galactose-
functionalized 50:50 CPTEG:CPH nanoparticles enhanced the expression of the co-
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stimulatory molecule CD86 and increased secretion of pro-inflammatory cytokines (i.e., 
TNF-α). Cell free supernatant samples were collected after 48 h to measure cytokine 
secretion using Luminex® Multiplex assay. For cell surface marker expression 
(presented as mean fluorescence intensity, MFI), cells were harvested 48 h after 
stimulation, stained and analyzed by flow cytometry. Data is the mean of at least three 
independent experiments performed in triplicate and error bars represent standard 
deviation. Groups identified with different letters are statistically significant.  
 
The design of an effective HIV vaccine may also benefit from the carbohydrate-
functionalized particles and new strategies for their rapid fabrication and 
optimization.The C-type lectin receptor DC-SIGN has been identified to play a critical 
role in the pathogenesis of HIV and current studies are looking for interactions between 
the HIV virus and other CLRs (i.e., mannose receptor)36. The ability of mannose-
functionalized polyanhydride particles to target this receptor was demonstrated in 
Chapter 8; however it has been also suggested that high-mannose structures may 
target DC-SIGN more efficiently25. Therefore, synthesis and attachment of higher 
functionality sugars to identify the sugar chemistry that can target this receptor efficiently 
may benefit immune response enhancement against HIV. Recent work in our 
laboratories has demonstrated the capability of 50:50 CPTEG:CPH nanoparticles to 
release and stabilize the gp41 antigen (Figure 11.7), which is a candidate antigen for 
the design of an efficacious HIV vaccine. These initial studies show the promise of using 
polyanhydride particles as HIV antigens carriers and their adjuvant properties may be 
enhanced by functionalizing their surfaces with CLR ligands. 
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Figure 11.7 50:50 CPTEG:CPH nanoparticles release and stabilize the gp41 antigen, 
which is a candidate antigen for the design of an efficacious HIV vaccine. (A) Release 
kinetics of gp41 from 50:50 CPTEG:CPH nanoparticles for 30 days. Protein 
concentration was determined by micro-BCA assay. (B) Antigenicity of released protein 
was maintained upon encapsulation and release from polyanhydride nanoparticles. 
Antigenicity was determined by specific-ELISA against three important HIV neutralizing 
antibodies (2F5, 4E 10, and Ze13). 
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